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ABSTRACT
Diethyltoluenediamine (CAS 68479-98-1) is a ring-ethylated analog of
toluenediamine (TDA) and like TDA, consists of the 2,4- and 2,6-diamine
isomers. DETDA was developed by Albermarle Corporation as a substitute for
TDA in some applications. To determine the uptake and distribution of 2,4and 2,6-DETDA, 5 groups of 4 adult male Sprague Dawley rats were gavaged
at 179 pmol/kg body weight with [3H]-2,4- or [3H]-2,6-DETDA. Multiple tissues
were collected at 1, 4, 8, 24 and 48 hours. Very high levels of label occurred in
the gastrointestinal system and bladder during the first 8 hours while liver and
kidney exhibited moderate levels. The concentration of radioactivity in most
tissues except the stomach, duodenum, caecum, colon, bladder and thyroid
was greatest at the 4 hour time point. Thyroid levels, at the 24 and 48 hour
time points, were the highest of all tissues examined. By 8 hours, urinary
excretion became the primary route of elimination. By 24 hours, over 60% of
the labeled compound had been excreted and by 6 days less than 4% of label
remained in the tissues. Low levels of residual label was found in all tissues
examined at day 6. To determine urinary and fecal excretion pattens of 2,4and 2,6-DETDA, 5 adult male Sprague Dawley rats were gavaged at 179
pmol/kg body weight of [3H]-2,4- or [3H]-2,6-DETDA. Urine and feces were
collected for 6 days then blood and tissues were collected at euthanasia on
day 6. Excretion data revealed that the primary route of elimination of DETDA
was the urinary system with the majority of label being excreted in the first 24
hours. Compared to the 2,4-isomer, 2,6-DETDA exhibited a higher rate of
xvi
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urinary excretion. Both 2,4- and 2,6-DETDA demonstrated covalent binding to
rat liver DNA and liver protein.

xvii
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INTRODUCTION
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is an industrial
compound utilized as a polyurethane chain extender in reaction injection
molded applications. DETDA is commercially supplied as a mixture of isomers
with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4-diamine (2,4DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA) and 0.5-3%
dialkylated m-phenylenediamine. DETDA has been manufactured by
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years
under the name Ethacure®100 (1.1). DETDA also has uses as curing agents
for polyurethanes and epoxies, antioxidants, lubrication, wire coatings and
replacements for more toxic industrial compounds, such as 4,4'-methylenebis2-chloroaniline (MOCA) and toluenediamine (TDA). Ethacure has been
analyzed using standard laboratory studies including acute and subchronic
toxicity tests as well as a battery of mutagenicity and carcinogenicity in vitro
tests. Results from a two-year feeding study in rats showed DETDA related
effects on the pancreas, liver, thyroid and eyes as well as increased tumors in
the liver and thyroid glands of male rats (I.2). These findings along with the
structural similarity to the known mutagenic noncarcinogen:carcinogen pair2,6- and 2,4-toluenediamine (TDA) dictated the need for a metabolic study of
the DETDA mixture (I.3-I.5).
Through a proprietary process, Ethacure is synthesized from
toluenediamine, an intermediate compound widely used in industry. TDA is
1
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used primary in the synthesis of toluene diisocyanate, a cross-linking agent in
the production of polyurethane foam. It is also used as an intermediate in the
synthesis of dyes used in textiles, wood stains and pigments (1.4,1.6-1.8).
Because of the proprietary nature of DETDA, a review of existing
industrial information and literature on this compound was not possible.
However, it is known that studies into its metabolism, absorption, distribution,
and excretion have not been conducted. In an attempt to understand the
characteristics and biotransformation of DETDA, a critical review of the closely
related compound toluenediamine was undertaken. The metabolism,
absorption, distribution, and excretion of two isomers of toluenediamine, 2,4TDA and 2,6-TDA, have been studied. In addition, 2,4-TDA has been found to
be carcinogenic in rats (1.3,1.4,1.9) while 2,6-TDA is a known mutagen (1.5,1.10).
Because of the inherent dangers associated with the mass production
of chemical compounds, worker exposures must be kept to a minimum, but the
inherent risks of exposure must also be defined. Methods of detecting both
acute and chronic exposure to humans is desirable and in most instances is
dictated by governmental agencies. Therefore, understanding how the DETDA
compound is absorbed, distributed, metabolized and excreted in a mammalian
system is important and must be explored in order to accurately establish
safety guidelines for workers and the general population.
In this study, the absorption, distribution and excretion of both 2,4DETDA and 2,6-DETDA was evaluated in young adult male Sprague Dawley
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rats. In order to perform these studies, analytical methods of detection and
quantitation (HPLC, GC, Liquid Scintillation Counting), extraction protocols,
and certain physical characteristics (pK, values, extinction coefficients,
wavelength characteristics) of DETDA needed to be known and were explored.
Ethacure was tritiated then separated into the 2,4- and 2,6-DETDA
isomers. Acetylated DETDA metabolites were synthesized and used in a
preliminary metabolism study in male Sprague Dawley rats.
Forty-eight hour distribution studies on both the 2,4- and 2,6-DETDA
isomers were earned out using the tritiated DETDA. A 6 day urinary and fecal
excretion study, including a day 6 distribution point, was also conducted on
both isomers. Lastly, covalent binding of DETDA to rat liver DNA and liver
protein was also evaluated.
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CHAPTER 1
LITERATURE REVIEW
Historical Overview of Chemical Carcinogenesis
Excessive exposure to chemical agents suspected of causing cancer
was first noted in 1761 when Hill found that usage of tobacco snuff was related
to development of nasal cancer (1.1). A few years later, Dr. Percivall Pott
found a correlation in men between chronic exposure to chimney soot and
development of scrotal cancer (1.2). A few years after Pott's findings, the
Danish chimney sweepers's guild recommended that chimney sweeps take a
daily bath to remove the soot (1.3). The success of these recommendations
became apparent a century later when Butlin found a decreased incidence of
scrotal cancer in northern European sweeps compared to English workers, who
did not regularly bathe (1.4).
By the middle of the 1800's, German factories were using aromatic
amines as precursors in the synthesis of dyes, requiring synthesis of large
quantities of these chemicals (1.5). Within 50 years, Rehn demonstrated that
chronic exposure to aromatic amines in an aniline-dye factory resulted in
urinary bladder cancer (1.6). In 1892, Butlin and others, found skin cancer to
be correlated with exposure of tars and paraffin oils in northern European
workers (1.4,1.7,1.8). These findings were noted in the British Workmen's
Compensation Act in 1907 when epitheliomas and skin ulcerations from
handling pitch and tars were added to the document (1.9). From that point on,
5

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

6

aromatic amines such as 2-naphthylamine, benzidine, and 4-aminobiphenyl
became increasingly implicated in the carcinogenic process (1.5,1.10-1.14).
In the early 1940's research on the carcinogenesis of aromatic amines
began in earnest and provided a solid foundation for the present day discipline
of chemical carcinogenesis (1.5,1.10,1.11,1.14-1.16).
Toluenediamine Characteristics
DETDA is a proprietary compound, thus there is little information in the
open literature on this material except for patents dealing with synthesis and
industrial use. Because of structural similarities to TDA (Fig. 1.1), DETDA is
expected to be absorbed, distributed, metabolized and excreted like TDA.
Each of these points as well as the carcinogenic and mutagenic properties of
2,4- and/or 2,6-TDA must be explored in order to gain insight into the potential
metabolism of DETDA.
Industrial uses of 2,4-TDA are primarily as an intermediate in the
synthesis of toluene diisocyanate, a cross-linking agent in the production of
polyurethane foam, as well as dyes used in textiles, wood stains and pigments
(1.17-1.19). As early as 1913, 2,4-TDA was the object of study by researchers
because of its widespread use and extensive worker exposure. In 1976, the
production of 2,4-TDA in the United States alone was 233 million pounds
(1.20,1.21). TDA was a component of oxidation activated hair dyes sold overthe-counter until 1971 and was used at concentrations as high at 1 mg/kg
(1.22). These hair dyes were removed from the market after Ito reported TDA
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to be carcinogenic in rodents (1.17,1.23,1.24). Later it was also found to be
mutagenic, with S-9, in the Ames test (1.22,1.25).
Pharmacokinetic aspects of chemical toxicants
Absorption
Absorption is the process whereby a substance moves across biological
membranes to gain access to the bloodstream of an organism. Pulmonary,
gastrointestinal, and dermal absorption are the three basic routes by which
xenobiotics enter the body. Other routes such as subcutaneous, intraperitoneal, and intramuscular are important in the administration of medicinal
compounds and as a route for medical research, but are generally not
applicable to TDA or DETDA.
Pulmonary absorption of 2,4-TDA
2,4-TDA is a dark brown solid material with particles ranging from submicroscopic to millimeter in size. Because much of TDA is present as a dust, it
can act as both an aerosol and particulate matter (1.25). As with all par
ticulates and aerosols, the limiting absorption parameters of the compound are
particle size and water solubility. Particles larger than 5 pm tend to be
deposited in the nasopharyngeal area. These particles are usually removed by
sneezing, coughing or swallowing. Soluble particles may be dissolved into the
mucous blanket and be absorbed into the bloodstream before it can be
removed. Particles 2-5 pm are generally deposited into the tracheobronchiolar
regions. These particle can be removed by the ciliated cells of the respiratory
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tract by generating a retrograde movement of the mucous layer. Reflex
coughing and sneezing increases the rate of removal of these particles.
Particles 1 pm or smaller migrate down to the alveolar sacs where they are
absorbed into the bloodstream or removed by macrophages and cleared by the
lymphatic system (1.26). Therefore, it is the smallest particles that generally
pose the most risk from exposure. The use of filters or respirators in high
exposure areas significantly reduces this risk. Pulmonary absorption studies of
particulate TDA have not been conducted.
DETDA is a clear amber liquid with a vapor pressure of less than 0.001
mm Hg @ 20°C (1.27). The low volatility of DETDA means that very little
compound should be present in the air of the workers environment. In the case
of DETDA as an aerosol, it would be treated as with TDA according to particle
size. Again, under normal situations, this scenario would be unlikely but could
arise during equipment or reactor malfunction. Generally this may be insig
nificant as a route of absorption.
Gastrointestinal absorption of 2,4-TDA
The movement of most toxic substances across cellular membranes
occurs by simple diffusion. This diffusion will occur primarily in the part of the
intestinal tract where the compound can exist in the non-ionized, or lipidsoluble form (1.26,1.28).
Both TDA and DETDA can be used to illustrate how the pIC, of a
compound and the pH of the organ involved can effect the absorption of that
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compound. The pK„ of the two ionizable amine groups has been empirically
determined in our lab by the titration method to be 2.6 and 5.3 for TDA and 2.5
and 4.6 for DETDA.1 In rats, the average stomach and small intestine pH was
found to be 4.4 and 6.8 respectively2 (1.29). Using the Henderson-Hasselbalch
equation (Figure 1.2), the ratio of ionized to non-ionized TDA can be
approximately determined in both the stomach and small intestine (1.26,1.28).
In the rat stomach (pH 4.4), the amine group with a pK„ of 2.6 will be 62
times as likely to be in the nonionized state, while the second amine group (pK,
of 5.3), will be 8 times as likely to be ionized. In the small intestine (pH 6.8),
the amine group with a pK, of 2.6 will be 16,667 times as likely to be in the
nonionized absorbable state, while the second amine group (pK, of 5.3), will be
31 times as likely to be nonionized. Therefore, if no other factors are involved,
TDA will be moderately absorbed from the stomach and highly absorbed from
the small intestine.
In man, gastric secretion pH levels range from 1.0-3.5 while small
intestine pH varies from 7.5-8.0 (1.30). Taking the average gastric pH from the
above values and again applying the Henderson-Hasselbalch equation, it can
be seen that differences in pH produce profound differences in theoretical
absorption (Table 1.1).

See Chapter 2 for details on titration method of determining pK, for both TDA and DETDA.
pH of both gastric and small intestinal contents will vary. Diet, stress, feeding habits and
coprophagy can greatly affect pH levels. Values used are an average from a study done
on bacterial flora of the alimentary tract.
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<pK-pH)=log S'.onizedl
[nonionized]
Figure 1.2

Henderson Hasselbalch equation used to determine ratio of
ionized to non-ionized TDA and DETDA.
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Table 1.1

Analysis of the relationship between the pK of amin$ groups and organ content pH to the differences
in theoretical absorption of TDA and DETDA.

Com pound S pecies

Organ

pKa of am ine pH of organ Ratio of ionized
Favon
contents
group
to nonionized absorpt

TDA

R at

Stom ach

2.6

4.40

0.0 16

Yes

TD A
TDA
TDA

R at
R at
R at

Stom ach
Intestine
Intestine

5.3
2.6
5.3

4.40
6.80
6.8 0

7 .9
0 .0 0 0 0 6
0.032

No
Yes
Yes

TDA

H um an

Stom ach

2 .6

2.25

2.24

No

TDA
TDA
TDA
D E TD A

H um an
H um an
Hum an
R at

Stom ach
Intestine
Intestine

2.25
7.75
7.75

1122
0 .0 0 0 0 0 7
0 .0 0 3 5

No
Yes
Yes

Stom ach

5.3
2 .6
5.3
2.5

4.40

0.0 13

DETDA
DETDA
DETDA
DETDA
DETDA

R at
R at
R at
H um an
Hum an

Stom ach
Intestine
Intestine
Stom ach
Stom ach

4 .6
2 .5
4 .6
2 .5
4.6

4.4 0
6.60
6.80
2.25
2.25

1.59

Yes
No

0 .0 0 0 0 5
0 .0 06
1.78
224

Yes
Yes
No
No

DETDA

Hum an

Intestine

2.5

7.75

0 .0 0 0 0 0 6

Yes

DETDA

Hum an

Intestine

4 .6

7.75

0 .0 0 0 7

Yes
ro
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There are however, numerous other factors involved in the absorption of
TDA firom the gastrointestinal tract. Surface area, blood flow to the area,
solubility, concentration at the site of absorption, intestinal contents, gastric
emptying time and biotransformation by gut bacteria all affect absorption to
some degree (1.31-1.33). Within these factors, however, considerable
interspecies differences can be found. For example the rat, unlike the human,
tends to have considerable bacterial flora in the forestomach and upper small
intestine with the capacity of metabolizing a compound and altering the
absorption process (1.34). Bacteria have the capability to metabolize some
compounds before absorption takes place, with the possibility of altering the
absorption process. At the same time, the absorption rate of the compound in
the small intestine will be greater than the absorption rate in the stomach even
when the compound is mostly ionized in the intestine and nonionized in the
stomach (1.31). This can be attributed mainly to the villi and microvilli
architecture of the mucosal surface of the small intestine which increases the
surface area 600-fold compared to the gastric mucosa (1.26).
In the experimental environment, factors such as stomach contents,
concentration of the compound and solubility can usually be controlled
resulting in a more standardized absorption profile. In the uncontrolled
situation, such as workers in a production facility, absorption would be
expected to be inconsistent resulting in significant differences between
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individuals. Oral dosing of the TDA compound must be considered possible
because of airborne TDA particles as well as contamination on workers hands
which may not be washed prior to hand-mouth contact.
Timchalk et al. administered 60 mg/kg [14C]-2,4-TDA orally to male
Fisher 344 rats and recovered 93% of the dose at 48 hours. Of that 93%,
fractions from urine, tissues and cage washing comprised 76%. The remaining
17% of the radioactivity was distributed in the feces (1.35). Since fecal
distribution could be a mixture of non-absorbed compound as well as
compound excreted into the bile, actual TDA absorption would be a minimum of
76% of the administered dose. Because TDA has been shown to easily
penetrate the gastrointestinal mucosa, the oral exposure was of concern as a
potential route.
Dermal absorption of 2,4-TDA
In order to understand the dermal absorption of TDA, a review of the
anatomy and physiology of skin should be undertaken (1.26,1.32,1.36,1.37).
The properties of skin allow it to be both a barrier to environmental, biological,
and chemical agents as well as a primary route for the administration of certain
medicinal compounds. A compound may enter the systemic circulation through
the skin, by first passing through the epidermis or appendages (hair follicles,
sweat glands, sebaceous glands) which are more important for ions and large
polar molecules. The skin is composed of two major divisions, the epidermis
and the dermis. The epidermis is subdivided into the stratum comeum, stratum
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granulosum, stratum spinosum and stratum germinativium. The stratum
comeum is the rate limiting barrier allowing transport only by passive diffusion.
It is a comified layer, replaced every 3-4 weeks in humans, composed of
densely packed inactive keratinized cells which have lost their nuclei. These
exfoliated cells are continually being replaced by cells stemming from the basal
layer of the epidermis. In man, the thickness of the stratum comeum varies
from 0.07 to 0.12 mm over most of the body, but can be as thick as 1.4 mm on
the soles of the feet. Polar substances probably diffuse through protein
filaments in the stratum comeum while nonpolar compounds diffuse through
the lipid matrix between the filaments, their rate limited by the lipid solubility
and molecular weight of the compound.
Once a compound passes the stratum comeum, diffusion through the
porous, aqueous lower layers of the epidermis occurs. The stratum
granulosum, spinosum and germinativum make up this lower layer which is a
very poor barrier against diffusion.
The dermis is the layer where compounds are able to enter the systemic
circulation through the vascular and/or the lymphatic system. This layer
consists of connective tissue, sebaceous glands, sweat glands and ducts,
blood vessels, capillaries, lymphatics, fat and hair follicles. The rate of
diffusion through the dermal layer depends not only on the physical
characteristics of the compound in question but on factors such as blood flow,
interstitial fluid flow, concentration gradient, area and thickness of the
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membranes involved, and the partitioning of the molecules between the
membrane and aqueous phase (1.28).
There are also many biological factors which attribute to the absorption
of a compound through the skin (1.38). Only intact skin can form an adequate
barrier to the environment. Any agent that damages or denudes the stratum
comeum (trauma, disease) will markedly increase absorption across the skin,
often as much as 100-fold. Absorption will also vary with the body site
involved, but this also depends on the type of compound in question.
The absorption of hydrocortisone has been shown to be greatest in the
scrotum, followed by forehead, scalp, back, forearm, palm and plantar surface
(1.39). With water, as the stratum comeum thickness increases, diffusivity also
increases resulting in a fairly uniform permeability (1.38). Besides the stratum
comeum thickness, the density of hair follicles, the concentration of sweat and
sebaceous glands and the amount and depth of underlying capillaries in the
skin will also modify the permeability. Species differences will also play a role
in absorption. In general, for topically applied compounds, rabbit skin is
usually the most permeable followed by rat, miniature swine, rhesus monkey
and man. The skin of monkeys and pigs seem to have absorption qualities
similar to human skin for many compounds whereas rat and rabbit skin is
generally more permeable. Bartek et al. found that the caudal back skin of the
rat was about 2-3 times as permeable as the forearm skin of man (1.40). A
study by Feldmann etal. concluded that human scalp was about 3.5 times as
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permeable as the forearm (1.39). These two studies seem to indicate that at
least, in terms of permeability, human scalp and rat skin (from the caudal back
area) seem to be similar (1.41). However, most studies involving an animal
model for human skin have followed the recommendations of the 1977
publication “The Guidelines for Preclinical and Clinical Testing of New
Medicinal Products” published by the Association of the British Pharmaceutical
Industry, which encourages the use of piglets as a human model because of
the similarities of skin structure (1.38).
Marzulli et al. found that [14C]-2,4-TDA in acetone applied topically to
monkey abdomens and human forearms resulted in 54% and 24% skin
penetration respectively (1.42). In contrast, two earlier studies involving the
closely related compound 2,5-TDA in hair dye formulations, showed absorption
rates of between 0.2% and 1% (1.43,1.44). Although there is limited data on
the dermal absorption of 2,4-TDA, these studies show that TDA can be
absorbed dermally and as such, the public should be protected from exposure
(1.24). Because of the structural similarity of DETDA to TDA, the expectation
is that DETDA will also be absorbed through the dermal route.
The skin also has the ability to metabolize or biotransform many
compounds into active or inactive metabolites. The rate and extent of
biotransformation can alter the rate and amount of parent compound entering
the systemic circulation. At the same time, blood flow through the skin affects
the percutaneous absorption of xenobiotics that penetrate the stratum
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comeum. Blood flow is a dynamic process that changes rapidly depending on
body temperature, stress, disease, and the ambient environment (1.38).
Intraperitoneal absorption of 2,4-TDA
As mentioned before, the i.p. route is used by both researchers and the
medical community for the quick administration of compounds into the
circulatory system. This route results in the rapid absorption of the compound
because of the vast surface area and rich blood supply of the peritoneal cavity.
These compounds are absorbed primarily by uptake through the portal
circulation and must therefore make a first pass through the liver before
entering the systemic circulation. In some cases, this “first pass effect” can
completely extract and metabolize a compound, precluding access to the
general circulation and the other organ systems.
Intravenous administration of 2,4-TDA
The i.v. route of administration totally eliminates the absorption factor
because the compound is introduced directly into the systemic circulation
giving it almost instantaneous access to any body organ. This route is
especially useful in research because it allows the elimination of absorption
factors which can be difficult to quantify.

Pisftibntign
Once access to the systemic circulation occurs, either through
absorption or i.v. administration, the compound is distributed throughout the
body tissues. Distribution is generally a fairly rapid process but depends

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

19

largely on tissue blood flow and the rate of diffusion of the compound from the
capillary beds into the tissue cells. Other factors involved are mass of the
target tissue relative to body weight, pH of the body fluids involved, lipid
solubility and molecular weight of the compound, degree of ionization and
binding affinity for plasma and tissue proteins.
There is a significant difference in the rate of blood flow to tissues
(1.26,1.31,1.45). The heart, liver, kidneys, and brain receive large quantities of
blood relative to their body weight. In contrast, muscle, fat, skin, and much of
the viscera receive markedly less. Blood flow to each tissue, however, will vary
depending on the body functions occurring at the time.
Each capillary bed is fed by an arteriole and drained by a venule. Blood
flows intermittently through these capillaries by contractions of metarteriole and
precapillary sphincters controlled primarily by oxygen concentration. For lipidsoluble substances, the compound can rapidly diffuse across the capillary
membrane directly and mix with interstitial fluid and plasma. Small watersoluble substances and ions, on the other hand, are thought to pass through
intercellular clefts or pores between adjacent capillary endothelial cells. Very
polar molecules and larger ions, because they are surrounded by a hydration
shell, utilize special transport mechanisms in order to traverse the membrane.
These water soluble molecules are also excluded from the central nervous
system by the blood-brain barrier. The actual rate of diffusion is proportional to
the difference of the concentration of the compound on both sides of the
capillary cell membrane (1.46).
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The concentration of a compound in the blood of an animal depends on
the volume of distribution of that compound. Body water can be broken down
into three groups: plasma water, interstitial water, and intracellular water. The
distribution of a compound in the body is complex and usually associated with
more than one compartment. Lipid soluble compounds, because of their
nature, distribute easily into the interstitial and intracellular compartments.
Lipid-insoluble compounds, on the other hand, have a very limited distribution
pattern because of the associated problems with membrane permeability.
Tissue binding and tissue reservoirs can also dramatically affect
distribution of a compound. The binding of certain compounds to plasma
proteins, weak acids to albumin and weak bases to c^-acid glycoproteins, can
significantly limit their distribution since only the unbound or free-fraction of a
drug or compound is in equilibrium with the plasma membrane. The high
molecular weight of a compound-protein complex prevents it from freely
crossing the capillary cell membrane therefore preventing distribution into other
compartments.
Tissues with a high percentage of body mass (muscle, fat, bone) can
often act as a reservoir or storage depot. A compound in a tissue depot will be
in equilibrium with the free-fraction of the compound located in the plasma. As
the concentration of compound in plasma decreases, due to metabolism or
excretion, more compound is released from the reservoir to restore the
equilibrium. This same reservoir concept also occurs with plasma proteins
since the ligand-protein complex is a reversible process (1.26,1.31).
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The binding of a compound to plasma proteins can be determined using
a Scatchard plot (1.26,1.47). The bound to free-ligand ratio is plotted on the
ordinate while the concentration of bound ligand is plotted on the abscissa.
From this plot, the number of ligand binding sites per molecule of protein as
well as the affinity constant (k,) for the ligand-protein complex can be
determined. Non-linearity of the plot is indicative of more than one type of
binding site each with different affinities.
Unger et al. evaluated 23 tissues plus blood and feces after i.p. dosing
with 2,4-[14C]TDA (1.19). For the majority of tissues sampled, the greatest
amount of radioactivity was recorded at the 1 hour time point. Exceptions were
the gonads, kidney, lung, muscle, blood and epididymis which had highest
levels at 0.5 hours while the large intestine and aorta showed highest levels at
the 2 hour time point. As expected, high blood flow areas tend to have high
concentrations per gram of tissue as seen with the liver, kidney and adrenal
gland levels. High concentrations in the intestinal tract are probably indicative
of biliary excretion into the small intestine. In the tissues evaluated, not
counting the intestines and their contents, the liver had the greatest percentage
of dose followed by the muscle and skin. These three tissues have all
developed tumors upon exposure to 2,4-TDA.
At the same time, Grantham et al. were comparing the metabolism of
rats and mice after administering an i.p. dose of [14C]-2,4-TDA (1.48). Although
only a few tissues were evaluated in this study, the higher concentrations were
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again recorded in the liver and kidney. Interestingly, at 24 hours after dosing,
the rats had significantly higher tissue concentrations of 2,4-TDA compared to
mice, presumably because of the lower excretion rate in rats.
These two studies provide the only detailed information on the
distribution of TDA in the mammalian system. Comparisons between oral,
dermal, I.P. and I.V. dosing have not been undertaken. Because of the
carcinogenic and mutagenic properties of 2,4-TDA, comparative studies in man
are unavailable.
DETDA is expected to closely follow the distribution pattern of TDA
because of similar structure and properties (pk,, solubility, molecular weight).
The difference in TDA distribution between rats and mice may be an indication
that DETDA distribution may also differ within animal models.

Metabolism
The animal kingdom is constantly being exposed to a wide array of
chemical agents. The fate of these agents is either elimination or accumulation
in the organism. Some compounds can be eliminated entirely unchanged in
the urine, bile, feces, milk, expired air, perspiration and saliva. These are
predominately water soluble substances. Lipophilic compounds, even if
excreted, are able to readily cross cell membranes and be reabsorbed into the
body. Over time, some lipophilic substances will accumulate in high
concentrations in selected tissues often causing detrimental effects in the
organism. Fortunately, the body has been provided with enzyme systems that
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are capable of making lipophilic substances more hydrophilic, allowing them to
be readily excreted. This process, termed biotransformation, often involves
more than one enzymatic process chemically modifying the parent compound
at one or more positions producing a chemically distinct compound, or
metabolite, which is usually more water soluble and less likely to be
reabsorbed.
There are basically two types of biotransformation reactions: phase I
reactions and phase II reactions (1.49). Phase I generally involve oxidation,
reduction or hydrolysis of the compound which adds or uncovers functional
groups on the molecule. Phase II enzyme systems utilize these functional
groups as sites for conjugation or synthesis reactions.
Biotransformation enzymes are located in multiple organ systems
including the liver, lung, kidney, intestines, skin, adrenal glands, placenta and
testes. The primary organ involved in metabolism is the liver since it is the first
line of defense for compounds entering the body through the intestinal or
intraperitoneal route of administration. Many compounds entering through the
dermal or respiratory route will eventually also pass through the liver as they
gain access to the general circulation.
It should be remembered that biotransformation of foreign compounds is
an integrated process between phase I and phase II enzymes even though the
discussion of each system and its components will be individualized for clarity.
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Phase I enzyme reaction
The biotransformation pathway which can add a functional group to a
compound is carried out by either the mixed-function oxidase (MFO), flavinmonooxygenase (FMO) or peroxidase-based co-oxidation system. Numerous
oxidation-reduction reactions are also carried out by enzymes as part of the
phase I system.
Mixed-Function Oxidase Systems
The MFO system is composed of two enzymes: NADPH-cytochrome P450 reductase and cytochrome P-450, a heme-containing enzyme, both
contained within the phospholipid membrane of the endoplasmic reticulum.
With the exception of red blood cells and skeletal muscle, cytochrome P-450
has been found in all body tissue cells. More than 40 cytochrome P450 genes
expressing different protein enzymes have been isolated in the rat while more
than 20 different proteins are encoded by the multi-gene family in humans
(1.49-1.52). The most common isoform involved in aromatic amine metabolism
is the PAH and isosafrole inducible CYP1A2 ( P-450 1A2, rat p-450d, mouse
P3-450, rabbit LM4, human HLd or P450PA) enzyme which can catalyze,
among others, the N-oxidation reaction (1.52-1.54). In some instances the
CYP1A1( P-450 1A1, p-450c) isoform is also able to catalyze N-oxidation
reactions on aromatic amines but probably is involved more in the oxidation
reactions of polycyclic aromatic hydrocarbon compounds (1.55,1.56). This
generality depends on the substrate or compound oxidized and the species
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involved in the reaction. In the past, the cytochrome P450 system was thought
to be more involved in the N-hyroxylation of primary arylamines whereas the
FMO system was more involved in secondary and tertiary arylamines (1.57).
This should be taken only as a generality as the FMO system has been shown
to catalyze all three classes of amines (1.49).
Concerning 2,4-TDA, Cunningham et al. found that the cytochrome P450 enzyme produced an N-hydroxylated intermediate, probably at the 4
position, which was subsequently acetylated resulting in a mutagenic
metabolite. Because induction by (3-naphthoflavone caused an increased
mutagenicity with 2,4-TDA in the TA98 Ames tester strain, the P4501A1
enzyme isomer is thought to catalyze the hydroxylation reaction (1.17,1.58).
Whether the P4501A2 isomer, generally thought to catalyze most primary
arylamines, was also involved in the hydroxylation was not mentioned.
As with most aromatic amines, DETDA is expected to undergo some
degree of N-hydroxylation reactions. However, it is unknown at this time what
effect the ethyl groups will have on this reaction. With the 2,4-DETDA isomer,
any N-hydroxylation reaction will probably favor the 2 amine over the 4 amine
because of the ortho positioned ethyl groups.
In the 2,4-TDA compound, there are 3 ring positions (3, 5 and 6)
capable of being hydroxylated. Waring et al. showed that orally administered
2,4-TDA resulted in aromatic or ring hydroxylation occurring at all three of
these positions (1.18,1.48). Similar results were seen with 2,6-TDA, where
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both ring hydroxylation (3 and 5 positions) and acetylated amino group
metabolites were detected in urine samples following exposure in male F344
rats (1.59). N-hydroxylation of the amine groups was probably a prerequisite to
the acetylated metabolites produced (1.11,1.60).
In addition to aromatic ring and N-hydroxylation reactions, alkyl or Coxidation can be a route of detoxification when alkyl groups are present on the
compound. This can occur at the last or next-to-last carbon as an oxygen atom
is inserted into the carbon-hydrogen bond (1.49).
In the mouse, Grantham et al. discovered that C-oxidation of the TDA
methyl group forming benzoic acid metabolites was a major reaction pathway.
These metabolites often formed glycine conjugates prior to excretion (1.48). In
another study, the rat, guinea pig and rabbit produced no detectable amounts
of benzoic acid metabolites.
With DETDA, both methyl and ethyl alkyl groups are present on the
aromatic ring. C-hydroxylation on the benzylic carbon of the ethyl groups is
expected to occur with probable conjugation reactions involving glucuronidation
and/or sulfation following. Oxidation of the methyl group to a benzoic acid
metabolite is also expected.
These studies suggest that the phase I cytochrome P450 enzyme
system does play a significant role in the disposition of both 2,4- and 2,6-TDA.
DETDA is expected to undergo phase I enzymatic reactions producing many of
the same metabolites seen with TDA.
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Flavin Monooxvaenase System
The NADPH-dependent FMO system has been isolated from a number
of species including the rat, mouse, pig, rabbit and human. The amount of
enzyme is usually highest in the liver but does vary from species to species.
The mechanism of action differs considerably from the P450 enzyme in which
there is an initial binding of the substrate to the enzyme forming a complex in
which oxygen binds to a reduced iron molecule. With FMO, oxygen first binds
to the hydroperoxyflavin then later transfers to the substrate. In this reaction
there is no need for an activated substrate, therefore any electron-rich
compound that can be oxidized by a hydroperoxide may possibly serve as a
substrate (1.51,1.61). The FMO system is more likely to catalyze a secondary
or tertiary amine compound but definitely has the capability to utilize a primary
amine as a substrate (1.49). Therefore, both TDA and DETDA could possibly
utilize this enzyme as an avenue to N-hydroxylation. No published data is
available at this time concerning TDA or DETDA as a substrate for the MFO
system.
Phase II enzyme reactions
The phase II biotransformation system involves a number of biosynthetic
conjugation reactions requiring activated cofactors or substrates. These
energy requiring reactions involve the linking of an endogenous moiety to the
compound or metabolite of interest generally leading to detoxification and
excretion. A wide range of functional groups are derivatized by these enzymes
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including: -OH, -COOH, -NH2, -NR2, -SH and epoxides (1.62). However, in
some cases, these conjugation reactions can produce metabolically activated
compounds capable of binding to DNA, RNA, proteins and other tissue
nucleophiles. There are eight classical conjugation reactions: glucuronidation,
glucose conjugation, sulfation, methylation, acetylation, cyanide detoxication,
glutathione conjugation and amino acid conjugation (1.62,1.63). For the
purpose of this project only four reactions will be reviewed: glucuronidation,
sulfation, acetylation and glutathione conjugation.
UDP-Glucuronosvltransferase
Unlike most phase II cytosolic enzymes, UDPGT (uridine diphosphate
glucuronosyltransferase) is localized in the endoplasmic reticulum. This
enzyme catalyzes the reaction between a high-energy nucleotide, UDPglucuronic acid, and the compound's functional group, usually -OH, -COOH, or
-NH2. The resulting conjugate is a more polar, water-soluble compound
capable of being excreted in the urine or bile. Highest activity is in the liver
followed by kidney and intestinal mucosa. There are two gene superfamilies in
the human enzyme, UGT1A and UGT2A/UGT2B, which catalyze phenols,
arylamines, bilirubin and endogenous or exogenous steroids. Glucuronidation
is considered to be a high-capacity but low affinity conjugation reaction
(1.49,1.50,1.62).
N-hydroxylated arylamine metabolites produced by the P-450 enzyme
system have been shown to be N-glucuronidated in the liver before being
excreted in the urine. These N-glucuronides are slower to be hydrolyzed by
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3-glucuronidase than 0- or S-glucuronide species making them more stable
metabolites(1.49). Although O-glucuronidation does occur with arylamines,
Kadlubar et al. found this to be a minor pathway with compounds such as the
hydroxylamines of napthylamine, aminobiphenyl, aminofluorene and
aminoazobenzene (1.64). Differences between species and substrate
specificities in the N-glucuronidation of arylamines were also pointed out. For
most of the arylamines tested, the human enzymes had lower activity than
those of dogs and rats. Some species appear to fail to glucuronidate
xenobiotics (1.49). The domestic cat, lion, lynx, and Gunn rat are unable to
form glucuronides of phenol, naphthol and other phenol derivatives.
Glucuronidation of TDA (molecular weight 140) produces a glucuronic
acid conjugate with a molecular weight of 332. Glucuronides of molecular
weight less than 250 are generally excreted in the urine while molecular
weights greater than 350 are usually excreted in the bile. These weights are
nominal and do vary among species. It is expected with TDA that most
glucuronic acid conjugates would be excreted in the urine. With DETDA, this
may not be the case because of the slightly higher molecular weight.
Grantham et al. compared urinary metabolites in the rat vs. mouse after
the administration of an i.p. dose of [14C]-2,4-toluenediamine (1.1 pCi/mg,
77mg/kg body wt). They found that metabolite conjugation with glucuronides
was more than doubled in mice over rats (17.4% of the administered dose vs.
7.5%) (1.48,1.65). Waring ef al. compared metabolites in rabbits, rats and
guinea-pigs after oral dosing of 50mg/kg of 2,4-TDA. Glucuronides amounted
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to 46%, 34% and 65% respectively after 48 hour urine collection. There
appears to be greater glucuronidation upon oral dosing compared to
intraperitoneal injection (1.18). For TDA in rodents, glucuronidation plays a
significant role in the detoxification of the compound (1.65). This is due to a
plethora of functional groups made available by phenolic and N-hydroxylated
metabolites produced by phase I reactions. With orally administered DETDA
ring hydroxylated species should be minimal but C- and N-hydroxylation may
occur resulting in glucuronide metabolites similar to TDA.
Sulfotransferase
This cytosolic enzyme has been isolated in a number of organs including
the liver, kidney, intestines and lungs (1.66). Sulfotransferase is involved in
the formation of sulfate monoesters with compounds having an available
hydroxyl group. These compounds can be phenols or phenolic groups,
alcohols, hydroxylamines, hydroxysteroids, bile salts, and arylamines. As with
glucuronidation, a donor group is required. In this case, the sulfate donor is
provided by the cofactor 3'-phosphoadenosine-5’-phosphosulfate (PAPS).
PAPS synthesis is a two-step process involving ATP sulfurylase and adenosine
5'-phosphosulfate kinase. ATP sulfurylase first forms adenosine 5phosphosulfate (APS) from inorganic sulfate (obtained from the oxidation of
cysteine) and ATP. Next adenosine 5'-phosphosulfate kinase adds a
phosphate group from ATP to the 3'-position of APS producing the needed
cofactor.
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Detoxifying sulfotransferases have been classified into four groups: aryl
sulfotransferase, hydroxysteroid sulfotransferase, estrone sulfotransferase, and
bile salt sulfotransferase. Of these groups, aryl sulfotransferase is of interest
because of its ability to conjugate phenols and hydroxylamines. This enzyme
is a high-affinity, low capacity system. In low substrate concentrations, sulfate
esters may be the predominant conjugate, but as the concentration of substrate
increases, glucuronides would predominate due to the higher capacity of the
glucuronidation enzyme system. The pig, opossum, and brachymorphic mice
have been found to be deficient in sulfotransferase enzyme activity. The
predominant route of excretion of sulfate esters appears to be urine
(1.49,1.62,1.67).
Grantham et al. compared urinary metabolites in the rat and mouse after
the administration of an i.p. dose of [14C]-2,4-toluenediamine (1.1 pCi/mg, 77
mg/kg body wt). They found sulfate conjugation was almost the same in rats
and mice (10.1% of the administered dose vs. 9.6%) (1.48). No other studies
were found detailing sulfate conjugation with TDA. DETDA is expected to
undergo sulfate conjugation in similar manner to TDA.
Acetyl Transferases
Acetylation is a major pathway for the biotransformation of many
arylamine compounds earned out by a cytosolic acetyltransferase enzyme.
Arylamine N-acetylation, arylhydroxylamine O-acetylation and N,0acetyltransfer of arylhydroxamic acids has been shown to occur from a single
32 kDa protein in rat liver cytosol (1.68).
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The N-acetylation of arylamines is a two-step process. First, the acetyl
group from the needed cofactor, acetyl coenzyme A, transfers to the N-acetyl
transferase enzyme forming an acetyl-N-acetyl transferase. Secondly, the
amino group of the arylamine compound is acetylated with subsequent enzyme
regeneration (1.49,1.69).
Both the dog and fox are deficient in the N-acetyl transferase enzyme,
and therefore acetylate arylamine compounds poorly. Other species show
differing levels of N-acetylation activity, for example, hamster liver cytosol has
shown the greatest activity followed by guinea pig, rabbit, mouse and rat
(1.62,1.70-1.73). Within species, extrahepatic N-acetyl transferase activity
varies greatly among tissues. In rabbits, the highest levels have been found in
duodenum and lung with decreasing levels in thymus, ovary, spleen, uterus,
adrenals, leukocytes, kidney, bone marrow, salivary gland, pancreas,
erythrocytes and brain (1.69).
Acetylation polymorphism has been reported in the human, mouse,
rhesus monkey and hamster. This genetic based polymorphism is usually
classified as “fast” or “slow" based on the enzymes ability to acetylate
isoniazid, sulfamethazine and other compounds (1.49,1.69,1.74,1.75). In
humans, hepatic N-acetyltransferase polymorphism has been linked to two
alleles at a single autosomal gene locus (1.75,1.76).
With many compounds, biotransformation does not always lead to
detoxification. In these situations, metabolism can produce a genotoxic
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compound. Human studies have demonstrated an association between rapid
acetylators and colo-rectal cancer and slow acetyiators and urinary bladder
cancer (1.64,1.68,1.74,1.77-1.82).
Dogs, which are very poor acetylators, are prone to bladder tumors upon
administration of carcinogenic aromatic amines making them good animal
models for slow acetylators in man (1.83). Lower et al. found that various
arylamines administered to dogs produced urinary bladder tumors, suggesting
that N-acetylation was not required in their formation (1.73). A later study
involving administration of carcinogenic arylacetamides to dogs resulted in
both bladder and liver tumors when the substrate was specific for
arylacetamide deacetylase enzyme systems (1.84). This study seemed to
indicate that the absense of the acetyl group was necessary for bladder tumor
formation.
In humans, acetylation polymorphism has resulted in fairly predictable
patterns of toxicity and tumor formation. In “slow acetylator” individuals,
isoniazid exposure often resulted in peripheral neuropathies while the
consequences for exposure in “rapid acetylators” was hepatitis
(1.69,1.82,1.85-1.90). It now appears as though “slow acetylators” may be at
higher risk for bladder cancer when exposed to carcinogenic arylamines (1.82).
In contrast, llett et al. showed a correlation between “rapid acetylators” and
colorectal carcinomas in 49 cancer patients (1.74).
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Multiple studies in rats have shown the relevance of N-acetylation in the
metabolism of toluenediamine. In two separate studies in Fischer 344 male
rats, Grantham et al. reported that 4-acetylamino-2-aminotoluene (5.7% and
5.2% of dose) and the 2,4-diacetylaminotoluene (2.6% and 1.4% of dose) were
significant urinary excretion products (1.48,1.65). Waring et al. found a high
percentage of phenolic metabolites and less than 3% mono- and di-acetylated
products in female Wistar rats (1.18). Timchalk et al. found comparable levels
of free 2,4-TDA and acetylated metabolites when oral and i.v. 3 mg [14C]-2,4TDA/kg were administered to Fischer 344 rats (1.35). Comparing the ratio
between free plus acetylated 2,4-TDA to total acid-labile metabilites they found
61% of detected metabolites as free or acetylated and 39% as other conjugates
when administered a 60 mg/kg oral dose while a 3 mg/kg dose resulted in
about 85% free and acetylated metabolites. From this study, lower in vivo
exposure levels seem to result in acetylation as the primary conjugation
reaction.
Using hamster liver cytosol, Glinsukon etal. found 2,4-TDA metabolized
to 3 acetylaminotoluene products. The primary metabolite was 4-acetylamino2-aminotoluene of which a small percentage was then metabolized to 2,4diacetylaminotoluene. The 2-acetylamino-4-aminotoluene was also found to be
further metabolized to 2,4-diacetylaminotoluene (1.91). From all indications, it
appears that the monoacetyl metabolite, 2-acetylamino-4-aminotoluene is only
a very minor metabolite and is probably further metabolized to the diacetylaminotoluene product.
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Kawakubo et al. studied the acetyltransferase activity of hamster skin in
arylamine metabolism (1.92). In their study, arylamine N-acetylation, 0acetylation of N-hydroxyarylamine and N,0-acetyltransfer of arylhydroxamic
acids were all demonstrated using hamster skin cytosol. A later study showed
human skin has a N-acetyltransferase activity comparable with hamster skin.
In the study, skin N-acetyltransferase activity was higher than liver activity and
seemed to indicate that a polymorphic acetylation was occuring with an
arylamine substrate (1.93).
At one time, skin was thought to be primarily a mechanical barrier
against hazardous chemicals. Studies now show that skin is a very com
plicated multifunctional organ with metabolic capabilities. Dermal exposure to
Ethacure could allow skin N-acetyltransferase enzyme systems to play a role in
biotransformation. This implies that the skin could either activate or inactivate
DETDA before it has a chance to enter the systemic circulation. As with most
arylamine compounds, skin exposure to Ethacure must be kept to a minimum.

Exgretipn
When a chemical is eliminated from the body, it does so either
unchanged or as a metabolite. The most important routes of excretion are
urinary and fecal. However the lung, sweat, milk, saliva, and tears are capable
of some excretion, generally in a minor capacity. In order for a compound to be
efficiently excreted from the body, it must be relatively polar. Biotransformation
reactions transform lipid soluble compounds into more polar substances
allowing for excretion.
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Urinary excretion
The kidney is generally thought of as the major organ for the excretion of
toxic compounds. Three processes are involved in renal excretion: glomerular
filtration, active tubular secretion, and passive tubular reabsorption (1.31,1.941.96).
Glomerular filtration
Approximately one-fifth of the total cardiac output flows through the
kidneys at any given time. As the blood flows through the glomerulus, plasma
is filtered through the glomerular membrane into Bowman’s capsule forming the
glomerular filtrate. Because of the glomerular membrane pore size,
substances larger than a molecular weight of 69,000 are excluded from the
filtrate. This molecular seive prevents virtually all plasma proteins from
becoming part of the filtrate while many smaller peptides are allowed to pass
through. The binding of xenobiotics to proteins greater than 69,000 can also
alter the rate of filtration as they are prevented from passing through the
glomerulus.
Active tubular secretion
Active tubular transport systems are located in the basolateral
membranes of the proximal kidney tubules. There are separate transport
systems for organic acids (anions) and organic bases (cations). As an active
transport system, the degree of secretion is a function of the number of binding
sites available to the xenobiotic. This means that other compounds capable of
binding to those sites will compete with the xenobiotic thus inhibiting its
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secretion. Protein-bound xenobiotics can be actively transported across the
tubular cells allowing them to be excreted into the renal tubules.
Passive Tubular Reabsorption
After glomerular filtration and secretion of the compound from the
peritubular capillaries, the nonionized forms of weak acids and bases are
passively reabsorbed, primarily in the distal tubules. The xenobiotic in the
lumen becomes more concentrated because of the efficient reabsorption of
water in the tubules. As a result, a concentration gradient is established
between the compound in the tubule lumen and the free compound in the
plasma. The pH of the tubular fluid directly affects the absorption. In an
alkaline urine, weak acids are rapidly excreted and poorly re-absorbed
because of ionization. In an acidic urine, weak acids are rapidly re-absorbed
and poorly excreted. The opposite effects occur when weak bases are
subjected to the same conditions. Strong acids and bases are ionized at
urinary pH and are almost totally excreted. As would be expected,
reabsorption also increases with lipid solubility.
The end result of these excretion mechanisms is the removal of a
constant fraction of the compound as blood flows through the kidneys.
Fecal excretion
Excretion in the feces is the other major pathway used by the body to
eliminate xenobiotics. Fecal excretion is comprised of three main components:
nonabsorbed compound, biliary excretion, and intestinal excretion (1.26,1.31,
1.97,1.98).
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Nonabsorbed compound
The absorption of a compound from the gastrointestinal tract is related
to the lipophilicity of that compound. Most drugs and chemicals have at least
some degree of lipophilicity, and are capable of being absorbed to some
extent. It is unlikely that any compound will be totally absorbed, the balance
contributing to fecal excretion.
Biliary excretion
The biliary system, as a component of fecal excretion, contributes
greatly to the removal of xenobiotics and their metabolites. The liver receives
both arterial blood from the general circulation and portal venous blood from
the intestinal system. This allows the liver to remove compounds entering the
body from the intestines as well as other routes. The removal by the liver of
compounds absorbed from the intestine before reaching the systemic
circulation is refered to as the “first-pass effect”. This often allows an ingested
toxic compound to be removed before it can be distributed to other parts of the
body.
As compounds are biotransformed in the liver, more water soluble and
excretable metabolites are generally formed. These metabolites are then
excreted directly into the bile or passed through the kidneys for elimination.
The molecular weight of the parent compound or metabolite plays a significant
role in the route of elimination. There is however, considerable species
variation in these molecular weight ranges (1 99). Low molecular weight
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compounds are generally excreted into the urine while those with weight above
about 325 generally are excreted into bile. For the most part, large
amphipathic molecules tend to be excreted through biliary transport. The
excretion of compounds into bile involves at least four transport systems, two
systems for organic acids, one for organic bases, and one for neutral
compounds (1.26,1.97). Analogous to renal tubular transport systems, similar
compounds can compete for binding sites inhibiting excretion into the bile.
Some xenobiotics are removed from the systemic circulation by binding
to intracellular proteins such as ligandin and metallothionein. The binding of
the protein to the agent, while protecting cellular organelles from toxic effects,
can sometimes restrict elimination into bile.
Intestinal excretion
In some situations, a xenobiotic can be directly transfered into the
intestinal lumen from the blood, probably through passive diffusion (1.98).
Compounds excreted into the bile are not always eliminated from the
body. The hydrolysis of conjuated xenobiotics by intestinal bacteria can
transform the polar compound into a much more lipophilic one allowing for
reabsorption. This process have been termed “enterohepatic circulation” and it
often results in higher blood levels or longer half-lives for the compound than
would ordinarily be expected (1.26,1.97).
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Toluenediamine elimination
Grantham et at. studied metabolism in male Fischer rats using an i.p.
dose of radiolabeled 2,4-TDA (1.65). By the fifth day 98.6% of the dose was
recovered with 76.4% excreted into the urine and 22.2% in the feces. At the 24
hour time point (81% recovery), 73% was urinary excretion and 8% fecal.
Later Grantham etat. looked at the excretion levels of 2,4-TDA in both
male Fischer rats and male NIH Swiss strain mice after i.p. dosing (1.48).
Results revealed that almost 90% of radioactivity versus 74% was excreted in
the urine of mice and rats respectively by the end of the experiment. Most of
the urinary elimination was complete by 24 hours in both species while total
excretion of radioactivity took only 48 hours in the mice compared to 6 days in
the rats. Fecal excretion, as a percent of dose, was greater in rats than mice.
After 24 hours, fecal excretion became the primary route of excretion in the rat.
Unger et at. also looked at excretion of 2,4-TDA in mice for 24 hours
after i.p. administration (1.19). One hour after dosing, almost 50% of the label
was excreted into the urine with a total of about 52% at 24 hours. Fecal
excretion accounted for 22% of the label at the 24 hour period. Again it
appears as though excretion shifts from urinary to fecal a few hours after a
single i.p. dose. Urinary excretion was much less in the mouse than in the
Grantham et al. study where approximately 90% of the dose was excreted in
the urine by the 24 hour time point.
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Grantham’s results seemed to be confirmed in an i.p. 2,4-TDA study by
Reddy et al. in male F344 rats. At 24 hours, about 70% of the administered
dose was recovered in the urine (1.100).
When 2,4-TDA was administered orally or i.v. to F344 rats, urine
excretion accounted for 64-72% of the dose while 20-31 % was recovered in the
feces (1.35). There was no significant difference between a high and low dose
oral administration of 2,4-TDA. Again with this study, the major excretion
pathway was the urinary system and not the biliary system.
Cunningham et al. administered radiolabeled 2,6-TDA to male F344 rats
by gavage (1.59). By 24 hours, about 86% of the label was recovered in the
urine and less than 5% in the feces. By 72 hours, almost all label had been
recovered with about 90% and 10% accounted for by urine and feces
respectively.
The 2,6-TDA isomer appears to have a higher urinary excretion rate
than 2,4-TDA. Both isomers, however, appear to be rapidly excreted with the
majority of compound eliminated by 24 hours.
Mutagenesis
Introduction
Mutagenesis can be defined as the induction of DNA damage resulting
in genetic alterations ranging from simple changes in DNA base pairs (gene
mutations) to changes in chromosome structure (aberrations) or chromosome
number. Early research in mutagenesis centered around the discovery that
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ionizing radiation induced mutations in Drosophila melanogaster. Mutations
are now and will always be of vital interest because of potential impact on
future generations. Mutations may involve either germ cells or somatic cells or
both. Germ cell mutations may result in an increased incidence of genetic
diseases in successive generations. Somatic mutations are believed to be an
initial step in carcinogenesis.
Gene or point mutations
Point mutations are changes that occur in the DNA sequence within a
gene. They are generally classified as either base-pair substitutions or frameshift mutations.
In a base-pair substitution, the replacement of one base pair for another
occurs (ex. G C by A T). Base-pair substitutions are either transitions or
transversions. In a transition, the purine.pyrimidine orientation does not
change (i.e. guanine is replaced by an adenine) while in a transversion, a
purine would be replaced by a pyrimidine or vice versa (i.e. guanine is replaced
with a thymine or cytosine). Chemical and physical mutagens often result in
point mutations.
Frame-shift mutations can occur when base pairs are either losts or
gained within a gene. The addition or deletion can cause a shift in the reading
frame of the mRNA produced from an altered DNA template resulting in the
failure to produce a functional protein.
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Chromosome aberrations
An aberration occurs when a mutation involves a change in the structure
of a chromosome. An aberration may occur in only a small segment of a
chromosome, on a single chromatid, or an entire chromosome. The changes
associated with the mutation can be stable or unstable. Stable aberrations can
be passed on through cell division becoming a permanent part of the cell
population. The more common examples of stable mutations are deletions,
duplications, inversions and translocations. These mutations may involve large
segments of DNA encoding many genes. Unstable aberrations usually result in
cell death because of the loss of needed genetic material. Evidence is often
present as an acentric fragment, a ringed structure or dicentric chromosome.
Unstable aberrations are easily detected and often used as evidence of
chromosome damage or breakage (1.101,1.102).
Chromosome number
Mutagenic events can also lead to changes in chromosome number.
When one or a few chromosomes are involved, the condition is termed
aneuploidy. When complete sets of chromosomes are involved, the term is
polyploidy (1.101). These types of mutations are generally referred to as
numerical chromosome aberrations in contrast to the previously discussed
structural aberrations.
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A mutagen exerts its effect on an organism by altering the structure of its
DNA. This alteration can be either physical, chemical or both in nature. With
chemical mutagens, adduct formation is one possible result, that is the addition
of some electrophilic product to the nucleophilic DNA structure. In some
circumstances, DNA-adducts with aromatic amine compounds have been
shown to result in transversion mutations. Activated aflatoxin B, induced G C
to T A transversions possibly due to apurinic sites created within the DNA
(1.103).
Aromatic amines were some of the earliest chemicals found to be
carcinogenic. Years later that carcinogenicity was found to be linked to the
formation of arylamine-DNA adducts (1.5). For the most part, the major sites
for arylamine-DNA adducts have been the C8, N2 and O6 positions of guanine.
The N6and C8 position of adenine occurs much less frequently (1.104,1.105).
Beland et al. examined a variety of N-hydroxylated arylamine compounds for
DNA adduct formation relative to bladder cancer (1.106). In their study, the
predominant adducts were C8 deoxyguanosine derivatives. They also found
that these adducts resulted in frameshift mutations in the TA1538 strain of
Salmonella typhimurium. Humphreys et al., in their work with aminofluorene,
found evidence that these C8-guanine-arylamine adducts were formed through
an intermediate N7-adduct utilizing an S,^ mechanism (1.105,1.107,1.108).
Although the C8-guanine is prevelant in arylamine reactions, it is by no means
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the only adduct formed (1.109). Kadlubar et al. showed N-hydroxy-2naphthylamine to react at the N2and C8 position of guanine as well as the N6
position of adenine in contrast to N-hydroxy-1-naphthylamine which forms
primarily 0 6-guanine adducts (1.110,1.111). In their in vitro study, the C8
adducts, comprising about 50% of the DNA binding, were found in both ringopen and ring-closed forms. Beland et al. examined a number of arylamine
compounds including 1- and 2-naphthylamine, 4-aminobiphenyl and 4acetylaminobiphenyl, 4-acetylamino-4'-fluorobiphenyl, 3,2'-dimethyl-4aminobiphenyl, 2-acetylaminofluorene, benzidine and 2-acetylaminophenanthrene (1.104). DNA adducts included deoxyguanosin-C8-, N2-, and
0 6-derivatives, as well as deoxyadenosin-N6- and C8-derivatives.
Alterations in the DNA can also occur by non-covalent interactions with
compounds. This transpires with the intercalation of xenobiotics between
adjacent stacked base pairs in the double helix causing the DNA to unwind at
that site. Intercalation usually occurs with planar aromatic compounds rather
than bulky PAH type compounds. The resulting physical distortion of the DNA
helix is thought to lead to the deletion or insertion of base pairs during DNA
replication occasionally resulting in frame-shift mutations (1.101,1.112).
Freund et al. found that DNA sequences capable of transformation into the ZDNA conformation may be hot spots for spontaneous deletions (1.113). Ames
et al. looked at a number of known carcinogenic aromatic amine compounds
and their metabolites and found them to be potent frameshift mutagens for
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Salmonella typhimurium (1.114). They also found that when the intercalating
agent had side chain groups which were covalently bound to DNA, its potency
as a frameshift mutagen was often dramatically increased.
Mutagenicity of 2.4- and 2.6-Toluenediamine
For years researchers have recognized both 2,4- and 2,6-TDA as
mutagenic compounds. Early studies in rats also confirmed that the 2,4-isomer
was carcinogenic in a number of organ systems (1.20,1.23). TDA has been
studied in a number of bacterial and mammalian mutagenicity tests with
contrasting results. Also, correlation of mutagenicity test results with
carcinogenicity has been somewhat equivocal in many of the tests.
Basic mutagenicity tests
Tests for mutagenicity of natural substances, chemicals and
pharmaceuticals is now a standard component of toxicology. Multiple
experimental platforms have been used including bacteria, viruses, fungus,
cultured plant and animal cells, insects and animals. Dozens of tests have
been developed but most mutagenicity testing is carried out with a small
battery of standardized tests. Test procedures relative to the mutagenicity of
2.4- and 2,6-toluenediamine are reviewed below.
2.4-Toluenediamine
Ames test
The Ames Salmonella assay has been the mainstay of mutagenesis
testing for many years. The test usually employs different Salmonella
typhimurium strains developed by Dr. Bruce Ames that have been mutated at
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the histidine operon resulting in a histidine-dependent bacteria (1.115-1.118).
These bacteria are unable to grow on media that is deficient in the amino acid
histidine. Bacterial growth on histidine deficient media is an indication of
reversion back to the wild-type histidine operon. The frequency of the
appearance of these bacterial colonies have been correlated to the muta
genicity of many of the compounds tested. Different strains of bacteria allow
for detection and differentiation of point and frameshift mutations (1.101,1.115,
1.118-1.120).
Over time, introduction of selected traits in these bacterial strains have
made them much more sensitive to mutations. Some of these changes include
deficiencies in DNA-repair and increases in ceil membrane permeability to
larger molecules.
A major drawback of the Ames assay, the lack of phase I biotrans
formation enzymes present in mammalian systems, was corrected by supplying
rat liver post-mitochondrial supernatant to the bacteria in a special preparation
termed ‘SS-mix1(1.115,1.121). With the addition of biotransformation enzymes,
a previously untested class of compounds gained access to a widely used
bacterial mutagenicity assay.
Although there have been a few discrepancies in the test results with
some strains, 2,4-TDA is considered mutagenic in the Ames assay. The
frameshift tester strains, TA1537 and 1538, provide clear and reproducible
results of mutagenicity while a newer strain, TA100, which incorporates a
resistance transfer factor ( makes test more sensitive to certain classes of
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compounds) has been equivocal in its results (1.115). The TA98 strain,
another R factor strain, has been consistently positive in its assay results.
All strains of the Ames Salmonella assay have required that 2,4-TDA
undergo metabolic activation by some process in order for the compound to
become mutagenic. This means that 2,4-TDA is not a direct acting mutagen.
Although activation is usually accomplished with the S-9 mix, primary rat
hepatocytes and even plant cell incubation assays have been utilized to
metabolize the compound to the activated forms (1.17,1.122). When the S-9
activation system was used with the Ames assay, it appeared that Nhydroxylation of the 4-amino nitrogen with subsequent acetylation carried out
by an O-acetyltransferase in the Salmonella bacteria was responsible for the
mutagenic qualities seen in 2,4-TDA. When an acetyltransferase-deficient
bacterial strain (TA 98/1,8-DNP6) was used, mutagenic activity was severely
curtailed while a strain with increased acetyltransferase activity (YG1024)
resulted in increased mutagenic activity. Prior induction of rats using Aroclor®1254, phenobarbital or 3-napthoflavone has also been shown to dramatically
increase the mutagenicity of 2,4-TDA because of the resulting increased phase
I biotransformation activity (1.17,1.123).
Multiple studies have shown that 2,4-toluenediamine is mutagenic in the
Salmonella strains TA98, TA100, TA1537, TA1538, and YG1024 as long as
metabolic activation has occurred. Mutagenicity has not occurred in any of
these Salmonella bacteria strains without the presence of an activation system
(1.17,1.100,1.122,1.124-1.126).
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Although the Salmonella assay is the most utilized, it is by no means the
only test in the arsenal. 2,4-TDA has been extensively assayed in a number of
in vivo and in vitro tests systems, often with equivocal results.

AiKaJine.eiutjon assay
The alkaline elution assay is a measure of DNA strand breakage. Cells
are placed on a filter then lysed with a detergent solution. An alkaline solution
is pumped through the filter in order to cause the DNA to unwind and separate
into strands. DNA which has been damaged by genotoxic agents will result in
strands of differing lengths and molecular weights. The smaller fragments
elute faster than the larger segments. An increased rate of elution is indicative
of DNA strand breakage (1.127,1.128).
Parodi et al. showed a weak positive response for 2,4-TDA in the in vivo
alkaline elution assay. The assay was performed in young male Sprague
Dawley rats after i.p. administration (1.129). In contrast, negative results were
obtained by Sina et al. when the compound was tested in an in vitro alkaline
elution/rat hepatocyte assay (1.130). These test results seem to suggest that
2,4-TDA is a weak “breaker" of DNA.
Unscheduled DNA synthesis (UPS)
Unscheduled DNA synthesis has been used as a measure of DNA repair
in response to chemical exposure. It has been shown to be an indicator of both
genotoxicity and carcinogenicity. The test is generally conducted in hepatocyte
tissue cultures. In the cell, scheduled synthesis of DNA occurs during the S or
DNA synthesis phase of the cycle. Unscheduled synthesis is that which occurs
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in the non-S-phase of the cycle. [3H]Thymidine, when incubated with cells in
the S phase, is incorporated into the nucleus of the cultured cells and shows up
as silver grains when examined autoradiographically. Cells not in S phase will
not incorporate the [3H]thymidine into the nucleus. Cells which are exposed to
toxic doses of chemicals will generally undergo DNA repair synthesis which
can be detected by the tritiated thymidine label (1.131,1.132).
In the rat liver unscheduled DNA synthesis assay, two studies on 2,4TDA using Fischer 344 rats produced positive results. Another study by
George et al. on the same compound produced a weak positive result, but only
when modifications were made from the Mirsalis study involving homogen
ization of the dosing formulation (1.133-1.136). These results suggested that
2,4-TDA was capable of causing genotoxic effects.
Micronucleus test
The micronucleus test is a simple, commonly used assay for measuring
chromosome damage. Micronuclei, or Howell-Jolly bodies as they are known
in the medical field, are very small nuciei-looking bodies composed of
chromosomal fragments. These micronuclei arise from disruptions in the
mitotic or meiotic process or as a result of chromosomes not separating totally
at anaphase. Polychromatic erythrocytes (PCE), present in large numbers in
the bone marrow of the rat or mouse, are commonly used for the assay. The
micronucleus, which is retained in the polychromatic erythrocyte after expulsion
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of the main nucleus, can be observed with a microscope or detected with flow
cytometry. Generally 1000 polychromatic erythrocytes per animal are
evaluated for micronuclei (1.137,1.138).
A F344 and PVG rat bone marrow micronucleus test on 2,4-TDA had a
negative outcome. The test was later repeated but at a dose toxic to the cells,
making the interpretation of the weak positive result questionable (1.133).
HGPRT/CHO test
One of the most common forward-mutation assays is the HGPRT/CHO
test. This assay detects a single mutation occurring in the HGPRT
(hypoxanthine guanine phosphoribosyltransferase) locus of Chinese hamster
ovary cells. The HGPRT gene is located on the X chromosome. The gene
produces an enzyme that catalyzes the reaction that converts hypoxanthine
and guanine to IMP (inosine monophosphate) and GMP (guanosine mono
phosphate). The basis of the test involves substituting a purine analog (usually
6-thioguanine, 6GT) for the base which results in a lethal nucleotide when
phosphorylated by the enzyme. If the HGPRT gene is inactivated by mutation,
the cells are able to grow because the toxic metabolite is not produced.
Mutagenicity is calculated by the number of 6GT resistant cells found after
chemical exposure of the cell population. The HGPRT assay is able to detect
both base-pair and frame-shift mutations. It is a sensitive and reproducible test
and unlike the Ames test, uses mammalian cells. Problems with the test
include standardization of protocol, long test times and metabolic activation
needed for indirect-acting compounds (1.139).
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L5178Y TK+/- assay
Like the HGPRT locus, the TK locus is also associated with a salvage
pathway. The TK locus is generally associated with the L5178Y mouse
lymphoma cell line. The thymidine kinase (TK) enzyme catalyzes thymidine
monophosphate (TMP) production from exogenous thymidine. Thymidine
kinase (TK) producing cells are selected against by growing them in a medium
containing the thymidine anologs, bromodeoxyuridine (BUdR) or
trifluorothymidine (F3TdR). These analogs are phosphorylated then
incorporated into the cellular DNA where they become toxic to the cells. Only
cells deficient in thymidine kinase survive. If the TK gene is inactivated by
mutation, the cells are able to grow because the toxic metabolite is not
produced (1.140).
Coppinger et al. evaluated the mutagenicity of 2,4-TDA in cultured
mouse lymphoma and Chinese hamster ovary cells (1.141). The assay was
performed at both the TK and HGPRT loci for each line of cells. 2,4-TDA was
found to be mutagenic in both cell lines at the TK locus. However, in the
mouse lymphoma cells, the positive result only occurred without S-9 metabolic
activation. Both cell lines were non-mutagenic at the HGPRT locus with or
without S-9 activation. It appears from this study that the TK locus may be a
more sensitive indicator than the HGPRT locus for the mutagenicity of TDA.
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Sex-linked recessive lethal test
The sex-linked recessive lethal test (SLRL) in Drosophila melanogaster
was first used in the 1920's for testing the mutagenicity of radiation. Over the
years numerous modifications have been made to the assay allowing it to
detect mutations ranging from single base pairs to large chromosome
aberrations in the X chromosome of the test subject. The test exposes wildtype males to a potential mutagen. Post exposure, these males are individually
mated at 2-3 day intervals to 3-5 virgin females containing multiple inverted
chromosomes with appropriate genetic markers. The F1 females from these
matings should each have one X chromosome from a treated wild-type male.
These females are then mated with the genetically altered males and the F2
generations examined. If a lethal mutation occurred on the X chromosome of
the F1 female, then the wild-type males will not be present in the offspring
(1.142-1.144).
Drosophila melanogaster was one of the first systems used as an
indicator of mutagenesis. The sex-linked recessive lethal test is thought to be
a very sensitive and reproducible assay. 2,4-TDA was found to be weakly
mutagenic by Blijleven etal. in the SLRL assay (1.142).
Dominant lethal test in rodents
A dominant lethal mutation is a mutation in a germ cell which causes the
death of the first generation progeny. The dominant lethal test in rodents is a
measure of embryo and fetal lethality in the offspring of a treated male. The
death of the embryo generally occurs between the two-cell stage and
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implantation. These lethal mutations are almost always clastogenic in nature.
Males are first treated with the suspected mutagen usually at the maximum
non-toxic concentration. They are then placed into cages with untreated
females for mating. Females are killed at a set time after mating and the uterus
examined for living embryos and post-implantation deaths. Mutagenicity can
be determined by an increase in dead implantations, an increase in the number
of females with non-viable implants, or a decrease in the number of live
embryos. This test is economical but is insensitive and has a high
spontaneous background frequency and a non-linear response. Because the
test is designed to detect clastogenic events, a potent mutagen is generally
required in order to detect a frequency of response above the background
level. The response obtained is often a result of multiple mutagenic events
rather than an event at just one locus (1.145).
Soares et al. tested 2,4-TDA for mutagenicity in both the dominant lethal
assay and sperm morphology test in DBA/2J mice. The treated males were
subsequently mated to CD-1 females. The females were killed 17 days after
initial exposure to the males and the uterine contents examined. The assay
was negative as there was no indication of an increase in lethals over control
values. In the sperm morphology test, there was no detectable increase in
abnormal sperm over controls (1.146).
Sister chromatid exchange
This test indicates that a reciprocal exchange of genetic material has
occurred between homologous sections of two sister chromatids on a
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chromosome. One assay method used involves exposing possible mutated
cells to BUdR (5-bromodeoxyuridine), a thymine analog, then allowing one
round of DNA synthesis to occur. A second round of DNA synthesis in the
absence of BUdR is carried out with the result that only one of the sister
chromatids in each chromosome incorporates the thymine analog. Staining of
the genetic material allows visualization and counting of the number of
exchanges occurring in the chromosomes (1.120,1.132,1.147-1.149).
Parodi et al. tested 2,4-TDA for mutagenicity in the sister chromatid
exchange (SCE) assay using Swiss male mice (1.150). Results indicated a
weak positive response in the induction of SCEs in bone-marrow cells.
2,6-Toluenediamine
Ames test
Although the 2,6-TDA isomer has not been studied as extensively as
2.4-TDA, it has also been subjected to multiple mutagenicity assays. As with
2.4-TDA, metabolic activation was required for mutagenicity in all Salmonella
tester strains that were used. Tester strains TA98, TA100 and TA1538 all
showed that 2,6-TDA displayed mutagenic activity when first subjected to
metabolic activation. The non-activated compound showed no mutagenic
activity in any of the tester strains (1.59,1.151 -1.153).
Unscheduled DNA synthesis (UPS)
An evaluation of 2,6-TDA in primary rat hepatocytes using the
unscheduled DNA synthesis (UDS) assay showed negative results at multiple
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concentrations and 20-hour in vitro exposures (1.154). This negative result
was confirmed in UOS studies earned out by George et at. and Mirsalis et al.
(1.133,1.136).
Alkaline elution assay
In the alkaline elution assay, a test measuring DNA strand breaks,
results were different for rat liver in vivo vs. in vitro exposures. Rats exposed to
an in vivo high dose of 2,6-TDA (2000 mg/kg) gave a positive response in
primary rat hepatocytes while an exposure at half that amount was negative.
When primary rat hepatocytes were exposed in vitro to concentrations ranging
from 1 to 10 mM results were again negative (1.154).
Micronucleus test
George et al. conducted the rat bone marrow micronucleus test using
F344 and PVG rats on 2,6-TDA. Their data showed a dose related weak
positive response in contrast to a negative response in bone marrow and liver
obtained in young male albino Sprague Dawley rats by Allavena et al. (1.133,
1.154).
Sister chromatid exchange
Sister chromatid exchange assay in CHO cells without S-9 metabolic
activation produced a positive result at concentrations of 50-160 pg/ml. When
the assay was conducted with S-9, the highest concentration tested (500 pg/ml)
gave only a weak positive result (1.148). A summary of the test results for both
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the 2,4- and 2,6-TDA isomers are compiled in Table 1.2 and illustrate the
responses to the various tests.
Correlation of mutagenicity to carcinogenesis
Mutagenicity of a chemical compound has been looked upon as a
sentinel for potential carcinogenic activity. This is the rationale behind the
mutagenicity testing of a compound before a large investment is made in
production. However, a major problem with mutagenicity testing has been in its
ability to correctly predict carcinogenic compounds from non-carcinogenic
ones. The mutagenicity of a compound does not automatically translate into
carcinogenicity, and by the same token, a carcinogenic compound may not be
mutagenic in all assays. The 2,4-TDA isomer has been found to be carcino
genic in rats while the 2,6-TDA isomer has proven negative (1.17,1.20,1.23,
1.24,1.59,1.155). The 2,6-TDA isomer is considered to be a genotoxic
noncarcinogen. Because of its structure and positive responses in many short
term mutagenicity tests, it would be expected to be carcinogenic in nature.
However, as can be seen in Table 1.2, the known carcinogenic 2,4-TDA isomer
is negative in many mutagenicity assays while the non-carcinogenic 2,6-TDA is
positive.
Of all the mutagenicity tests performed, the Salmonella/microsome test
is the most used as a widespread screening test. McCann et al. reported that
90% of the carcinogens they tested in the Salmonella/microsome test were
mutagenic while other researchers claimed between 78 and 95% correlation
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Table 1.2

Compiled results from a battery of mutagenicity tests on both 2,4- and 2,6-toluenediamine.
Abbreviations: w=weak, Pos=positive, neg=negative. Tests are discussed fully in text.

Test

Strain

Activation

Results
2 .4 -T D A

Ames
Ames
Ames
Ames
Ames
Alkaline elution
Alkaline elution
UDS
Micronucleus
TK/CHO
TK/mouse lymphoma
HGPRT/CHO
HGPRT/mouse lymphoma
SLRL
Dominant lethal
Sperm morphology
S.C.E.
S.C.E.
S.C.E.

1537
1538
TA100
TA98
YG1024

+S9
+S9
+S9
+S9
+S9

+/-S9
-S9
+/-S9
+/-S9

-S9
+S9

Pos
Pos
Pos/Neg
Pos
Pos
wPos
Neg
Pos, w Pos
Neg
Pos
Pos
Neg
Neg
wPos
Neg
Neg
w Pos

References

2 ,6 -T D A

Pos
Pos
Pos
Pos/Neg
Neg
Neg/Neg
w Pos/Neg

Pos
wPos

{171}
{121,126,196}
{89,121,171,196}
{51,65,89,171,196}
{51}
{305,106}
{310,106}
{106,146,154,260,317}
{106,146}
{91}
{91}
{91}
{91}
{92}
{193}
{193}
{309}
{351}
{351}
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(1.124,1.156-1.158). Fassina etal. looked at the induction of 6-thioguanine
resistant mutants in V79 Chinese hamster cells by a group of 12 carcinogenic
aromatic amine compounds of differing oncogenic potency. Results showed
there was no correlation between the carcinogenic potency and the mutagenic
response obtained in this test system (1.159). In fact, 2,4-TDA, a potent
carcinogen had a negative response in inducing the mutant cells. The
dominant lethal test in rats, a very insensitive assay, showed no evidence of
mutagenicity in the carcinogenic 2,4-TDA compound. Also, there was no
indication of abnormal sperm formation in exposed rats (1.146). The 2,6-TDA
isomer, a non-carcinogen, gave positive results in the SCE and chromosome
aberration tests indicating a probable clastogenic effect. It also consistently
produced a positive result in the Salmonella/micosome test (1.59,1.148,
1.151-1.153).
These examples are given to illustrate that no one mutagenicity test
should be relied upon in the determination that a compound is mutagenic or
carcinogenic. Many factors must be considered in the evaluation of any
compound as to how extensive the testing procedure must be. For example,
how much of the compound will be produced? Will people or animals be
directly exposed? Will environmental contamination be a factor? Is the
compound stable and what, if any, are the breakdown products? As is always
the case, monetary factors will be of concern. The Salmonella assay is
relatively inexpensive while large scale long-term animal testing can be a
significant investment, even for a large corporation. However, if one relies just
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on the Salmonella test, a false positive result could prematurely condemn a
relatively safe and possible valuable compound from ever reaching the market.
Our present state of knowledge about mutagenicity and carcinogenicity,
decreasing finances for extensive research and testing, and concerns about
the use of animal models for test protocols leaves researchers with little choice
but to rely on mutagenicity tests that may not always be consistent with results
from a full battery of in vivo and in vitro assays or as an indicator of an agents
further perusal.
Chemical Carcinogenesis

Introduction
Ever since an association between chemical exposures and the onset of
cancer was established in the late 1700's, there has been an active quest for
the mechanisms involved in chemical carcinogenesis (1.2). In most areas of
the world, cancer is a leading cause of death. Cancer generally refers to any
disease caused by uncontrolled growth and metastasis or spread of abnormal
cells. Even though industrial chemicals are a major focus in the cause of
cancer, there are many other known and often more serious cancer causing
agents. Life style choices regarding alcohol, tobacco, diet and exposure to
excessive UV radiation account for the majority of new cancer cases each year.
Fortunately, money spent on educating the public has the potential of
producing large scale reductions in future cases of cancer or at least ensures
that the choice can be made by the public. Despite the untold billions of dollars
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spent on cancer research in the last 50 years and the volumes of knowledge
gleaned from the effort, the fact remains that approximately one out of every
five deaths occuring in the United States results from cancer (1.160).
Lifestyle carcinogen exposures are generally elective in nature. There
are however, many cancer causing chemical agents, both organic and
inorganic, that the general public may contact through environmental, occu
pational or medical exposure. Because the volume of material on chemical
carcinogenesis is immense, the scope of this review will focus on arylamine
compounds and on 2,4- and 2,6-toluenediamine.
Carcinogenic agents can be classified according to structure, mode of
action or type of tumor produced. Most chemical carcinogens are classified
according to their reactions with cellular macromolecules and whether or not
the compound is active in the parent form or must be biotransformed to an
active electrophile. A gentoxic chemical is one that is capable of chemically
interacting with and altering the DNA within a cell. Genotoxic agents can be
either activation-independent (direct acting) or activation-dependent (indirectacting) chemicals. Direct acting carcinogens do not require metabolic
activation in order to interact with macromolecules. These agents are often
simple alkylating agents such as chloro-ethyl ether and methylnitrosourea
(MNU) or inorganic substances such as nickel and cadmium. Activationdependent chemicals become reactive electrophiles through biotransformation
reactions. An epigenetic carcinogen does not act directly on DNA but rather
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involves some other biological mechanism in order to transform a normal cell
(1.112,1.161,1.162).
The reaction between the carcinogenic aromatic amine electrophile and
a cellular nucleophile is primarily Sn2 in nature (1.105,1.112). An Sn2
(bimolecular nucleophilic substitution) reaction is characterized by the
displacement of a leaving group from an electrophilic compound when attacked
by a nucleophile. Before this displacement occurs, all the groups are involved
in the formation of a planar transition state. As the leaving group departs, an
inversion of the sterochemistry of the electrophilic compound results.
Indirect-acting carcinogens must be activated or biotransformed by
enzyme systems in order to form an electrophile capable of a cellular
interaction. Common examples of these carcinogens are the common
polycyclic aromatic hydrocarbon (PAH) and aromatic amine compounds.
These compounds are often stable entities until acted upon by mammalian or
bacterial enzyme systems producing either a detoxified or toxic species.
The mechanisms of carcinogenesis are extremely complex but some
steps in the process have been elucidated. In order to characterize the
neoplastic process, a multistage paradigm based on mouse skin models is
generally employed. This model separates the process into initiation and
promotion sequences. A third stage, the progression sequence, is considered
by some to be a separate entity while others consider it to be part of promotion
(1.162-1.165).
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Initiation
The initiation process is the sequence of steps in which a normal cell is
converted into a neoplastic one. Initiation probably represents a mutagenic
event caused by very low levels of carcinogenic agents (1.112). This process
is thought to occur rapidly and appears to be irreversible (1.14). In order for
the cell to undergo this transformation, the cellular constituents must first
interact with the carcinogenic chemical. The carcinogenic potential of aromatic
amine compounds varies with the ring system and the type and number of
substitutions appearing on those rings. For example, a methyl group placed
ortho to an amino group on the ring will often amplify the carcinogenic potential
of the compound while ring hydroxylation tends to increase the detoxification
process. Substitutents which block ring hydroxylation, increase lipid solubility,
or influence other ring substitutents ability to react can greatly influence the
carcinogenic potential of the chemical (1.166).
As previously mentioned, most aromatic amine compounds are indirectacting in nature, that is, they must be activated from the parent compound to a
proximate or ultimate carcinogen before they become reactive. This is evident
for most arylamines because tumor formation generally occurs at sites not
related to the route of administration (1.162). For most arylamines, this
requires the formation of a N-hydroxy derivative usually catalyzed by the
cytochrome P450 family of oxidative enzymes. These N-hydroxy arylamine
electrophiles often either bind directly to DNA or form the basis for further
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metabolic activation to other reactive metabolites or ultimate carcinogens
(1.15,1.64,1.166-1.168). The N-hydroxylated metabolites are not the only
reactive metabolites, but they have been known to engage in nonenzymatic
reactions forming covalent bonds with cellular macromolecules (1.168).
Fortunately, the reactivity of many of these N-hydroxylated metabolites to
nucleophiles appears to be quite low at neutral pH. However, the addition of a
second metabolic activation step involving in vivo esterification of the Nhydroxy group often results in a much more carcinogenic and reactive
electrophile, even at a neutral pH (1.15,1.79,1.167).
These electrophiliccarcinogens, compounds which are relatively
deficient in electrons, are able to react with nucleophiles having electrons
available for covalent binding. Nucleophilic sites are commonly found in DNA,
RNA, and proteins (1.112). Selected oxygen and nitrogen atoms on DNA and
RNA as well as sulfur, oxygen and nitrogen atoms in proteins are the sites
commonly involved in these reactions. Parent and precarcinogen compounds
are often metabolized to more than one metabolite resulting in multiple ultimate
carcinogens. With the multiplicity of nucleophilic sites available, it is not un
usual to observe different adducts from a single parent compound (1.14,1.162).
Kadlubar et al., working with N-hydroxyarylamines, showed that
enzymatic glucuronidation of 1-and 2-naphthylamines and 4-aminobiphenyl
resulted in N-glucuronidated metabolites which were subsequently excreted in
the urine. Their study indicated that the normally acidic conditions in both
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human and dog urine resulted in acid hydrolysis of the N-glucuronides forming
N-hydroxylamines. Subsequent elimination of the hydroxyl group on the
nitrogen as water under protonating conditions produced extremely reactive
lipophilic nitrenium ions capable of covalent binding to macromolecules in the
bladder epithelium (1.64). Results from studies like this, indicate the
importance of metabolic acitivation in the initiation process of most aromatic
amine compounds.
Once a reactive species has been generated by metabolic activation, it
may act directly on DNA (genetic effect) or act through some other biological
pathway (epigenetic effect) to initiate a carcinogenic response (1.112).
Genetic effect (DNA adduct formation)
A reactive electrophilic carcinogen is capable of forming covalent bonds
with almost all cellular macromolecules having a nucleophilic reaction site,
resulting in what is commonly called an adduct (1.169). Adduct formation with
RNA and proteins may produce toxic effects because these molecular products
may compromise the function or pool size of critical cellular proteins. For
example, proteins involved in gene expression, methylation enzymes or DNA
repair can alter cellular function or disrupt damage control efforts (1.162,1.1701.173).
Cellular DNA is often the target of covalent addition. These DNA
adducts can have serious ramifications because of the critical role that DNA
plays in cellular functions and cell reproduction. Fortunately multiple enzyme
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systems exist for the removal and repair of DNA damaged by adduct formation
and in most cases the damaged cell will fully recover (1.101,1.174). However,
DNA repair systems are not infallible and occasionally the system can become
overwhelmed by steady-state or an intense exposure to electrophilic agents
resulting in adducts which are not removed in an appropriate time frame.
With aromatic amines, DNA adduct formation can occur at nucleophilic
sites on both deoxyguanosine (dG) and deoxyadenosine (dA). The N2-dG, O6dG, C8-dG, C8-dA, and N6-dA derivatives are a few of the adducts observed
from different arylamine compounds with the C8-dG and N2-dG being the most
prevalent. The C8-dG or N-(deoxyguanosin-8-yl) derivative is thought to
originate as a N7-dG derivative, which when deprotonated, undergoes a
Stevens-like rearrangement producing a final C8-dG adduct (1.13,1.112,
1.167).
The importance of persistent in vivo DNA-arylamine adducts can be
seen in the devastating consequences of gene mutations and cancer. DNA
adducts are capable of inducing genetic mutations. Beland et al. looked at
DNA adducts of the arylamines N-hydroxy-acetylbenzidine, N-hydroxy-2aminofluorene, N-hydroxy-4-aminobiphenyl, and N-hydroxy-2-napthylamine
using Salmonella typhimurium strains TA1535 and TA1538. Results indicated
that a linear correlation existed between C8-deoxyguanosine adducts and the
induction of frameshift mutations in the bacterial DNA system (1.106).
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Aromatic amine adducts including C8-dG, N2-dG and N6-dA may induce
mispairing by changing the normal base-sugar conformation from anti to syn
with resulting helical distortion. Transformation from the normal B-DNA to a 2DNA conformation secondary to the DNA helix rotation is thought to occur
(1.112,1.168,1.175). These changes can result in unusual base-pair
alignments allowing bases that could not normally pair to form necessary
hydrogen bonds.
If not corrected by DNA repair mechanisms, a gene mutation can persist
during subsequent DNA replication. Bulky adducts on the DNA can also block
DNA polymerase from progressing along the DNA double helix resulting in a
possible deletion mutation (1.11,1.112).
DNA adduct formation is also associated with the initiation of carcin
ogenesis evidenced with the activation of oncogenes and suppression of
certain tumor-suppressor genes (1.170,1.172,1.173). Cancer formation, in
many situations, is thought to result from the accumulation of damage to the
genes in a single cell. The damage to the genetic code affects the ability of the
cell to restrain normal cell growth and reproduction resulting in tumor formation.
Ras genes, for example, are proto-oncogenes that are expressed at low levels
in most cell types and are necessary for normal cell functions. They encode
GTP-binding proteins involved in control of cell proliferation and differentiation.
Point mutations are responsible for turning these normal genes into oncogenes
by blocking an intrinsic GTPase activity preventing normal deactivation of the
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protein. Ras oncogenes have been isolated in almost all human cancers
leading to speculation that they might be involved in the initiation process of
neoplasia especially during times of cell proliferation. Other proto-oncogenes
are known to be involved as signal transduction elements, protein kinases,
DNA binding proteins, and growth factors. Once these genes are activated to
oncogenes, they have the ability to transform cells.
A similar situitation is seen with the p53 tumor suppressor gene. A
simplified version of the function of the gene is that it normally blocks the
division and growth of cells harboring damaged genes in which it is present by
sending them to an apoptotic pathway. When the p53 gene is mutated, the
cells are allowed to divide and grow with resulting tumor formation (1.162,
1.172).
Covalent Binding of Toluenediamine to DNA
2,4-Toluenediamine irreversible binding, both in vitro and in vivo, to liver
protein, RNA and DNA has been evaluated. In 1979, Aune et al. examined
both in vitro and in vivo covalent binding (1.123). Incubation of liver microsomes, NADPH and oxygen with tritiated 2,4-TDA resulted in products
covalently bound to microsomal proteins. However, when calf thymus DNA
was similarly incubated in microsomes, no indication of irreversible binding with
TDA was found. Male Wistar rats were administered i.p. injections with 100
mg/kg tritiated 2,4-TDA and sacrificed 4 hours later. Covalent binding of TDA
to liver and kidney protein at 268 and 130 pmol/mg protein, respectively, was
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found. Liver ribosomal RNA also contained covalently bound TDA at 54
pmol/mg. Interestingly, there was no evidence of covalently bound labeled 2,4TDA to liver DNA. These DNA results were surprising in light of the RNA
binding and the fact that 2,4-TDA is both mutagenic and carcinogenic. The
authors speculated that possibly unstable adducts were lost in the DNA
extraction process and therefore went undetected.
A few year later, Furlong et al. looked at the covalent binding of both
2.4- and 2,6-TDA to rat liver DNA (1.176). Hepatocytes from adult male F344
rats were allowed to incubate with 100 pM [14C]-labeled 2,4-TDA for 0, 1,4, 8,
and 24 hours. Isolated DNA showed a time-dependent linear increase of
covalent binding peaking at about 700 pmol/mg at 24 hours. When repeated
with both 2,4- and 2,6-TDA using the 24 hour time point, covalent DNA binding
was measured at 960 and 246 pmol/mg DNA, respectively. The DNA binding
was significantly lower for 2,6-TDA than 2,4-TDA which would be expected
since the 2,6-isomer is considered to be non-carcinogenic. The isolation and
identification of individual adducts was not attempted in the study.
Using “ P-postlabelling techniques, La et al. looked for covalently bound
2.4-TDA in liver, mammary gland, kidney and lung (1.177). Fischer-344 rats
were administered a single i.p. injection of 2,4-TDA at doses ranging from 4.1
to 2046 pmol/kg body weight. DNA adducts were found in all four tissues with
differences in adduct quantity noted. Tissues showing greatest carcinogenic
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responses, liver and mammary gland, had the greatest number of adducts. At
the highest concentration (2046 pmol/kg), 97 pmol/mg DNA were recovered.
Compared to previous in vitro results, the postlabelling experiment
conducted at higher TDA concentrations resulted in lower DNA adduct yields.
These results should be considered suspect as a review of the dosing
calculations show that the reaction mixture contained only 14 pmol (100 pCi) of
labeled ATP for binding to 6 nmol (2 pg) of DNA. The deficient amount of label
relative to substrate could account for the lower covalent binding results
obtained in the study.
Using amine-group specific monoclonal antibodies, Citro et al. showed
that 80% of the 2,4-TDA-DNA adducts involved the p-amino group while 10%
were attributable to the o-amino group (1.178). Metabolic activation of 2,4-TDA
with S9-mix produced DNA adducts only at the poly-d(G) and poly-d(G-C)
bases.
Epigenetic effects
Chemicals that interact with biological activities other than direct
interaction with cellular DNA as a basis for carcinogenicity are termed epi
genetic carcinogens. Many of these agents have the capacity to act as
promotors, increase DNA synthesis, or affect mitosis and cellular reproduction.
Many can interfere with or mimic hormone activity, cause immunosuppression
or induce peroxisome proliferation (1.162).
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One prominent example of an epigenetic factor is methylation of the
cytosine bases (5-methylcytosine) in DNA. Methylation of a gene is thought to
be part of the control mechanism used by the gene in preventing or limiting
expression of a protein product (1.171). The methylation characteristic of a
gene is a somatic genetic trait. When DNA is replicated, a hemimethylated
DNA strand is produced. In order to maintain the original methylation status, a
maintenance methylase enzyme converts these hemimethylated strands into
methylated strands using the cofactor S-adenosyl methionine. A mutation
produced in the methylase enzyme with resulting hypomethylation of promotor
sites or other controlling areas in the gene allows production of the protein
product via increased transcriptional activity (1.170,1.179,1.180).
It becomes quite evident that the mechanisms leading to the initiation of
neoplasia are diverse. Usually more than one event occurs in order for a cell
to become neoplastic. Whatever the event or events are, the end result is a
transformed cell with a different phenotype. These transformed cells may or
may not progress to tumors, depending on control by adjacent cells through
cell-to-cell communications involving gap junctions (1.162).
PromQtiQn

In the study of initiation and promotion, compounds are often divided
into complete and incomplete carcinogens (1.164,1.181). A complete
carcinogen is able to induce neoplasia without additional requirements such as
other added agents or specific conditions. Incomplete carcinogens need the
help of other agents or specific conditions in order to promote tumor activity.
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Because incomplete carcinogens require additional agents to induce tumor
formation, they are routinely employed in the study of the promotional aspects
of carcinogenicity.
The evolution of transformed cells to neoplastic cells can be separated
into conversion and propagation stages according to Boutwell et al. (1.182).
Little is known about the events occurring during the conversion step. The
traditional model of conversion involves the transformation of an initiated cell
into a dormant tumor cell. The conversion step, demonstrated in NMRI mouse
skin models, was found to be reversible with about a 10 week half-time period
(1.183). This reversal ability separated it from the irreversible initiation stage of
carcinogenesis.
The propagation step centers around the activation of converted
“dormant tumor cells” with subsequent clonal expansion of those cells. In most
situations, propagation requires multiple exposures of a promotion agent and is
often a reversible process. These agents are usually tissue specific,
non-mutagenic and need not be metabolically activated in order to promote
tumor production (1.165). Croton oil was one of the first substances found to
act as a promoting agent. The most widely used compounds in the study of
promotion mechanisms have been the phorbol esters. These diterpene esters
can be very potent promotors depending on the molecular structure of the
compound. The more potent promotor molecules generally contain both
lipophilic and hydrophilic aspects in their structure causing them to be
sequestered in cellular membranes (1.16,1.165). Most of the research related
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to promotion has been conducted in the mouse skin model with these agents,
especially TPA (12-O-tetradecanoylphorboM 3-acetate) (1.163,1.184,1.185).
In addition to these diterpene esters, many other compounds have been used
as promoting agents including fatty acids, fatty acid methyl esters, phenols,
linear alkanes, bile acids, cigarette smoke condensate, DDT, PCB, hormones,
saccharin, cycla-mate and phenobarbital, to name afew (1.163,1.165).
Over the years, the majority of data compiled on promotion has been
gleaned through research using the mouse skin model. The mechanism of
actions of phobol ester promotors are complex but are becoming clearer.
The repeated application of phorbol esters on mouse skin generally
resulted in symptoms such as inflammation, erythema, edema, and hyperplasia
(1.165). These skin changes, however, are the types of reactions often seen
with non-promoting chemicals after topical application. Studies on the cellular
and molecular aspects of phobol ester-skin interactions provided the infor
mation needed for a deeper understanding of the promotion process.
The phorbol ester receptor site was identified by Ashendel et al. as a
calcium phospholipid-dependent protein kinase C (1.186). The binding of
phorbol esters to protein kinase C activates the enzyme with subsequent
phosphorylation of multiple substrates resulting in a myriad of biochemical
changes that occur with promotion. Second mesengers such as diacylglycerol
affect cellular responses by binding to and activating a protein kinase. The
phorbol ester is thought to mimic the actions of the second messenger
diacylglycerol.
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Work by Hennings and Boutwell showed that promotors are capable of
increasing both DNA and RNA synthesis (1.187). Changes in protein synthesis
not related simply to increased cell division or cellular hyperplasia are also
found in skin treated with promotor agents.
Ornithine decarboxylase (ODC), a polyamine biosynthesis rate-limiting
enzyme, has been found to be induced by the application of TPA as well as
other promotor agents. This enzyme is associated with tissue undergoing rapid
cell division. Weeks et al. showed that TPA was able to increase ODC acitivity
in mouse skin more than 100-fold upon application of the promotor. They also
showed that epidermal putrescine levels were promotor dose-dependent and
correlated with the size and growth rate of papillomas (1.112,1.184). It appears
that promotor agents have the ability to increase ODC activity with a subse
quent increase in polyamine synthesis. The regulation of these polyamines
seems to play a relevant role in the mechanism of tumor formation.
Prostaglandin hormones have also been found to play a role in
carcinogenesis (1.185). These hormones are synthesized from essential fatty
acids in response to different physical, chemical and hormonal factors.
Arachidonic acid, a component of the phospholipid cellular membrane, is
released by the enzymatic action of phospholipase A^ The resulting free fatty
acid is ultimately transformed into prostaglandin by prostaglandin synthetase.
The prostaglandins are involved in multiple calcium-dependent regulatory
enzymes including ATPase, protein kinase, phosphodiesterases and the
cyclases.
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The role of prostaglandin in the promotion of neoplasia is still rather
obscure. It is however, thought to influence at least some of the events
responsible for tumor promotion. The tumor promotor TPA has been shown to
produce a significant increase in PGE levels in topically treated mice (1.188).
Also in vitro ODC activity induced by TPA is enhanced by prostaglandin PGE2
and inhibited by indomethacin (1.185).
The inflammatory response that occurs in mouse skin after the
application of phorbol esters appears to be a vital element in the carcinogenic
process. Fischer et al. found a marked increase in vascular permeability in the
skin of mice treated with TPA (1.189). This increased permeability is probably
the result of released histamine binding to histamine receptors in the skin. This
binding produces contraction of the endothelial cells resulting in exaggerated
gaps between cells allowing the release of edema-forming plasma. In the
study, an increase in the permeability and number of papillomas was found to
be dose-dependent with TPA administration.
The phorbol ester TPA has been shown to produce alterations in a
cellular plasma membrane Na7H+ exchange system. Rosoff et al. found that
70273 pre-B-lymphocyte cell line exposure to TPA resulted in increased [Na+], a
rise in cytoplasmic pH and a differentiation of the cell line. These ion transport
alterations may be the result of protein kinase C activation caused by phorbol
ester binding (1.164).
Inhibition of cell-to-cell communication has been attributed to exposure
of phorbol esters. Low molecular weight substances, up to 1200 daltons, which
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regulate growth functions are able to pass from one cell to another through
specialized cell membrane gap junctions (1.190). Klann et al. found that gapjunctional intercellular communication capacity decreased with successive
stages of mouse skin carcinogenesis (1.191). It appears as though these low
molecular weight substances may be prohibited from transferring the factors
needed to prevent or inhibit the growth of initiated cells (1.192).
Studies indicate that free radicals are important in all stages of
carcinogenesis. Free radicals can be generated either directly or indirectly by
some carcinogens and tumor promotors (1.193). The inhibition of neoplasia by
antioxidants has been shown to occur with a variety of carcinogens as well as
radiation in multiple species and targets (1.181,1.194). Slaga et al. found that
the covalent binding of B(a)P and DMBA to epidermal DNA could be inhibited
by the widely used antioxidant food additives, butylated hydroxytoluene (BHT)
and butylated hydroxyanisole (BHA) (1.181,1.195). Studies have shown that
inhibition of neoplasia by antioxidants and related compounds can occur at the
intiation (1.181,1.196) or promotion stage (1.181,1.196-1.199) as well as the
progression stage (1.181,1.200,1.201).
Carcinogenicity testing of 2.4-Toluenediamine
As mentioned before, industrial uses of 2,4-TDA are primarily as
intermediates in the synthesis of toluene diisocyanate, a cross-linking agent in
the production of polyurethane foam. However it has also been used as a hair
dye component, dyes in textiles, wood stains and pigments (1.17-1.19).
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Because of its worldwide use and extensive worker exposure, TDA has been
and still is the focus of study by researchers. Recently, the discovery of low
levels of TDA leaching out of polyurethane-covered silicone gel implants has
spurred new research into toluenediamine carcinogenicity (1.202-1.205).
In a 1955 study, Umeda provided one of the first indications that
toluenediamine might be carcinogenic (1.206). Twenty adult rats were injected
subcutaneously on a weekly basis with a 0.4% solution of 2,4-toluenediamine
in propylene glycol. After 28 injections, the 9 surviving rats had all developed
subcutaneous rhabdomyosarcomas at the site of injection. However, Umeda
found no metastasis and no internal organ changes in any of the rats.
Propylene glycol was questioned as possibly enhancing the carcinogenic
potential of TDA.
In a 1969 study, Ito et a/, fed male Wistar rats diets of 0.1 or 0.06
percent 2,4-toluenediamine for 36 weeks (1.23). One hundred percent of the
rats fed the 0.1% TDA developed multiple hepatocellular carcinomas with 66%
of these having metastatic lesions in lymph nodes, lungs, omentum or
epididymis. The 0.06% group also developed multiple liver tumors in 64% of
the rats with subsequent metastasis in the lymph nodes and omentum. In both
groups, the primary tumors were only carcinomas of hepatic origin. As a direct
result of this study, oxidation activated human hair dyes containing 2,4-TDA
were removed from the market in 1971.
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The next two studies were conducted with topical applications of 2,4TDA. Burnett et al. looked at the recently banned oxidation activated hair dyes
containing 2,4-TDA (1.207). When applied topically to male and female Swiss
Webster mice once a week or every other week for 18 months, no evidence of
toxicity or carcinogenicity was seen. Giles et al. applied 0.2% and 0.6%
solutions of 2,4-TDA to Swiss-Webster mice of both sexes in a 2 year skinpainting study (1.208). Even though these mice had a high spontaneous
incidence of lung cancer, there were no significant differences in lung tumors
over control groups. There were also no significant differences in skin tumors
over control groups except for the positve controls. The results of both topical
studies were in contrast to the outcomes obtained by Umeda and Ito.
Bridges et al. (1.209) were critical of the dermal study by Giles et al.
They concluded that statements pertaining to the noncarcinogenic nature of
2,4-TDA relative to mouse skin and lung cancer were misleading and possibly
wrong due to small sample sizes and extremely high spontaneous cancer rates.
They recommended that the study be repeated with adequate sample sizes.
In 1978 Weisburger ef al. conducted long-term toxicity tests on 2,4-TDA
along with numerous other aromatic amines in both male Sprague Dawley rats
and male and female HaM/ICR mice (1.210). Compounds were administered in
the diet for approximately 24 months. The 2,4-TDA was dosed at both 250 and
500 mg/kg (250 and 500 ppm) of diet. Male rats had a significant increase in
subcutaneous fibromas plus an increased incidence of liver tumors. The study
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also resulted in rats with multiple tumors. Some of these multiple tumors
involved a fibroma along with a transitional cell carcinoma, pituitary, skin, lung
or thymic tumor. Treated mice showed no significant differences from controls
but did show numerical increases in hepatocellular carcinomas and vascular
tumors.
Another long term oral study was carried out on male and female F344
rats by Cardy (1.211). Doses of 50 and 100 ppm were fed to the rats for a
period of 2 years. Results indicated a significant increase in benign plus
malignant liver neoplasms in males compared to the negative control group.
The females had an increased incidence but it was not significant. A new
finding was the significant increase in benign and malignant mammary tumors
in the female rats seen in both high and low dose groups. Lung tumors,
mesotheliomas, pancreatic acinar and islet cell adenomas, subcutaneous
fibromas and fibrosarcomas were also found but not at significant levels. The
study also revealed significantly increased preneoplastic liver lesions and
chronic renal disease in the treated rats. The mammary gland tumors raised
new questions about the possible association of breast cancer and oxidation
activated hair dye use by women.
A 1979 study by Reuber (1.212) was carried out on B6C3F, male and
female mice using 2,4-TDA. Doses of 100 and 200 ppm were fed to the rats for
a period of 100 weeks. High dose results showed 39% of females and 27% of
males developed liver carcinomas. Low dose results revealed 30% of females
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and 32% of males developed liver carcinomas. None of the female controls
developed liver carcinomas while 25% of the males did. Liver carcinomas were
significantly elevated for female mice compared to controls while male mice
showed no significant differences.
In 1979, the National Cancer Institute released the results of a bioassay
on 2,4-toluenediamine fed to both F344 rats and B6C3F1 mice (1.20). Rats
were dosed with 2,4-TDA at 125 or 250 ppm for 40 weeks. The low dose group
was then dropped to 50 ppm until 63 weeks or time of death. The high dose
group was decreased to 100 ppm and euthanized at an earlier time period.
Mice were dosed at either 100 or 200 ppm for 101 weeks. Both male and
female rats showed dose-related incidences of hepatocellular carcinomas that
were significantly different from control groups. Incidences of mammary gland
carcinomas or adenomas in females were also dose related and highly
significant compared to control rats. Male rats also showed a dose related
incidence of subcutaneous fibromas that were significantly greater than the
control group. Results from the mouse study showed a significant increase in
both lymphomas and hepatocellular carcinomas in females. There were no
significant increases in tumors in the male population compared to controls.
The exposure of workers to TDI (toluene diisocyanate) and associated
2,4-TDA and the results of numerous carcinogenicity studies prompted the
National Institute for Occupational Safety and Health (NIOSHA) in 1991 to
recommend that all isomers of both TDI and TDA be regarded as potential
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occupational carcinogens. They also recommended that worker exposure be
limited to the lowest feasible concentrations of these compounds (1.213).
The conflicting outcomes regarding 2,4-TDA in long term high dose oral
and subcutaneous studies compared to topical studies carried out at expected
exposure concentrations must be addressed. Topical studies showed no
evidence of carcinogenicity or toxicity at those expected exposure concen
trations. Carcinogenicity was not elicited until massive doses were adminis
tered to animals over long periods of time in routes of administration that would
be unlikely in most situations. The effects of gut bacteria, pH, first-pass liver
metabolism and possible effects on nutrients are just a few of the major
differences between oral and topical administration. The most likely occu
pational exposure scenario involves long- term, lovtKlose oral and dermal
exposure. Questions and concerns about the type and relevance of
carcinogenesis testing required by regulatory agencies has been debated for
years.
A prime example about the extrapolation of high-dose, long-term animal
studies to extremely low-dose, long-term human exposure is seen in women
with polyurethane-covered breast implants. Polyurethane-sponge-covered
silicone gel implants are hydrolyzed in vivo to the reactive monomers 2,4- and
2,6-toluenediisocyanate which are then converted to 2,4- and 2,6-toluenediamine (1.205). These degradation products have been detected in plasma
and urine for many years after implantation. TDA has also been found
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covalently bound to plasma proteins allowing them to be used as biomarkers in
these patients (1.204). In one study, plasma levels of TDA ranged from 0.4 to
4 ng/ml plasma. These plasma levels were similar to those found in factory
workers producing polyurethane products (1.204). Urine levels of TDA were
also found to be consistant at very low levels over long time periods (1.202,
1.203).
Basing the added risk of carcinogenesis from these implants from
extrapolated rat and mouse studies leaves a degree of uncertainty. The effects
of long-term or life-long low-dose exposures may never fully be known.
Ultimately, society will have to determine what exposure risks it is willing to
tolerate, not only for TDA but for all manufactured chemicals and products.
Carcinogenicity testing of 2.6-Toluenediamine
The compound 2,6-TDA is a by-product in the manufacture of the
carcinogen 2,4-TDA. It is extensively used in the syntheisis of toluene
diisocyanate (TDI), dyes, foams, and elastomers and therefore has the
potential for occupational exposure. The fact that 2,6-TDA is a known mutagen
and its close structural relationship to the carcinogenic 2,4-TDA prompted the
NCI to test the compound as part of its Carcinogenesis Testing Program.
In 1980, the National Cancer Institute issued the results from this study
on 2,6-toluenediamine dihydrochloride (1.155). In this study male and female
F344 rat were administered either 250 or 500 ppm 2,6-TDA in the diet for 103
weeks. Male and female B6C3F1 mice were treated with 50 or 100 ppm of the
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agent for the same time period. The study showed that 2,6-TDA was not
carcinogenic in either dose range for both rats and mice. There was, however,
a significant weight gain depression of 27% and 17% for high-dose and lowdose female mice, respectively.
Conclusion
Results of multiple research studies on both 2,4- and 2,6-toluenediamine
are fairly conclusive. 2,4-TDA is indeed both a mutagenic and carcinogenic
compound while 2,6-TDA is mutagenic but not carcinogenic. Differences in
carcinogenicity in these very similar compounds may be due in part to
differences in biotransformation. Both compounds should be treated as
hazardous to both animal and human populations and attempts should be
made to limit exposure.
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CHAPTER 2
OETDA: PHYSICAL CHARACTERISTICS AND
ANALYTICAL METHODS OF DETECTION
Introduction
The compound 2,4-toluenediamine (TDA) is widely used in industry as
an intermediate. Its primary use is in the synthesis of toluene diisocyanate, a
cross-linking agent in the production of polyurethane foam. It is also used as
an intermediate in the synthesis of dyes used in textiles, wood stains and
pigments (2.1-2.4).
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is a compound
utilized as a polyurethane chain extender in reaction injection-mold
applications. DETDA also has uses as a curing agent for polyurethanes and
epoxies, as an antioxidant, lubricant, wire coating and as a replacement for
more toxic industrial compounds, such as MOCA (4,4'-methylenebis-2chloroaniline) and toluenediamine. DETDA has been manufactured by
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years
under the name Ethacure®100 (2.5). Through a proprietary process, Ethacure
is synthesized from toluenediamine. It is commercially supplied as a mixture of
isomers with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4diamine (2,4-DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA)
and 0.5-3% dialkylated m-phenylenediamine.
Results from a two-year feeding study of DETDA in rats showed
effects on the pancreas, liver, thyroid and eyes as well as increased tumors in
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the liver and thyroid glands of male rats (2.5). These findings, along with the
structural similarity to the known mutagenic noncarcinogenrcarcinogen pair 2,6and 2,4-toluenediamine (TDA), dictated the need for a metabolic study of the
DETDA mixture (2.1,2.6,2.7). DETDA was expected to be absorbed,
distributed, metabolized and excreted in a similar manner to TOA.
Biotransformation reactions were expected to produce metabolites similar to
those found with TDA.
In order to conduct such a study, analytical methodology was required.
In the development of these analytical methods of detection and quantitation,
certain physical characteristics of the compounds of interest needed to be
known. For example, the pK, values of a compound are essential information
used in thin layer, HPLC and GC method development. Extinction coefficient
and UV absorption data are used in determining the concentration of a solution
and the best wavelength for monitoring. In the case of Ethacure, these
characteristics were not defined.
Because Ethacure and 2,4-TDA are structurally similar (Fig. 2.1), it
was expected that pK„ values and absorption characteristics would be
comparable. Since Ethacure is a mixture of isomers (primarily 2,4-DETDA),
characteristics were determined using the mixture rather than individual
isomers. Therefore pK, and extinction coefficient values are representative of
Ethacure and not DETDA alone.
To detect, identify, and quantify DETDA and associated possible
acetylated metabolites (see Chapter 3 for synthesis of standards),
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chromatography methods had to be established. Chromatography allows for
the separation and resolution of a mixture into individual components or
solutes. The degree of separation of the mixture depends on the sorption of
the components by a stationary phase. For most forms of chromatography,
migration through this stationary phase occurs by way of a mobile fluid (liquid
chromatography) or an inert gas (gas chromatography). As the mobile phase
carries the sample through the stationary phase, solutes that are more soluble
in the mobile phase (less affinity for the stationary phase) travel faster through
the column eluting at a faster rate (2.8,2.9). Such factors for DETDA needed to
be determined.
The present study determined the pic, and extinction coefficient values
for Ethacure and 2,4-toluenediamine. Both HPLC (high-performance liquid
chromatography) and GC (gas chromatography) methods for DETDA analysis
were developed incorporating multiple detection systems.
Materials and Methods
Equipment
The Orion pH meter (model 701A) was purchased from Orion
Research Incorporated, Cambridge, MA02138. A Coming Rugged Bulb
Combination electrode (No. 476561) was purchased from Coming, Inc.,
Coming, NY 14831. A Compact Infusion Pump, Model 975 was obtained from
Harvard Apparatus, Millis, MA. 02054. The Hitachi U-2000 Spectrophotometer
was purchased from Hitachi Instruments, Inc., Houston, Tx 77272. Sigma Plot
software was from Jandel Scientific, San Rafael, CA 94901. ESA Model 5200A
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Coulochem II electrochemical detector, Model 5010 standard analytical
coulometric cell and ESA Model 580 solvent delivery module were purchased
from ESA, Inc., Chelmsford, MA 01824. The Shimadzu LC-600 Liquid
Chromatograph pump and Shimadzu SPD-10AV UV detector, Easychrome
software and DT 2802 A/D converter board were obtained from Shimadzu
Scientific Instruments, Columbia, MD 21046. A C18 Partisphere 5pm
4.6x250mm reverse-phase column (No. 4621-1502), guard column (No. 46410002) and holder (No. 4651-0002) were purchased from Whatman Laboratory
Division, Clifton, NJ 07014. Hewlett-Packard 5890 Gas Chromatograph, NP
detector, 7673A automatic sampler, Hewlett-Packard 3392A integrator,
Hewlett-Packard 5895A Gas Chromatograph and FID detector were all
purchased from Hewlett-Packard Co., Wilmington, DE 19808. The DB-5 fusedsilica capillary gas chromato-graph column (30m, 0.25 mm i.d. x 0.25 pm film)
was purchased from J&W Scientific, Folsom, CA 95630.
Chemicals and supplies
The 2,4-diaminotoluene (2,4-TDA, 98%), barium oxide granules (No.
22,360-3), dibutylamine (99%) and phosphoric acid (99.999%) were obtained
from Aldrich Chemical Company, Inc., Milwaukee, Wl 53233. Sodium
hydroxide pellets, methanol (Nanograde®) and hydrochloric acid were obtained
from Mallinckrodt Chemicals, Paris, KY 40361. The acetonitrile was from
Curtis Matheson Scientific, Inc., Houston, TX 77251. The potassium hydroxide
(PX-1480-1) was purchased from EM Science, Gibbstown, NJ 08027. Vericel
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Membrane Filters (0.45pm, FP-450, 47mm No.66480) were purchased from
Gelman Sciences, Ann Arbor, Ml 48106.
Determination of pK,
Determination of pKa was carried out using an Orion pH meter with a
Coming combination electrode (2.10,2.11). Ethacure (1 g) or 2,4-TDA (500
mg) was dissolved in 100 ml of 0.1 M HCI. Twenty-eight ml of sodium hydroxide
(1M) was titrated into the HCI solution at a flow rate of 2.8 ml per minute using
an infusion pump. The pH determinations were simultaneously recorded with a
personal computer connected to the pH meter using an Omega A/D converter.
The titration data were converted into graphic form using Sigma Plot software.
Extinction coefficients
Extinction coefficients for 2,4-TDA and Ethacure 100 were calculated
using a Hitachi U-2000 Spectrophotometer (2.12). A 0.135 pmol solution of
Ethacure in methanol was prepared by serial dilution of a 0.0135 mmol solution
and absorbance was measured from 200 to 440 nm. A 0.0122 pmol solution
of2,4-TDA in methanol was also prepared by serial dilution of a 0.122 pmol
solution and absorbance measured from 200 to 440 nm.
Chromatography Systems
HPLC-electrochemical detection
Instrumentation
An ESA Model 5200A Coulochem II electrochemical detector with a
Model 5010 standard analytical coulometric cell was coupled to an ESA Model
580 solvent delivery module. Data was collected using Easychrome software.
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Mobile phase
The mobile phase for the reverse phase system was 16.5%
acetonitrile, 100 mM dibutylamine phosphate at a pH of 3.0 prepared as
follows: place 165 ml of acetonitrile into a 1000 ml beaker and dilute to 900 ml
using 18 mO cm'1 water. Add 16.8 ml of distilled dibutylamine3and dilute with
water to 980 ml. Adjust pH to 3.0 using full strength phosphoric acid then
dilute with water to 1000 ml. Re-adjust pH if needed then filter through a 0.45
pm membrane filter.
Hydrodynamic voltammetrv
Hydrodynamic voltammetry was used to determine the optimum
oxidation or reduction potential of the compound to be used in electrochemical
detection (Table 2.1 lists equipment settings for hydrodynamic voltammetry
determinations). A set concentration of analyte was injected into the HPLC
while maintaining a constant voltage. A voltage giving no or very little
response was first used then increased in 50 mV increments until maximum
peak values were obtained. The peak height or area was recorded and the
potential then changed. After equilibration, another sample was injected. Peak
height/area vs. potential were plotted creating a graph used in determining the
optimum voltage for each compound of interest. The ideal potential should be
about 50 mV above the voltage plateau on the graph. HDV determinations
were carried out for Ethacure and 2,4-monoacetylated DETDA.
See Appendix A for distillation protocol.
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Table 2.1

Equipment settings for hydrodynamic voltammetry determinations

Model 5200A
Coulochem II
Potential
(mV)

Model 580 Solvent
Delivery System

Variable Flow Rate
(ml/min)

Series 4500 Microscribe
Chart Recorder

1

Chart Speed
(cm/sec)

60

Current
(MA)

10

Pressure
(bar)

144

Signal input
range

Low

Filter
(seconds)

2

Column

C18

Span
(mV)

100

Output
(volts)

1

Mobile Phase 16.5% ACN
100 mM
DBAP
pH 3.0

Offset
(percent)
Guard Cell

0

Sample size

20

(ng)

850

(mV)
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Chromatography conditions
A Whatman C18 Partisphere 5pm 4.6x250mm and guard column was
used in the reverse-phase system for chromatography separation. For best
separation and detection of 2,4- and 2,6-DETDA, the detector potential was set
at +500 mV versus a Ag/AgCI reference electrode. For the monoacetylated
metabolites, the best potential was +725 mV. This latter potential was higher
than anticipated from the hydrodynamic voltammetry values obtained. Guard
cell potential was set at +850 mV and the E3 electrode set at 100 mV. Flow
rate was set at 1ml/min.
HPLC-UV detection
Instrumentation
All HPLC-UV analyses were performed on a Shimadzu LC-600 Liquid
Chromatograph pump and a Shimadzu SPD-10AV UV detector. Data was
collected using Easychrome software.
Mobile Phase
Mobile phase for the reverse phase system was 16.5% acetonitrile,
100 mM dibutylamine phosphate at a pH of 3.0. To prepare, place 165 ml of
acetonitrile into a 1000 ml beaker and dilute to 900 ml using 18 mQ cm'1water.
Add 16.8 ml of distilled dibutylamine and dilute with water to 980 ml. Adjust pH
to 3.0 using full strength phosphoric acid then dilute with water to 1000 ml. Re
adjust pH if needed then filter through a 0.^5 pm membrane filter.
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Chromatography conditions
A Whatman C18 Partisphere 5pm 4.6x250mm column and guard
column was used in the reverse-phase system for chromatography separation.
The best separation and resolution was achieved using a 100 mM dibutylamine
phosphate buffer (pH 3.0) and a flow rate of 0.5 ml/min. A detector setting of
295 nm was used for the 2,4- and 2,6-DETDA isomers while 240 nm was used
for the acetylated metabolites.
Gas chromatography-NP detector
Instrumentation
Analysis was performed using a Hewlett-Packard 5890 Gas
Chromatograph equipped with a NP detector, 7673A automatic sampler and
3392A integrator.
Chromatography conditions
The GC-NP conditions used for the analysis of DETDA and
acetylated-DETDA metabolites were as follows: chromatographic separations
were achieved using a 30 m J&W Scientific DB-5 capillary column (0.25 mm
i.d. x 0.25 pm film); helium carrier gas (60 p.s.i.g.) was set at a flow rate of
approximately 30 ml min'1; hydrogen gas (20 p.s.i.g.) was set at a flow rate of
approximately 4 ml min'1; air (30 p.s.i.g.) was set at a flow rate of approximately
100 ml min'1; GC oven temperature was programmed (Table 2.2) from 120°C to
300°C (final hold 1 min.) at 5°C min'1; injector and detector temperatures were
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Table 2.2

Oven
Temp
°C
120

Table 2.3

Oven
Temp
°C
100

Initial QC parameters for a Hewlett Packard 5890 Gas
Chromatograph, NP detector, 7673A autosampler and a
30 meter J&W Scientific DB-5 capillary column.
Initial Final InjectDet.
Rate
Initial
Temp Temp Temp Temp °C/min Time
°C
°C
°C
°C__
(min)
120

300

250

300

5

0

Final Run
Time Length
(min) (min)
1

37

GC parameters for a Hewlett Packard 5890 Gas
Chromatograph, FID detector and a 30 meter J&W
Scientific DB-5 capillary column.
Initial Final Inject Det. Rate
Initial Final
Run
Temp Temp Temp Temp °C/min Time Time Length
°C
°C
°C
°C_________ (min) (min) (min)
100
188
200

188
200
300

250

320

30
3
30

0
0

25.73
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set at 250°C and 300°C respectively; injections (0.5 min. splitless) were
performed either manually (2 pi) or by autosampler (1 pi).
Gas chromatography-FID detector
Instrumentation
Analyses were performed using a Hewlett-Packard 5895A Gas
Chromatograph equipped with a flame ionization detector (FID) and
ChemStation software.
Chromatography conditions
The GC-FID conditions used for the analysis of DETDA and
acetylated-DETDA metabolites were as follows: chromatographic separations
were achieved using a 30 m J&W Scientific DB-5 capillary column (0.25 mm
i.d. x 0.25 pm film); the helium carrier gas (60 p.s.i.g.) was set at a flow rate of
approximately 20 ml min'1; the hydrogen gas (20 p.s.i.g.) was set at a flow rate
of approximately 30 ml min'1; air (30 p.s.i.g.) was set at a flow rate of
approximately 400 ml min'1; the GC oven temperature was programmed from
100°C to 188°C at 30°C min'1, then 3°C min'1to 200°C, then 30°C min'1to
300°C (Table 2.3); injector and detector temperatures were set at 250°C and
320°C respectively; injections (0.5 min. splitless) were performed manually (2.6
Ml).
Results
BK^values for 2.4-TPA and Ethacure
Before the start of the titration, the amine groups (-NH2) of both
Ethacure and 2,4-toluenediamine are mostly in an ionized form (-NH3+) due to
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the dissociation of HCL into hydrogen protons and chloride counter ions
present in the solubilized solvent. Each amine group is capable of acting as a
proton donor and as such is referred to as an acid. As the hydroxide is added,
the (NH3+) dissociates. The resulting free H+ reacts with the hydroxide (OH )
forming water and a nonionized amine group (-NH2) . At the midpoint of the
titration, the concentration of (-NH3+) equals that of (-NH2). The pH at this point
is equal to the pIC, of the amine group (2.10).
Each compound has two amine groups, each with its own pIC,. Figure
2.2 plots pH against the amount of NaOH added over time. The pK„ of each
amine group for Ethacure and TDA is the pH at the midpoint of the curved
segments on the graph. For Ethacure those pK, points are at pH 2.5 and 4.6
while for 2,4-TDA the values are 2.6 and 5.3.

ExIipgtiQn coefficient?
The absorbance or optical density (OD) of a substance is a measure
of the amount of light absorbed by that substance. Each substance has a
characteristic wavelength at which maximum absorbance takes place. This
wavelength can be used as an aid in the identification of that substance when
presented as an unknown. Two pure substances with maximum absorption
atthe same wavelength can often be identified by differences in their extinction
coefficients. The extinction coefficient is a measure of the absorbance per
mole of the substance in question.
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Figure 2.2

Top: graph depicting pKa of 2,4-TDA amine groups (pH 2.6 and
5.3) Bottom: graph depicting pKa of Ethacure amine groups (pH
2.5 and 4.6).
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The extinction coefficient is a derivative of the Beer-Lambert Law (Fig.
2.3). Depending on the units of concentration, the extinction can be expressed
as either molar or millimolar. Maximum absorption of Ethacure and 2,4-TDA
was found to occur at 296 and 241 nm respectively. Using the Beer-Lambert
Law equation, millimolar concentrations of Ethacure and 2,4-TDA, and a
cuvette with a 1-cm light path, the extinction coefficients were determined to be
2790 mM'1cm'1and 8493 mM'1cm'1(Table 2.4), respectively.
Hydrodynamic voltammetry
The hydrodynamic voltammetry results for Ethacure are presented in
Table 2.5 and Figure 2.4. Maximum peak height was obtained at a potential of
500 mV. HDV results for monoacetylated 2,4-DETDA revealed a peak
potential of 550 mV as seen in Table 2.6 and Figure 2.5.
Retention Times for Chromatography
Electrochemical detection
The 2,4- and 2,6-DETDA retention times were 4.07 and 4.73
respectively. The monoacetylated metabolites of 2,4-DETDA had retention
times of 5.33 and 5.59 minutes. Because the acetyl metabolites could not be
resolved satisfactory, work on the electrochemical detector was discontinued.
UV detection
The 2,4- and 2.6-DETDA isomer retention times were 4.3 and 5.0
minutes respectively. The 2,4-monoacetylated-DETDA metabolites eluted as a
single peak at 5.6-5.8 minutes. The 2,6-monoacetylated-DETDA metabolite, as
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Table 2.4

Tabulation of absorption characteristics and pKa of Ethacure and
2,4-TDA.

Compound
Extinction
pK^
pK^
________________(mM) @ A_____________________________
Ethacure 100

2790 @ 296

2.5

4.6

2,4 TDA

8493 @241

2.6

5.3

Figure 2.3

The Beer-Lambert Law used to determine the extinction
coefficient of a substance once the absorbance and concentration
are known. E=extinction coefficient, A=absorbance of the
substance in solution, t=length of the light path through the
solution (usually 1 cm), C=concentration of the substance in
solution.
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Table 2.5

Hydrodynamic voltammetric results for Ethacure™100 (20 ng
sample of Ethacure). Equipment settings listed in Table 2.1.
Potential
Peak Height
(mV)________ (cm)
200

0.35

250

1.78

300

2.78

350

3.25

400

3.60

450

4.05

500

4.20

550

3.80

600

4.05

4.50
4.00
3.50
3.00
2.50
x 2.00
a. 1.50
1.00
0.50

0.00
200 250 300 350 400 450 500 550 600

Potential (mV)

Figure 2.4

Graphical results of Table 2.5. Note maximum peak height for
hydrodynamic voltammetry of Ethacure is at 500 mV.
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Table 2.6

Hemodynamic voltammetric results for a 20 ng sample of 2,4acetylated-DETDA. Note peak potential at 550 mV for both the 2and 4-position amine groups.
Potential (mV)

Peak Height
Peak
Amine Pos. 4 HeightAmine
____________________________ Pos. 2
750
700
650
600
550
500
450
400

2.35
2.75
3.4
4.1
4.42
3.45
1.16
0.2

2.77
3.15
3.9
4.8
5.18
4.08
1.74
0.3

6.00
Amine Pos. 4
Am ine Pos. 2

i

5.00

4.00

f 3.00

<
e8

a.

2.00

1.00

0.00 i

400 450

Figure 2.5

500 550 600 650
Potential (mV)

700 750

Graphical results of Table 2.6. Note maximum peak height for
both the 2- and 4-position amine groups occurs at 550 mV.
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expected, eluted as a single peak at 7.6 minutes. The diacetylated metabolites
of 2,4- and 2,6-DETDA had retention times of 11.2 minutes and 19.2 minutes
respectively. As with the electrochemical detector, resolution of the acetylated
metabolites was unsatisfactory (see Appendix B for representative example).
The HPLC-UV system was, however, later used to verify the purity of tritiated
2,4- and 2,6-DETDA (Chapters 5 and 6).
Gas chromatography-NP detector
Retention times for 2,4- and 2,6-DETDA as well as 2,4- and 2,6-monoand diacetylated-DETDA metabolites analyzed using GC-NP chromatography
were recorded in Table 2.7. Although the NP detector system proved to be a
satisfactory method of analysis, unresolvable equipment problems forced a
switch to the GC-FID system.
Gas chromatography-FID detector
Retention times for 2,4- and 2,6-DETDA as well as 2,4- and 2,6-monoand diacetylated-DETDA metabolites and internal standard diazepam using
GC-FID chromatography were recorded in Table 2.8. This GC-FID analytical
method was utilized in an extraction efficiency experiment (Chapter 3) and in
preliminary metabolism studies (Chapter 4).
Discussion
The piC, values, structure, and molecular weight of Ethacure and 2,4TDA are very close. Therefore, based on the Henderson-Hasselbalch
equation, the ratio of ionized to non-ionized compound at varying pH levels
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Table 2.7

2,4- and 2,6-DETDA, 2,4- and 2.6-monoacetylated DETDA
metabolites, 2,4- and 2,6-diacetylated metabolites were analyzed
with a Hewlett Packard 5890 Gas Chromatograph, NP detector,
7673A automatic sampler and a 30 meter J&W Scientific DB-5
capillary column giving the following retention times.
Compound

Retention Time (min)

2,4-DETDA

14.65

2,6-DETDA

15.46

2,4-monoacetylated DETDA (Pos. 4)

21.16

2,4-monoacetylated DETDA (Pos. 2)

21.40

2,6-monoacetylated DETDA

21.91

2,4-diacetylated DETDA

26.52

2,6-diacetylated DETDA

27.30

Table 2.8

2,4- and 2,6-DETDA, 2,4- and 2.6-monoacetylated DETDA
metabolites, 2,4- and 2,6-diacetylated metabolites and internal
standard diazepam were analyzed with a Hewlett-Packard 5890
Gas Chromatograph, FID detector and 30 meter J&W Scientific
DB-5 capillary column giving the following retention times.
Compound

Retention Time (min)

2,4-DETDA

5.93

2,6-DETDA

6.24

2,4-monoacetylated DETDA (Pos. 4)

9.47

2,4-monoacetylated DETDA (Pos. 2)

9.62

2,6-monoacetylated DETDA

10.08

2,4-diacetylated DETDA

13.78

2,6-diacetylated DETDA

14.40

Diazepam

16.39
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should be very close. The ionization status of a compound directly affects its
ability to be absorbed across cellular membranes as diffusion will occur
primarily in the part of the intestinal tract where the compound can exist in the
non-ionized, or lipid-soluble form (2.13). Based on pIC, values alone, DETDA
would be expected to be orally absorbed in a similar manner to toluenediamine.
However, such absorption is dependent on other parameters as well.
Knowledge of pKa values for DETDA will be useful in HPLC method
development by providing information needed for reverse-phase column buffer
selection. Extinction coefficients provide needed absorption information for
HPLC and spectrophotometry analysis.
The HPLC and GC analytical methods developed provided more than
adequate detection and separation of the primary isomers composing Ethacure
(2,4- and 2,6-DETDA). Significant problems were encountered in the
development of the HPLC method. As a weak base, DETDA presented a
chromatography challenge common to many aromatic amine compounds.
Band-tailing, resolution and excessive retention time problems had to be
addressed (2.14). Band-tailing is commonly caused by the sample compound
interacting with silanol groups in the column packing. Mobile phase modifiers
are often used with basic compounds to block these secondary-retention sites
thereby reducing the effects (2.15). Dibutylamine phosphate (pH 3.0) was able
to provide a solution to these problems for the 2,4- and 2,6-isomers (2.14).
The adsorption of positively charged lipophilic ions to the non-polar surface of
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the column results in a positively charged surface. The positive charged basic
compound is then less able to bind to the column, probably due to electrostatic
repulsion. As seen in the reported retention times for HPLC-UV, 2,4- and 2,6DETDA eluted first followed by the monoacetylated metabolites and finally the
diacetylated species. This would be expected as the parent compound would
have the first amine groups positively charged (the second amine group
minimally ionized) followed by monoacetylated metabolites with a single
positive charge and diacetylated metabolites with no positive charges.
Despite the addition of mobile phase modifiers and the use of an endcapped column, excessive band-tailing of the monoacetylated metabolites
could not be resolved adequately.
HPLC chromatography coupled with an electrochemical detector has
been shown to provide a significant increase in sensitivity over UV detection for
some compounds (2.9). As a sample enters the analytical cell, the electro
chemical detector measures a change in current as the potential across a cell
is held constant. This current change translates into characteristic peaks for
the analyte of interest.
The study showed, as expected, that HPLC-Electrochemical Detection
provided a reliable and reproducable method of detection for both 2,4- and 2,6DETDA. As with the HPLC-UV method, the conditions employed provided
good 2,4- and 2,6-DETDA separation. However, the 2,4- and 2,6-mono
acetylated metabolites again exhibited excessive band-tailing making positive
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identification questionable. The diacetylated-DETDA metabolites did not
undergo adequate oxidation or reduction and therefore were not able to be
detected by this method. Because each metabolite has its own ideal oxidationreduction potential, the ability to analyze multiple components of a mixture
would be limited using electrochemical detection. It would however, be ideal
for monitoring trace amounts of DETDA parent compound in urine samples.
The problems encountered by HPLC chromatography were resolved
with gas chromatography. The separation and resolution of the compounds of
interest was adequate for both identification and quantitation using either the
NP or FID detector.
In conclusion, HPLC chromatography proved to be an adequate
method of analytical detection for DETDA isomers but not for the associated
acetylated metabolites. Gas chromatography provided good separation,
resolution and acceptable retention times for both DETDA and metabolites.
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CHAPTER 3
SYNTHESIS AND EXTRACTION OF ACETYL
METABOLITES OF DETDA
Introduction
2,4-Toluenediamine is an intermediate compound widely used in
industry. Its primary use is in the synthesis of toluene diisocyanate, a crosslinking agent in the production of polyurethane foam. It is also used as an
intermediate in the synthesis of dyes used in textiles, wood stains and
pigments (3.1-3.4).
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is a compound
utilized as a polyurethane chain extender in reaction injection-mold
applications. DETDA also has uses as a curing agent for polyurethanes and
epoxies, as an antioxidant, lubricant, wire coating and as a replacement for
more toxic industrial compounds, such as MOCA (4,4'-methyienebis-2chloroaniline) and toluenediamine. DETDA has been manu-factured by
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years
under the name Ethacure®100 (3.5). Through a proprietary process, Ethacure
is synthesized from toluenediamine. It is commercially supplied as a mixture of
isomers with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4diamine (2,4-DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA)
and 0.5-3% dialkylated m-phenylenediamine. DETDA is a proprietary
compound, thus there is little information in the open literature on this material
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except for patents dealing with synthesis and industrial use. Because of
structural similarities to TDA, DETDA is expected to be absorbed, distributed,
metabolized and excreted like TDA. Biotransformation of DETDA is expected
to produce metabolites similar to those found with TDA.
Multiple studies in rats have shown the relevance of N-acetylation in
the metabolism of toluenediamine. In two separate studies in Fischer 344 male
rats, Grantham et al. reported that 4-acetylamino-2-aminotoluene (5.7% and
5.2% of dose) and 2,4-diacetylaminotoluene (2.6% and 1.4% of dose) were
significant urinary excretion products (3.6,3.7). Waring et al. found a high
percentage of phenolic metabolites and less than 3% mono- and di-acetylated
products in female Wistar rats (3.2). Timchalk et al. found comparable levels of
free 2,4-TDA and acetylated metabolites when oral and i.v. 3 mg 2,4-[14C]TDA/kg were administered to Fischer 344 rats (3.8). Comparing the ratio
between free plus acetylated 2,4-TDA to total acid-labile metabilites they found
61 % of detected metabolites as free or acetylated and 39% as other conjugates
when administered a 60 mg/kg oral dose while a 3 mg/kg dose resulted in
about 85% free and acetylated metabolites.
Using hamster liver cytosol, Glinsukon et al. found 2,4-TDA
metabolized to 3 acetylaminotoluene products (3.9). The primary metabolite
was 4-acetyl-amino-2-aminotoluene of which a small percentage was then
metabolized to 2,4-diacetyl-aminotoluene. The 2-acetylamino-4-aminotoluene
was also found to be further metabolized to 2,4-diacetylaminotoluene. From all
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indications, it appeared that the monoacetyl metabolite, 2-acetylamino-4aminotoluene was only a very minor metabolite and was probably further
metabolized to the diacetylaminotoluene product.
In order to detect and quantify acetylated biotransformation products,
the expected metabolite standards were needed. The first metabolites to be
synthesized would be the mono- and diacetylated-DETDA species.
In order to analyze these compounds, isolation from the tissue or
matrix of interest must be carried out. This usually involves some form of
extraction procedure. Extracting the analytes out of a urine matrix is usually
done by either solvent extraction or employing some form of solid bondedphase. The goal of all extraction processes is to separate the compound of
interest from as many interfering compounds as possible. Solvent extraction
utilizes a two-phase system into which a compound from an aqueous phase is
partitioned into a second phase which is often organic in nature (3.10). The
ability to extract a compound from a matrix is determined to a large degree on
its ionization state. Selective extraction can be realized by altering the pH of
the matrix partitioning its components into acidic, basic, and neutral
compounds which can then be partitioned into the appropriate solvent phase
for collection.
Sorbent extraction involves both a liquid and and solid phase (3.11).
This solid phase is generally a functional group covalently bonded (stationary)
to a silica substrate. An aqueous matrix (mobile phase) with the dissolved
analyte is allowed to pass through the sorbent bed. If a compound has a
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greater affinity for the functional group on the stationary versus the mobile
phase, it binds to the bed surface. Other components in the aqueous phase
then pass on through the bed and are eliminated. Solid Phase Extraction was
chosen because it provided a method for washing away much of the inter
ference caused by the urine matrix resulting in cleaner chromatographs with
lower background interference and fewer unwanted peaks. It also allowed
multiple samples to be processed simultaneously.
This project details the synthesis of the mono- and diacetylated
metabolites of both 2,4- and 2,6-DETDA. NMR and/or GC/MS structural
identification of these metabolites are presented. Solid phase extraction
methods were developed (3.12) and extraction efficiencies obtained for DETDA
isomers and associated acetylated standards.
Materials and Methods
Equipment
The Hewlett-Packard 5890 Gas Chromatograph, 5970 Series MS
Detector and 7673A autosampler were purchased from Hewlett-Packard
Company, Wilmington, DE 19808. The DB-5 fused-silica capillary gas
chromatograph column was purchased from J&W Scientific, Folsom, CA
95630. Bond Elut LRC®, 1211-3002, 10 cc/100 mg C-8 bonded phase
extraction columns were from Varian sample preparation products, Harbor City,
CA 90710. The Filter Tube Vacuum Filtration Manifold System (VFM 3 No.
5503) was purchased from Amicon Corporation, Danvers, MA 01923. The
EVAPO-MIX® was obtained from Buchler Instruments, Fort Lee, NJ 07024. The
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Vortex-2 Genie was purchased from Scientific Industries, Inc., Bohemia, NY
11716.
Chemicals
Methanol (Nanograde®), isopropanol (Nanograde®), chloroform
(ChromAR®), dichloromethane (Nanograde®) and acetic anhydride were
purchased from Mallinckrodt Chemicals, Paris, KY 40361. Acetonitrile was
obtained from Curtis Matheson Scientific, Inc., Houston, TX 77251. DRIERITE
(calcium sulfate anhydrous) was purchased from W.A. Hammond Drierite
Company, Xenia, OH 45385. Pure 2,4-diethyltolunediamine and 2,6-diethyltolunediamine provided by Albemarle Corporation, Baton Rouge, LA 70801.
Diazepam-d5 was purchased from Sigma Chemical Co., St. Louis, MO 63178.
Dimethyl sulfoxide-d6 99.9 atom% D (2206-27-1, No. 23,692-6) was purchased
from Adrich Chemical Co., Inc., Milwaukee, Wl 53233. Potassium dihydrogenphosphate (KH2P04) was purchased from Fisher Scientific Co., Fair Lawn, NJ
07410. Potassium hydroxide was purchased from EM Science, Gibbstown, NJ
08027.
Synthesis of acetvl metabolites
Monoacetyl and diacetyl metabolites of 2,4- and 2,6-diethyltoluenediamine were synthesized (Figure 3.1) following adaptations of procedures
published by Glinsukon et al. (3.13).
The 2-acetylamino-4-amino-3,5-diethyltoluene and 4-acetylamino-2amino-3,5-diethyltoluene monoacetyl metabolites (Figure 3.2) were made by
dissolving 2.5 g (14 mmol) of 2,4-DETDA (diethyltoluenediamine) in 12.5 ml of
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Structures of the synthesized mono- and di-acetylated metabolite
standards for 2,4- and 2,6-DETDA. Because the 2,6-DETDA is a
symetrical molecule, there is only 1 possible monoacetylated
derivative.
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Synthesis of 2-acetylamino-4-amino-3,5-diethyltoluene and 4acetylamino-2-amino-3,5-diethyltoluene from 2,4diethyltoluenediamine starting material.
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dichloromethane. Acetic anhydride (1.321 ml, 14 mmol) was added dropwise
to the solution and stirred on medium speed for 60 minutes. Unreacted acetic
anhydride was quenched by stirring in 8 ml of 50:50 v/v chloroform/methanol
solution. The mixture was dried under a stream of nitrogen gas then dissolved
in 8 ml of hot 50:50 v/v isopropanol/water. The solution was fully cooled at 5°C
then stored at -20°C overnight. The resulting precipitate was suction filtered
and dried under CaS04 in a vacuum desiccator for 72 hours.
2,6-DETDA monoacetylated metabolites
The 2,6 monoacetylated metabolites (Figure 3.3) were synthesized by
dissolving 2.5 grams (14 mmol) of 2,6-DETDA in 12.5 ml of dichloromethane.
Acetic anhydride (1.321 ml, 14 mmol) was added dropwise to the solution and
stirred on medium speed for 70 minutes. Remaining unreacted acetic anhy
dride was quenched by stirring in 8 ml of a 50:50 v/v chloroform/methanol
solution. The mixture was dried under a stream of nitrogen gas then dissolved
in 8 ml of hot 50:50 v/v isopropanol/water. The solution was fully cooled at 5°C
then stored at -20°C overnight. The resulting precipitate was suction filtered
and dried under CaS04 in a vacuum desiccator for 48 hours.
2,4-DETDA diacetylated metabolites
The 2-acetylamino-4-acetylamino-3,5-diethylto!uene diacetyl
metabolites (Figure 3.4) were prepared by dissolving 2.5 g (14 mmol) of 2,4DETDA in 12.5 ml of dichloromethane. Acetic anhydride (5.284 ml, 56 mmol)
was added drop-wise to the solution and stirred on medium speed for 30
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Synthesis of 2,4-diacetylamino-3,5-diethyltoluene from 2,4diethyltoluenediamine starting material.
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minutes. Unreacted acetic anhydride was quenched by adding 10 ml of a
50:50 v/v solution of chloroform/methanol. The mixture was dried under a
stream of nitrogen gas then dissolved in 10 ml of hot 50:50 v/v
isopropanol/water. The solution was fully cooled at 5°C then stored at -20°C
overnight. The resulting precipitate was suction filtered and dried under CaS04
in a vacuum desiccator for 48 hours.
2,6-DETDA diacetylated metabolites
The 2-acetylamino-6-acetylamino-3,5-diethyltoluene diacetyl
metabolites (Figure 3.5) were prepared by dissolving 2.5 grams (14 mmol) of
2,4-DETDA in 12.5 ml of dichloromethane. Acetic anhydride (5.284 m l, 56
mmol) was added dropwise to the solution and stirred on medium speed for 30
minutes. Unreacted acetic anhydride was quenched by adding 10 ml of a
50:50 v/v chloroform/methanol solution. The mixture was dried under a stream
of nitrogen gas then dissolved in 15 ml of hot 50:50 v/v isopropyl/water. The
solution was fully cooled at 5°C then stored at -20°C overnight. The resulting
precipitate was suction filtered and dried under CaS04 in a vacuum desiccator
for 48 hours.
Spectra of DETDA and acetvl metabolites
Nuclear magnetic resonance spectra
2,4-DETDA, 2,4-Ac-DETDA (2-acetylamino-4-amino-3,5-diethyltoluene
and 4-acetylamino-2-amino-3,5-diethyltoluene), 2,6-DETDA, and 2,6monoacetylated-DETDA were submitted in d6-(DMSO) for 1H and 13C NMR
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anaylsis at the Chemistry Department of LSU using a Bruker AM 400 MHz
machine.
Gas chromatography-mass spectroscopy
2,4-DETDA, 2,4-Ac-DETDA (2-acetylamino-4-amino-3,5-diethyltoluene
and 4-acetylamino-2-amino-3,5-diethyltoluene), 2,4-Ac2-DETDA (2-acetylamino-4-acetylamino-3,5-diethyltoluene), 2,6-DETDA, 2,6-monoacetylatedDETDA and 2,6-Ac2-DETDA (2-acetylamino-6-acetylamino-3,5-diethyltoluene)
were analyzed on a Hewlett Packard 5890 Gas Chromatograph coupled to a
Hewlett Packard 5970 Series MS Detector and a 7673A autosampler.
Chromatographic separations were achieved using a DB-5 fused-silica
capillary gas chromatograph column. The GC/MS conditions used in the
identification of DETDA isomers and acetylated metabolites were as follows: a
30 m DB-5 column (0.25 mm i.d. x 0.25 pm film thickness); helium carrier gas
(80 p.s.i.g.) was set at approximated 2 ml min'1; GC oven temperature was
programmed from 50°C (hold for 1 min.) to 300°C (hold for 10 min.) at 30°C
min'1; injector port tempature was set at 250°C; interface temperature was set
at 300°C; splitless valve time was set at 0.75 min; mass range was set from 40
to 650 and multiplier voltage set at 2200.
Sample extraction procedure
One-half ml of urine sample, 10 ppm of diazepam (internal standard),
and 2.0 ml of 0.1 M potassium phosphate buffer (pH 7.0)4was added to a
See Appendix A for all buffer preparations.
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16x100 mm borosilicate glass culture tube (3.12). The mixture was vortexed on
a Vortex-2 Genie for 5 seconds on medium speed and the pH adjusted
between 7.0 and 8.0 with KOH or phosphoric acid if needed.
C-8 Bond Elute Certify™ columns, placed into Teflon stopcocks and
18- guage needles, were inserted into a modified vacuum filtration manifold.
Unused ports were plugged in order to control vacuum pressure. The columns,
while under less than 5 inches Hg vacuum pressure, were conditioned by
adding 2.0 ml of methanol followed by 2.0 ml of potassium phosphate buffer
(pH 7.0). The columns were not allowed to dry out during conditioning. The
sample mixtures were pipetted into labeled columns and allowed to pass
through. This process took at least 2 minutes to complete with the vacuum set
to less than 5 inches Hg. The column was washed by adding 4ml of potassium
phosphate buffer (pH 7.0). It was further washed with 2ml of 6% acetonitrile94% potassium phosphate buffer (pH 7.0) then dried under a full vacuum (15
inches Hg) for 10 minutes. The vacuum manifold cover was removed and the
needle tips blotted dry. A rack with labelled culture tubes was then placed into
the manifold in preparation for collection of eluted compounds. Compounds of
interest were then eluted with 1.0 ml of a 50:50 v/v acetonitrile/methanol
solution with no vacuum present. After 1 minute, 5 inches Hg vacuum was
applied to remove any residual eluent. Samples were then placed into an
EVAPO-MIX® at 45°C and evaporated to dryness under a stream of nitrogen
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gas. Samples were then restored to 0.5 ml with methanol, vortexed for 30
seconds, and transfered to labeled vials for later GC analysis.
Extraction efficiency
In order to ascertain the extraction efficiency of the solid phase
system, rat urine samples were spiked with DETDA, associated acetylated
metabolites, and diazepam (internal standard) at concentrations of 10, 5, 1 and
0.5 ppm. These samples were then extracted and prepared for GC-FID
analysis according to the stated extraction protocol. These urine samples were
compared to methanol spiked controls at the same concentrations. To
minimize variation in the study, unspiked normal rat urine samples were passed
through SPE C-8 columns using the same procedure as the spiked urine
samples. After nitrogen drying the eluent, these unspiked urine samples were
restored with methanol which was then used in the preparation of the spikedmethanol controls. Three sets of urine-spiked samples and methanol-spiked
controls were prepared. Each set was analyzed 3 times for a total of 9 runs at
each concentration.
Results
The resulting yields of the synthesized 2,4-Ac-DETDA, 2,6-Ac-DETDA,
2.4-AC2-DETDA and 2,6-Ac2-DETDA metabolites were approximately 86%,
80%, 78% and 89% respectively. Structural conformation of the synthesized
metabolites were obtained by NMR and/or GC/MS.
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Nuclear magnetic resonance spectra
2,4 DETDA, 2,6 DETDA and the monoacetyl metabolites were
analyzed using a Bruker AM 400 MHz machine. Data presented in Tables 3.1
and 3.2 provided conformation of the anticipated monoacetylated derivatives.
Gas chromatography-mass spectroscopy
2,4-DETDA, 2,4-Ac-DETDA (2-acetylamino-4-amino-3,5-diethyltoluene
and 4-acetylamino-2-amino-3,5-diethyltoluene), 2,4-Ac2-DETDA (2-acetylamino-4-acetylamino-3,5-diethyltoluene), 2,6-DETDA, 2,6-monoacetylatedDETDA and 2,6-Ac2-DETDA (2-acetylamino-6-acetylamino-3,5-diethyltoluene)
mass spectra data is presented in Table 3.3.
Extensive fragmentation of the DETDA isomers and metabolites
occured during the electron ionization. Molecular ions were observed for all
compounds analyzed. For the 2,4- and 2,6-DETDA isomers, the base peak
resulted from the loss of the aromatic methyl group. Ethyl group fragmentation
was notably missing in the 2,6-monoacetylated species. For the most part, the
2,6 species was similar to the 2,4 species in the fragmentation pattern
presented.
Extraction efficiency
The extraction efficiencies of the 2,4- and 2,6-DETDA isomers were
between 79% and 86%. Extraction efficiencies of associated acetylated
metabolites ranged from 89% to 116%. Extraction efficiencies for the
compounds at different concentrations are listed in Table 3.4.
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Table 3.1

NMR proton analysis data for 2,4 DETDA and monoacetylated
metabolites. Abrv. S=singlet, bS=broad singlet, d=doublet,
t=triplet, m=multiplet, q=quartet, H=protons, j=correlation
constant, ppm=parts per million, Ar=aromatic, subscripted
numbers=number of protons, superscripted numbers=position on
ring.
2,4-DETDA
Proton

2,4-Ac-DETDA
positon 2

2,4-Ac-DETDA
positon 4

Ar-CH3

1.94 ppm
S, 3H

1.94 ppm
S, 3H

2.04 ppm
S, 3H

h (1.2)- n 2

4.05 ppm
bS, 2H

8.96 ppm
S, 1H
j=2.31

4.34 ppm
bS, 2H
j=4.09

h 3- n2

NA

1.98 ppm
S, 3H
j=1.14

NA

4.05 ppm
bS, 2H

4.34 ppm
bS, 2H
j=4.09

8.96 ppm
S, 1H
j=2.31

NA

NA

1.98 ppm
S, 3H
j=1.14

6.42 ppm
S, 1H

6.65 ppm
S, 1H
j=5.24

6.65 ppm
S, 1H,
j=5.24

acetate
h 2- c3
h 3- c3

N4

h 3- n4
acetate

H2-C s
h 3- c5

H -C 6
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Table 3.2.

NMR proton analysis data for 2,6-DETDA isomer and
monoacetylated metabolites. Abrv. S=singlet, bS=broad singlet,
d=doublet, t=triplet, m=multiplet, q=quartet, H=protons,
j=correlation constant, ppm=parts per million, Ar=aromatic,
subscripted numbers=number of protons, superscripted
numbers=position on ring.

Proton

2,6-DETDA

2,6monoacetylated
DETDA

Ar-CH3

1.85 ppm
S, 3H

1.86 ppm
S, 3H

H2 - N2

4.07 ppm
bS, 2H

4.33 ppm
d, 2H

2.34 ppm
j=7.47

2.34 ppm
m, 2H
j=7.50

H3-C3

1.05 ppm
t, 3H
j=7.38

1.02 ppm
m, 3H
j=7.46

H -C 4

6.42 ppm
S, 1H

6.65 ppm
S, 1H

h 2- c5

2.34 ppm
q, 2H
j=7.47

2.47 ppm
m, 2H
j=5.09

h 3- c =

1.05 ppm
t, 3H
j=7.38

1.10 ppm
m, 3H
j=5.37

^(1-2) ■N6

4.07 ppm
bS, 2H

8.99 ppm
S, 1H

H3 -N6 ,
acetate

NA

1.99 ppm
S, 3H

h 2- c 3

q, 2H
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GC-MS data confirming the structures of 2,4-and 2,6-DETDA, 2,4-and 2,6-monoacetylated
DETDA and 2,4- and 2,6-diacetylated DETDA. Data presented as m/z and relative intensity
(%) which is shown in parenthesis.

M+

ft

01

Com pound

X
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Table 3.3

M-15

-CH2CH3
M-29

-COCHj
M-43

2,4-DETDA

178 (75)

163 (100)

149 (10)

2,4-Ac-DETDA(4)

220(100)

205 (36)

191 (38)

177 (70)

2,4-Ac-DETDA(2)

220 (76)

205 (32)

191 (15)

177 (60)

2,4-Ac2-DETDA

262 (38)

2,6-DETDA

178 (90)

163 (100)

2,6-Ac-DETDA

220 (55)

205 (46)

2,6-Ac2-DETDA

262(100)

233 (20)

-NHCOCHj

-COCHs

M-58

-CHjCHj
M-72

-NHCOCHs -NHCOCHj
-C O C H j

-N H C O C H j

M-101

M-116

148(14)
162 (22)

148(15)

204 (20)

161 (75)

146 (40)

161 (70)

146 (30)

149(14)

233(10)

177 (95)

162 (18)

219(75)

204 (16)

148 (25)

-4

148

Table 3.4

Cone.

Extraction efficiencies using solid phase extraction for DETDA
isomers, associated acetylated metabolites and diazepam
(internal standard) in rat urine relative to fortified methanol at
differing concentrations. Analysis performed on GC-FID.
Compound Methanol

Urine

% Extraction

10 ppm 2,4-DETDA
2,6-DETDA
2,4-Ac(4)
2,4-Ac(2)
2,6-Ac
2,4-A^
2,6-ACj
Diazepam

2105.43
1995.51
764.47
1072.51
1782.40
1779.60
1681.64
1777.84

1816.78
1762.36
813.88
1129.04
1857.52
1796.60
1758.06
1882.14

86.29
88.32
106.46
105.27
104.21
100.96
104.54
105.87

5 ppm

2,4-DETDA
2,6-DETDA
2,4-Ac(4)
2,4-Ac(2)
2,6-Ac
2.4-AC2
2.6-AC2
Diazepam

1082.90
1024.71
397.71
550.91
908.23
875.63
811.57
892.77

919.95
867.35
416.19
573.45
947.57
886.34
839.12
935.42

84.95
84.64
104.65
104.09
104.33
101.22
103.39
104.78

1 ppm

2,4-DETDA
2,6-DETDA
2,4-Ac(4)
2,4-Ac(2)
2,6-Ac
2.4-ACj
2.6-AC2
Diazepam

199.90
201.70
76.04
110.27
167.92
154.81
139.83
170.68

171.81
169.22
87.86
114.24
184.63
158.47
143.66
175.71

85.95
83.90
115.54
103.60
109.95
102.36
102.74
102.95

2,4-DETDA
2,6-DETDA
2,4-Ac(4)
2,4-Ac(2)
2,6-Ac
2,4-ACj
2,6-Ac,
Diazepam

104.21
110.78
38.87
57.61
85.80
77.41
68.36
85.90

82.67
88.77
40.08
56.37
87.82
74.08
60.57
92.88

79.33
80.13
103.11
97.85
102.35
95.70
88.60
108.13
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Discussion
The synthesis of both monoacetylated and diacetylated DETDA
metabolites was successful and reproducible. The structures of the 2,4- and
2,6-DETDA isomers and the 2,4- and 2,6-monoacetylated DETDA metabolites
were confirmed by both NMR and GC/MS analysis. The 2,4- and 2,6-diacetylated metabolites were confirmed by GC/MS spectra. Molecular ions,
extensive fragmentation patterns, and NMR confirmation of the monoacetylated
DETDA structures provided the confidence level needed for confirmation of the
diacetylated species.
As noted in Figure 3.1, monoacetylation of the 2,4-DETDA isomer was
expected to result in the 2-acetylamino-4-amino-3,5-diethyltoluene and 4acetylamino-2-amino-3,5-diethyltoluene metabolites. NMR analysis of the 2,4monoacetylated DETDA mixture confirms that a greater percentage of the
position 2 acetylated species was present in the sample. Stearic hindrance
from the ethyl groups ortho to the 4-position amino group was thought to be
responsible for a decreased yield for 4-acetylamino-2-amino-3,5-diethyltoluene
( approx. 42%) compared to 2-acetylamino-4-amino-3,5-diethyltoluene (approx.
58%).
The Varian Bond Elut LRC® C-8 bonded phase extraction columns
provided an efficient and reproducible method for extracting DETDA, its
monoacetylated and diacetylated metabolites from urine. Resulting GC-FID
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chromatographs had minimal background interference and few unwanted
peaks.
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CHAPTER 4
METABOLISM OF DIETHYLTOLUENEDIAMINE
Introduction
2,4-Toluenediamine is an intermediate compound widely used in
industry (Figure 4.1). Its primary use is in the synthesis of toluene diiso
cyanate, a cross-linking agent in the production of polyurethane foam. It is also
used as an intermediate in the synthesis of dyes used in textiles, wood stains
and pigments (4.1-4.4).
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is a compound
utilized as a polyurethane chain extender in reaction injection-mold appli
cations. DETDA also has uses as a curing agent for polyurethanes and
epoxies, as an antioxidant, lubricant, wire coating and as a replacement for
more toxic industrial compounds, such as MOCA (4,4'-methylenebis-2chloroaniline) and toluenediamine. DETDA has been manu-factured by
Albemarle Corporation (formerly Ethyl Corporation) for more than 20 years
under the name Ethacure®100 (4.5). Through a proprietary process, Ethacure
is synthesized from toluenediamine. It is commercially supplied as a mixture of
isomers with the typical composition of 75.5-81% 3,5-diethyltoluene-2,4diamine (2,4-DETDA), 18-20% 3,5-diethyltoluene-2,6-diamine (2,6-DETDA)
and 0.5-3% dialkylated m-phenylenediamine. DETDA is a proprietary
compound, thus there is little information in the open literature on this material
except for patents dealing with synthesis and industrial use.
152
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Several studies in rats have shown the relevance of N-acetylation in
the metabolism of toluenediamine. In two separate studies in Fischer 344 male
rats, Grantham et al. reported that4-acetylamino-2-aminotoluene (5.7% and
5.2% of dose) and 2,4-diacetylaminotoluene (2.6% and 1.4% of dose) were
signif-icant urinary excretion products (4.6,4.7). Waring et al. found a high
percent-age of phenolic metabolites and less than 3% mono- and diacetylated
products in female Wistar rats (4.2). Timchalk et al. found comparable levels of
free 2,4-TDA and acetylated metabolites when oral and i.v. 3 mg 2,4-[14C]/kg
TDA were administered to Fischer 344 rats (4.8). Comparing the ratio between
free plus acetylated 2,4-TDA to total acid-labile metabilites they found 61 % of
detected metabolites as free or acetylated and 39% as other conjugates when
admin-istered a 60 mg/kg oral dose while a 3 mg/kg dose resulted in about
85% free and acetylated metabolites.
Using hamster liver cytosol, Glinsukon ef al. found 2,4-TDA
metabolized to 3 acetylaminotoluene products (4.9). The primary metabolite
was 4-acetyl-amino-2-aminotoluene of which a small percentage was then
metabolized to 2,4-diacetyl-aminotoluene. The 2-acetylamino-4-aminotoluene
was also found to be further metabolized to 2,4-diacetylaminotoluene. From all
indications, it appears that the monoacetyl metabolite, 2-acetylamino-4aminotoluene is only a very minor metabolite and is probably further
metabolized to the diacetyl-aminotoluene product.
Results from a two-year feeding study of DETDA in rats showed
effects on the pancreas, liver, thyroid and eyes as well as increased tumors in
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the liver and thyroid glands of male rats (4.5). These findings, along with the
structural similarity to the known mutagenic noncarcinogen:carcinogen pair 2,6and 2,4-toluenediamine (TDA), dictated the need for a metabolic study of the
DETDA mixture (4.1,4.10,4.11). DETDA was expected to be absorbed,
distributed, metabolized and excreted in a similar manner to TDA. Biotrans
formation reactions were expected to produce metabolites similar to those
found with TDA (Figure 4.2).
Using synthesized acetylated DETDA standards (Chapter 3), a pre
liminary rat study was performed to determine the extent of acetylation
occurring with DETDA during metabolism.
Materials and Methods
Materials
Chemicals
Methanol (Nanograde®) was purchased from Mallinckrodt Chemicals,
Paris, KY 40361. Acetonitrile was obtained from Curtis Matheson Scientific,
Inc., Houston, TX 77251. Potassium dihydrogenphosphate (KH2P04) was from
Fisher Scientific Co., Fair Lawn, NJ 07410. Hydrochloric acid was obtained
from Mallinckrodt Chemicals, Paris, KY 40361. Dibutylamine (99%) and
phosphoric acid (99.999%) were obtained from Aldrich Chemical Company,
Inc., Milwaukee, Wl 53233. Potassium hydroxide (PX-1480-1) was purchased
from EM Science, Gibbstown, NJ 08027. Wayne®Autoclavable Rodent BLOX®
8656 diet was purchased from Laboratory Diets, Madison, Wl 53711. Pure 2,4diethyltolunediamine, 2,6-diethyltolunediamine and Ethacure®100 provided by
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Albemarle Corporation, Baton Rouge, LA 70801. Diazepam-d5 was purchased
from Sigma Chemical Co., St. Louis, MO 63178. Vericel Membrane Filter
0.45pm (FP-450, 47mm No.66480) was from Gelman Sciences, Ann Arbor, Ml
48106.
Equipment
Bond Elut LRC® (1211-3002) 10 cc/100 mg C-8 bonded phase
extraction columns were from Varian sample preparation products, Harbor City,
CA 90710. The Filter Tube Vacuum Filtration Manifold System (VFM 3 No.
5503) was purchased from Amicon Corporation, Danvers, MA 01923. The
EVAPO-MIX® was obtained from Buchler Instruments, Fort Lee, NJ 07024. The
Vortex-2 Genie was purchased from Scientific Industries, Inc., Bohemia, NY
11716. Hewlett-Packard 5895A Gas Chromato-graph, FID detector and
ChemStation software were purchased from Hewlett-Packard Co., Wilmington,
DE 19808. The DB-5 fused-silica capillary gas chromatograph column was
purchased from J&W Scientific, Folsom, CA 95630.
Methods
Treatment protocol
One group of 4 young adult (10-12 weeks) male (1 control and 3
treatment, 172-186 g) Sprague Dawley rats (obtained from the L.S.U. Labora
tory Animal Medicine breeding colony) were randomly selected and placed into
individual metabolism cages for urine collection. Rats were fed a powdered 4%
fat diet (Wayne®Autoclavable Rodent BLOX® 8656 diet) and maintained in a
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12-hour light-dark cycle environment. They were placed into cages 24 hours
prior to dosing and were fasted for 16 hours to eliminate the effects of gastric
contents on absorption. Water was given ad libitum during the entire
experiment. Rats were orally dosed at 179 pmol/kg from a solution of 56
pmoi/ml of Ethacure in water using a 1.0 ml Hamilton #1001 syringe and a
curved ball-tipped 18-gauge x 3" feeding needle.
The urine from each rat was collected in iced containers for 4 time
periods (0-4, 4-8, 8-16 and 16-32 hours). Urine samples were prepared for
analysis using the solid phase extraction protocol established in Chapter 3.
A four-point standard curve (20,10,1, and 0.5 pg/ml) containing 2,4and 2,6-DETDA, 2,4- and 2,6-monoacetylated-DETDA, and 2,4- and 2,6diacetylated-DETDA in methanol was used to determine a limit of quantitation.
Sample extraction procedure
One-half ml of urine sample, 10 ppm of diazepam (internal standard),
and 2.0 ml of 0.1 M potassium phosphate buffer (pH 7.0)5was added to a
16x100 mm borosilicate glass culture tube. The mixture was vortexed on a
Vortex-2 Genie for 5 seconds on medium speed and the pH adjusted between
7.0 and 8.0 with KOH or phosphoric acid if needed.
C-8 Bond Elute Certify™ columns, placed into Teflon stopcocks and
18- gauge needles, were inserted into a modified vacuum filtration manifold.
Unused ports were plugged in order to control vacuum pressure. The columns,
See Appendix A for all buffer preparations.
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while under less than 5 inches Hg vacuum pressure, were conditioned by
adding 2.0 ml of methanol followed by 2.0 ml of potassium phosphate buffer
(pH 7.0). The columns were not allowed to dry out during conditioning. The
sample mixtures were pipetted into labeled columns and allowed to pass
through. This process took at least 2 minutes to complete with the vacuum set
to less than 5 inches Hg. The column was washed by adding 4ml of potassium
phosphate buffer (pH 7.0). It was further washed with 2ml of 6% acetonitrile94% potassium phosphate buffer (pH 7.0) then dried under a full vacuum (15
inches Hg) for 10 minutes. The vacuum manifold cover was removed and the
needle tips blotted dry. A rack with labeled culture tubes was then placed into
the manifold in preparation for collection of eluted compounds. Compounds of
interest were then eluted with 1.0 ml of a 50:50 v/v solution of acetonitrile and
methanol with no vacuum present. After 1 minute, 5 inches Hg vacuum was
applied to remove any residual eluent. Samples were then placed into an
EVAPO-MIX® at 45°C and evaporated to dryness under a stream of nitrogen
gas. Samples were then restored to 0.5 ml with methanol, vortexed for 30
seconds, and transferred to labeled vials for later GC analysis.
Chromatography
Instrumentation
Analysis was performed using a Hewlett-Packard 5895A Gas
Chromato-graph equipped with a FID (flame ionization detector) detector and
Chem-Station software (Chapter 2).
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Chromatography conditions
The GC-FID conditions used for the analysis of DETDA and
acetylated-DETDA metabolites were as follows: chromatographic separations
were achieved using a 30 m J&W Scientific DB-5 capillary column (0.25 mm
i.d. x 0.25 pm film); helium earner gas (60 p.s.i.g.) was set at a flow rate of
approximately 20 ml min'1; hydrogen gas (20 p.s.i.g.) was set at a flow rate of
approximately 30 ml min'1; air (30 p.s.i.g.) was set at a flow rate of approx
imately 400 ml min'1; GC oven temperature was programmed from 100°C to
188°C at 30°C min'1, then 3°C min'1to 200°C, then 30°C min'1to 300°C;
injector and detector temperatures were set at 250°C and 320°C respectively;
2.6 pi manual injections (0.5 min. splitless) were made. Standard curves were
run before and after the sample analysis.
Results
Only 2 of the 3 rats administered Ethacure were quantitatively
evaluated because of the questionable dosage administered to one of the rats.
In the first rat, 4.0% of the administered dose was recovered as both 2,4- and
2,6-DETDA (parent compound) by 32 hours. In the second rat, 4.4% of the
administered dose was recovered as both 2,4- and 2,6-DETDA. None of the
expected acetylated DETDA metabolites were detected in the urine above 500
ng/ml (limit of quantitation) in any of the 3 rats treated (see Appendix C).
Discussion
Acetylation is considered to be one of the major biotransformation
reactions for aromatic amines in most species (4.12). It was therefore expected
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that both mono-acetylated- and/or diacetylated-DETDA metabolites would
encompass a portion of the biotransformation profile of DETDA. The lack of
acetylated metabolites in the urine of the Ethacure treated male Sprague
Dawley rats was surprising. The experiment was repeated with a single male
Sprague Dawley rat to confirm the results. The outcome was the same with
4.3% recovery of the 2,4- and 2,6-DETDA isomers and no acetylated
metabolites seen by 32 hours. Extraction efficiency of 2,4- and 2,6-DETDA
isomers from the urine matrix ranged from 79.33% to 88.32% (Chapter 3).
Excretion studies (Chapter 5 and 6) for 2,4- and 2,6-DETDA showed
that the majority of label was eliminated through the urinary system. Because
no attempt was made to assay the bile for metabolites, any acetylated
metabolites excreted via the biliary system were undetected.
This study was designed as a preliminary experiment to ascertain the
presence or absence of parent compound and acetylated metabolites in urine
samples. Protocols to determine a limit of detection was not incorporated in
this study but was estimated to be approximately 200 ppb. The limit of
quantitation for 2,4- and 2,6-DETDA and the mono- and diacetylated-DETDA
metabolites was approximately 500 ppb determined by 4 point standard curves
(1^=0.998-0.999). The unexpected results from this preliminary study prompted
a change in direction for the DETDA project. Radiolabeled compound was
incorporated into the remainder of the study precluding the further use of GCFID.
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Reasons for the lack of acetylated DETDA metabolites in the urine are
unknown at this time. Possible explanations for the outcome could be species,
strain and sex variations, extremely low affinity for the acetyl transferase
enzyme and/or high affinity for other biotransformation enzymes. Extremely
low levels of acetylated metabolites might have gone undetected by a
moderately sensitive FID detector. Since toluene-diamine is known to be
acetylated in Fischer 344 rats, differences in structural conformation in DETDA
(ethyl groups) are most likely contributing to the lack of or extremely low levels
of acetylation. Because DETDA is easily acetylated with acetic anhydride
(Chapter 3), the ethyl groups do not appear to sterically hinder acetylation,
however it is more likely that the ethyl groups prevent the acetyltransferase
enzyme from binding in an optimal orientation.
The 2,4-toluenediamine compound has been reported to be carcino
genic in rodents (4.1,4.10,4.13). Results from a two-year feeding study of
DETDA in rats showed effects on the pancreas, liver, thyroid and eyes as well
as increased tumors in the liver and thyroid glands of male rats (4.5). The
carcinogenic potential of Ethacure appears to be much less than 2,4-TDA.
Whether the abscence or reduction in acetylation with DETDA could be related
to the decreased carcinogenicity relative to TDA needs to be further explored.
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CHAPTER 5
DISTRIBUTION, EXCRETION, AND COVALENT
BINDING OF 2,4-DIETHYLTOLUENEDIAMINE
Introduction
Diethyltoluenediamine (DETDA, CAS 68479-98-1) is an industrial
compound utilized as a polyurethane chain extender in reaction-injection
molded (RIM) applications. DETDA has also been used as a curing agent for
polyurethanes and epoxy resins, as an antioxidant, lubricant, a wire coating
and as a replacement for more toxic industrial compounds, such as
toluenediamine (TDA) and 4,4'-methylenebis-2-chloroaniline (MOCA) (5.1).
DETDA has been manufactured by Albemarle Corporation (formerly Ethyl
Corporation) under the name Ethacure®100 for more than 20 years. Ethacure
is a mixture of compounds (Figure 5.1) composed mostly of 2 major isomers,
2,4-DETDA (75-81%) and 2,6-DETDA (18-20%). Because it is a proprietary
compound, there is little information in the literature on this material except for
patents dealing with synthesis and industrial use. DETDA is expected to be
absorbed, distributed, metabolized and excreted in a similar manner to TDA, a
widely used industrial compound, because of structural similarities (5.2-5.4).
Standard laboratory studies, including acute and subchronic toxicity
tests, have been conducted on Ethacure. Results from a two-year feeding
study in rats, conducted by Albemarle suggested that DETDA may affect the
pancreas, liver, thyroid and eyes (5.5). These studies, and an interest by
165
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Albemarle in full understanding of the potential toxicity of DETDA prompted a
metabolic study of the mixture. Understanding of the distribution and excretion
of DETDA in a mammalian system is important to help establish proper safety
guidelines.
Tritiated Ethacure was prepared by the catalytic exchange of tritium
gas on Ethacure. The tritium label is characteristically exchanged at the less
labile benzylic positions on the ring (5.6). Labile tritium from the crude product
was removed but no attempt at purification or separation of isomers was made.
Distribution, excretion and covalent DNA-binding studies on the 2,4and 2,6-DETDA isomers needed to be conducted. Before the tritiated Ethacure
could be used, it was necessary to determine the stability of the label then
separate the mixture into major isomers.
This study entailed the oral administration of tritiated 2,4-DETDA to
adult male Sprague Dawley rats. Distribution and excretion profiles over time
in multiple tissues were acquired as well as DNA binding levels in liver tissue.
Materials and Methods
Materials
Equipment
The Hitachi U-2000 Spectrophotometer was purchased from Hitachi
Instruments, Inc., Houston, Tx 77272. The Shimadzu LC-600 Liquid Chromato
graph pump, Shimadzu SPD-10AV UV detector, Easychrome software and DT
2802 A/D converter board were obtained from Shimadzu Scientific Instruments,
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Columbia, MD 21046. The C18 Partisphere 5pm 4.6x250mm reverse-phase
column (No. 4621-1502), guard column (No. 4641-0002) and holder (No. 46510002) were purchased from Whatman Laboratory Division, Clifton, NJ 07014.
The PrepPak 25x10 Bondapak™ cartridge, (10 pm No.38505), PrepPak 25x10
pPorasil cartridge (10 pm No.38504) and RCM 25x10 cartridge holder
(No. 15814) were purchased from Millipore Corp., Waters Chromatography
Division, Milford, MA 01757. The Buchner Fractomette® Alpha 400 fraction
collector was purchased from Buchler Instruments, Fort Lee, NJ 07024. The
Packard Tri-Carb 4640 and 1900TR Liquid Scintillation Analyzer were
purchased from Packard Instrument Co., Meriden, CT 06450. The Wheaton
Overhead Stirrer (No. 903475) was purchased from Wheaton Instruments,
Millville, NJ 08332. The 10 ml Potter-Elevehjem Grinder (No. 358038) was
purchased from Wheaton, Millville, NJ 08332. The Burrell Model 75 Wrist
Action® Shaker was obtained from Burrell Corp., Pittsburgh, PA 15201. The
Sorvall GLC-2B General Lab Centrifuge was from Dupont Instruments,
Newtown, CN 06470. The Vortex-2 Genie was purchased from Scientific
Industries, Inc., Bohemia, NY 11716. The Eppendorf Microcentrifuge (No.
5415C) was purchased from Brinkmann Instruments, Inc., Westbury, NY
11590. The Ohaus E400D balance was purchased from Ohaus Corporation,
Florham Park, NJ 07932. Sigma Plot software was purchased from Jandel
Scientific, San Rafael, CA 94901. The Gilson Differential Respirometer (SC14) was purchased from Gilson Medical Electronics, Middleton, Wl 53562.
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Chemicals and supplies
Ethacure®100 was obtained from the Albemarle Corp., Baton Rouge,
LA 70801. Toluene, sodium hydroxide pellets, methanol (Nanograde®),
calcium chloride (No. 4160) and hydrochloric acid were obtained from
Mallinckrodt Chemicals, Paris, KY 40361. Ethanol (reagent grade, #AX04451), sodium chloride and potassium hydroxide (PX-1480-1) were from EM
Science, Gibbstown, NJ 08027. Ethanol (dehydrated, absolute-200 proof) was
purchased from McCormick Distilling Co., Inc., Weston, MS 64098.
Acetonitrile, acetone (high purity) and ethyl acetate were purchased from Curtis
Matheson Scientific, Inc., Houston, TX 77251. Dibutylamine (99%),
magnesium chloride (hexahydrate, 99%), hydrogen peroxide (30 wt. %, No.
21,676-3) and phosphoric acid (99.999%) were purchased from Aldrich
Chemical Company, Inc., Milwaukee, Wl 53233. Guanidine isothiocyanate
ultrapure™ was purchased from Bethesda Research Laboratories,
Gaithersburg, MD 20877. Phenol:chloroform premixed with isoamyl alcohol
and EDTA (disodium salt dihydrate, >99% purity) were obtained from
Amresco®, Solon, OH 44139. Ammonium acetate, Trizma® hydrochloride, and
calf thymus DNA (sodium salt, D-1501) were purchased from Sigma Chemical
Co., St. Louis, MO 63178. Tris Base (ultrapure) was purchased from Tyron®,
Okemos, Ml 48664. SDS (sodium dodecyl sulfate, ultrapure) was purchased
from Life Technologies, Inc., Gathensburg, MD 20898. Millipore ultra free-MC
Low binding Cellulose 5,000 NMWL (No. UFC3LCC00) filters were purchased
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from Millipore Corporation, Milford, MA 01757. Vericel Membrane Filters
(0.45pm, FP-450, 47mm No.66480) were purchased from Gelman Sciences,
Ann Arbor, Ml 48106. Hionic-Fluor™ liquid scintillation cocktail (No.6013319),
Soluene-350, Pico-Prias vial, 6.5ml (No.6000192), and Vented Pico Holder
Adapter (No. 6013400) were purchased from Packard Instrument Co., Meriden,
CT 06450. Harvard perfectum animal feeding needle (curved ball-tipped 18gauge x 3", No. 7914) was purchased from Popper & Sons, Inc., Newhyde
Park, NY 11640. Wayne®Autoclavable Rodent BLOX® 8656 diet (powdered 4%
fat diet) was purchased from Laboratory Diets, Madison, Wl 53711. 50 ml
Coming polypropylene centrifuge tubes (No. 25331-50) were purchased from
Coming Inc., Coming, NY 14631. Nalgene® Wide-Mouth HDPE Bottles (No.
2104-0004,125 ml) were purchased from the Nalge Company, Rochester, NY
14602. Culture tubes (borosilicate) were purchased from Kimble Glass, Inc.,
Vineland, NJ 08360. Micro-centrifuge tubes (flat top/graduated, 1.5 and 2.0 ml)
were purchased from Dot Scientific, Inc., Burton, Ml 48519. Chemicals
purchased were reagent grade quality unless otherwise indicated.
Tritiated Ethacure was prepared by Amersham Life Science, Inc.,
Arlington Heights, IL 60005. The product was stored and shipped in 25 ml of
ethanol, had a total activity of 6.72 mCi/ml, a specific activity of 1.2 Ci/mmol
and a concentration of 0.0082 mmol/ml.
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Experimental Methods
Determination of tritiated Ethacure stability
A 1 mg/ml solution of Ethacure®100 (134 pCi/ml) was prepared by
mixing 20 pi of the 6.72 pCi/ml tritiated compound with 980 pi of a 1 mg/ml
solution of unlabeled Ethacure. 100 pg/ml solutions in water, 0.1M HCL and
0.1 M NaOH were made using the stock labeled solution then incubated for 1
hour. Samples were then neutralized using sodium acetate or glacial acetic
acid.
Fifty pi samples were chromatographed using a Shimadzu LC-600
Liquid Chromatograph, Shimadzu SPD-10AV detector (295 nm) and a
Whatman C18 Partisphere 5pm 4.6x250mm column. A 16.5% acetonitrile,
100mM dibutylamine phosphate buffer (pH 3.0) mobile phase (see Chapter 2)
was used at a 1 ml/min flow rate. Eluent was collected into 6.5 ml polyethylene
liquid scintillation vials using a Buchner Fractomette® Alpha 400 fraction
collector at 6 second intervals. Five ml of Hionic-Fluor™ liquid scintillation
cocktail was added to each vial and the radioactivity measured on a Packard
Tri-Carb 4640. Sigma Plot software was used to convert the raw data into
chromatographs for analysis.
Separation and purification of tritiated Ethacure
A 10 mCi aliquot of [3H]-Ethacure®100 (1.5 ml in ethanol) was
evaporated under a stream of nitrogen then restored to 0.75 ml using a 60:40
v/v solution of toluene and ethanol. Isomer separation was achieved under a
normal-phase preparative HPLC method using a Shimadzu LC-600 Liquid
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Chromatograph, a Shimadzu SPD-10AV detector (295 nm) and a PrepPak
25x10 pPorasil cartridge in a RCM 25x10 cartridge holder. ThelOmCi
sample was injected via a Rheodyne 1526 injector through a 1000 pi injection
loop and eluted at 2ml/min for 60 minutes in a filtered 60:40 toluene:ethanol
isocratic mobile phase. The 2,4- and the 2,6-DETDA fractions were collected
referenced to unlabeled Ethacure chromatographed under identical
parameters. Each fraction was collected, diluted to 10 ml with toluene, then
stored at -20°C (5.7).
The tritiated 2,4-DETDA fraction was checked for purity using a
Whatman C-18 reversed-phase column, a Shimadzu LC-600 Liquid
Chromatograph and a Shimadzu SPD-10AV detector (295 nm). To prepare the
sample, 5.36 pCi of [3H]-2,4-DETDA was placed into a 13x100mm borosilicate
culture tube and evaporated to dryness. One ml of a 50 pg/ml solution of
Ethacure dissolved in mobile phase was added to the tube and vortexed. A 50
pi sample was injected via a Rheodyne 1526 injector through a 50 pi injection
loop and eluted at 0.5 ml/min for 15 minutes in a 16.5% acetonitrile, 100 mM
dibutylamine phosphate buffer (pH 3.0) isocratic mobile phase (5.8).
After injecting the sample, 63 fractions were collected into 6.5ml
Pico-Prias liquid scintillation vials at 0.2 minute intervals using a Buchner
Fracto-mette® Alpha 400 fraction collector. Five ml of Hionic-Fluor™ liquid
scintillation cocktail was added to each vial and the radioactivity measured on
a Packard Tri-Carb 4640 Liquid Scintillation Counter. Quattro Pro 6.0 was
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used to generate graphs from the UV and CPM data. CPM values from each
peak on the generated graphs were totaled and the sums used to compute
isomer purity.
Distribution studies
Five groups of 4 young adult male (10-12 weeks, 216-293 g) Sprague
Dawley rats (obtained from the L.S.U. School of Veterinary Medicine,
Laboratory Animal Medicine breeding colony) were randomly selected and
placed into individual metabolism cages for urine and feces collection. Rats
were placed into cages 72 hours prior to dosing, fed a powdered 4% fat diet
(Wayne®Autoc!avable Rodent BLOX® 8656 diet) and maintained in a 12-hour
light-dark cycle environment. Rats were fasted for 16 hours prior to dosing
eliminating the effects of gastric contents on absorption. Water was given ad
libitum during the entire experiment. Tritiated 2,4-DETDA was diluted with nontritiated Ethacure (84 pmol/ml) in water to provide a labeled mixture with a
specific activity of 0.46 pCi/pmol. Rats were then orally dosed at 179 pmol/kg
from this solution of 84 pmol/ml of Ethacure using a 1.0 ml Hamilton #1001
syringe and a curved ball-tipped 18-gauge x 3" feeding needle.
Urine, feces, blood and tissues were collected at 5 time points: 1, 4, 8,
24 and 48 hours. A day 6 tissue distribution time point was incorporated in the
6 day excretion study. Rats were anesthetized with isoflurane at each time
point. Blood samples were taken by cardiac puncture using a heparinized 12
ml syringe with a 22-gauge needle then placed into labeled serum collection
tubes for later processing.
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Urine was collected into ice-filled containers until the time of
euthanasia. Each cage was washed with 12 ml of distilled water which was
added to the total urine collection. Urines were measured and samples were
refrigerated until analysis.
To remove any residual label, each cage was rinsed with
approximately 20 ml of methanol which was collected in 50 ml Coming
polypropylene centrifuge tubes. Tubes were centrifuged for 5 minutes at 2800
rpm in a Sorvall GLC-2B General Lab Centrifuge preparing a clarified
supernatant. After later analysis, methanol sample counts were added to urine
sample counts providing a total urine count.
All feces in the cage at each time point were collected and placed into
a 50 ml Coming polypropylene centrifuge tube. Small intestine contents were
placed into the tube along with the caecum and large intestine and a small
amount of water. This tissue was minced with a scissors then water added to
the 45 ml mark. The 24 and 48 hour samples required placement into 125 ml
polyethylene bottles which were filled to the 110 ml mark. All samples were
weighed then throughly mixed for a minimum of 48 hours using a Burrell Model
75 Wrist Action® Shaker.
The following tissues were removed from each rat at the time of death:
fat (epididymal fat pad), skin (ventral midline), skeletal muscle (right
quadriceps), thymus, lung (right caudal lobe), heart (apex), spleen (caudal
end), pancreas, bladder, kidney (right caudal area), liver (right caudal lobe),
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stomach (greater curvature), proximal duodenum, caecum (apex), colon
(proximal ascending), thyroid, and brain (right frontal lobe). Each tissue was
removed, trimmed and weighed. A small piece of tissue (about 100 mg, except
thyroid) was sampled from the same area of each organ, weighed and placed
into labeled 6.5 ml polyethylene liquid scintillation counting vials for
preparation.
In order to determine the percent of administered dose in each tissue
sampled, the organ weight was needed. The skin, stomach, small intestine,
caecum and colon presented difficult weighing problems at sampling time. To
obtain the needed weights, these organs were harvested from 5 untreated
young adult male Sprague Dawley rats. An average weight for each organ as a
percent of body weight was calculated. Also, the anatomy of the rat pancreas
made total dissection difficult and uncertain. To minimize variation, an average
pancreatic tissue weight from 30 rats in the distribution and excretion study was
calculated relative to body weight. This average weight was used in place of
individual weights for the purpose of calculating percent of administered dose.
Excretion studies
Five young adult male (10-12 weeks, 251-296 g) Sprague Dawley rats
(obtained from the L.S.U. School of Veterinary Medicine, Laboratory Animal
Medicine breeding colony) were randomly selected and placed into individual
metabolism cages for urine and feces collection. Rats were placed into cages
72 hours prior to dosing, fed a powdered 4% fat diet (Wayne®Autoclavable
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Rodent BLOX® 8656 diet) and maintained in a 12-hour light-dark cycle
environment. Rats were fasted for 16 hours prior to dosing eliminating the
effects of gastric contents on absorption. Water was given ad libitum during
the entire experiment.
Tritiated 2,4-DETDA was diluted with non-tritiated Ethacure (84
pmol/ml) in water to provide a labeled mixture with a specific activity of 0.48
pCi/pmol. Rats were then orally dosed at 179 pmol/kg from this solution of 84
pmol/ml of Ethacure using a 1.0 ml Hamilton #1001 syringe and a curved balltipped 18-gauge x 3" feeding needle.
Urine and feces were collected into ice-filled containers at 24 hour
intervals for 6 days. Each cage was washed with 12 ml of distilled water which
was added to the total urine collection. Urines were measured and samples
were refrigerated until analysis.
Feces in the cage at each time point were placed into 125 ml
polyethylene bottles. On day 6, rats were anesthetized with isoflurane and
blood collected by cardiac puncture using a 12 ml heparinized syringe and 22gauge needle. Contents from the stomach, small intestine, caecum, and large
intestine were added to the day 6 time points. Water was added to the 110 ml
level of all bottles and the weights recorded. Bottles were then shaken for a
minimum of 48 hours using a Burrell Model 75 Wrist Action® Shaker ensuring
equal and through mixing of intestinal contents.
The following tissues were removed from each rat at the time of death
for a day 6 distribution study: fat (epididymal fat pad), skin (ventral midline),
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skeletal muscle (right quadriceps), thymus, lung (right caudal lobe), heart
(apex), spleen (caudal end), pancreas, bladder, kidney (right caudal area), liver
(right caudal lobe), stomach (greater curvature), proximal duodenum, caecum
(apex), colon (proximal ascending) and brain (right frontal lobe). Each tissue
was removed, trimmed and weighed. A small piece of tissue (about 100 mg,
except thyroid) was sampled from the same area of each organ, weighed and
placed into labeled 6.5 ml polyethylene liquid scintillation counting vials for
preparation.
Characterization of urine fractions
Five urine samples from the [3H]-2,4-DETDA excretion experiment (24
hour time point) were analyzed to determine the percent of excreted label that
was water soluble, organic soluble or present as acid-labile conjugates. 200 pi
of each urine sample was placed directly into Hionic-Fluor™ liquid scintillation
cocktail and counted. To determine the total organic fraction, 200 pi urine
samples in 1.5 ml Eppendorf microcentrifuge tubes were extracted 3 times with
1.0 ml of ethyl acetate. The 3 extracts were placed directly into Hionic-Fluor™
liquid scintillation cocktail and counted. To determine total acid-labile
conjugates, urine samples were acid hydrolyzed (5.9). Each 200 pi sample
was placed into a 2.0 ml Eppendorf microcentrifuge tube, acidified with 3 drops
of 1M HCL, heated to 100°C for 60 minutes then neutralized with 3 drops of 1M
NaOH. Each hydrolyzed sample was extracted 3 times with 1.0 ml of ethyl
acetate. The combined extracts were placed into 20 ml liquid scintillation vials
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containing Hionic-Fluor™ liquid scintillation cocktail and counted on a Packard
1900TR Liquid Scintillation Analyzer.
Ionic and hydrostatic binding of DETDA with DNA
Besides the covalent binding seen between DNA and macromolecules
or xenobiotics, other forms of binding must be considered. Ionic or
electrostatic, hydrogen and Van der Waals bonds are sometimes formed
between these molecules (5.10). In order to determine if covalent binding had
occurred between DETDA and DNA, these other types of binding had to be
ruled out (5.11).
A 1 mg/ml solution of calf thymus DNA and a 5 mg/ml solution of
Ethacure was prepared in TE buffer. In a 15 ml borosilicate test tube was
mixed 1 ml of the DNA solution, 1.0 ml of TE buffer and 200 pi of a 2.98 pCi/ml
solution of [3H]-2,4-DETDA in TE buffer. The mixture was incubated for 1 hour
at 37°C in a Gilson shaking water bath. A 400 pi sample of this mixture was
pipetted into Hionic-Fluor™scintillation cocktail and counted with a Packard
1900TR Liquid Scintillation Analyzer. To determine if DNA binding had
occurred, another 400 pi of the tritiated mixture was passed through a Millipore
5000 molecular weight cutoff filter. The filter was centrifuged for 30 minutes at
14,000 rpm on a Eppendorf microcentrifuge. The filter was then rinsed with
300 pi of TE buffer. The eluent, minus the DNA with possible labeled DETDA,
and the TE buffer wash was then counted. To release any DNA-bound tritiated
DETDA trapped by the filter, 500 pi of a 5 mg/ml solution of Ethacure was
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passed through the filter system by centrifugation. The Ethacure, by
competitive binding, should have displaced any labeled DETDA from the DNA
and allowed it to be washed through the filter and counted.
To determine if any labeled DETDA was bound to the filter, control
samples without DNA were also run. 400 pi of the 2.98 pCi/ml solution of [3H]2,4-DETDA in TE buffer was added to 3.6 ml of TE buffer. 400 pi of this
solution was centrifuged through a Millipore filter. The filter was washed with
TE buffer and the combined eluents counted. Evidence of ionic binding was
achieved by comparing non-filtered labeled DETDA to labeled DETDA that
passed through the cut-off filter before and after competitive binding with
Ethacure. This data was then compared to data obtained with the control
samples. All procedures were conducted in triplicate, the results of which were
averaged.
Covalent binding studies
Three young adult male (10-12 weeks, 159-211g) Sprague Dawley
rats (obtained from the L.S.U. School of Veterinary Medicine, Laboratory
Animal Medicine breeding colony) were randomly selected and placed into
individual metabolism cages. Rats were placed into cages 72 hours prior to
dosing, fed a powdered 4% fat diet (Wayne®Autoclavable Rodent BLOX® 8656
diet) and maintained in a 12-hour light-dark cycle environment. They were
fasted for 16 hours prior to dosing to minimize the effects of gastric contents on
absorption. Water was given ad libitum during the entire experiment.
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ONA extraction from the livers of rats previously exposed to tritiated
DETDA at levels of 0.05 pCi/g of body weight resulted in counts just above
background level. In order to place confidence in the study, a much higher
dose of tritiated DETDA was administered. Tritiated 2,4-DETDA was diluted
with unlabeled Ethacure to attain a specific activity of 8.42 pCi/pmol. Rats
were dosed at 179 pmol/kg from labeled solutions of 84 pmol/ml of Ethacure in
water prepared the morning of the experiment. A 1.0 ml Hamilton #1001
syringe and a curved ball-tipped 18-gauge x 3" feeding needle was used to
gavage the rats.
Twenty-four hours after dosing, rats were placed under isofiurane
anesthesia then euthanized by exsanguination at which time the livers were
harvested and weighed. Small pieces of liver tissue (about 100 mg) were
excised, weighed and placed into labeled 6.5 ml polyethylene liquid scintillation
counting vials for preparation.
DNA Extraction
The extraction of nucleic acid from the selected tissue required lysis of
the cellular membranes followed by the separation of the nucleic acid from the
resulting cellular debris. The nucleic acids were then partitioned into the
aqueous phase using phenol-chloroform-isoamyl alcohol. The remainder of the
cellular debris, including the proteins, entered into the organic fraction or the
interface phase.
Liver samples (about 1g) were weighed before DNA extraction. To
disrupt the cellular membranes, 10 volumes of 3M guanidine isothiocyanate
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solution was added to each tissue. Using a Wheaton overhead stirrer and a 10
ml Potter-Elevehjem grinder, the mixture was throughly homogenized
(5.12-5.14). To partition the nucleic acids into the aqueous phase, 1 volume of
phenol:chloroform:isoamyl alcohol (25:24:1) was added to the homogenate.
After through mixing (45 seconds) with a Vortex-2 Genie, the phases were
separated by centrifuging the mixture at 2800 rpm for 10 minutes in a Sorvall
GLC-2B General Lab Centrifuge. The lower organic phase was removed and
transferred to a 50 ml Coming centrifuge tube. The entire process was
repeated twice more after which the top aqueous phase was transferred to a 50
ml centrifuge tube.
Nucleic acid precipitation
One-tenth volume of 5M sodium chloride and 2 (original) volumes of
100% ethanol was added to the aqueous layer producing a stringy precipitate

of DNA. The 5M sodium chloride was used to reduced the amount of RNA in
the precipitated nucleic acid (5.15). Each tube was centrifuged for 10 minutes
at 2800 rpm and the supernatant poured off. The DNA was washed 2 times in
ethanol, dried, then resuspended in 4 ml of TE buffer by shaking overnight in a
60°C water bath.
Twenty units (0.2ml) of RNase A was added to each sample then
incubated for 60 min at 37°C to remove any residual RNA (5.12). The samples
were again extracted 3 times with 1 volume of phenol:chloroform:isoamyl
alcohol (25:24:1). DNA from the resulting aqueous layer was precipitated with
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2 volumes of ethanol. The samples were centrifuged and the supernatant
removed. The DNA was washed 2 times in ethanol, dried under nitrogen, then
resuspended in 2 ml of TE buffer by shaking overnight in a 60°C water bath.
DNA concentration was determined by absorbance using a Hitachi U-2000
spectrophotometer. 200 pi of each sample was placed into a 6.5 ml liquid
scintillation vial containing Hionic-Fluor™ scintillation cocktail then counted on
a Packard 1900TR Liquid Scintillation Analyzer.
Protein precipitation
Precipitation of cellular protein was accomplished by adding 1.5
volumes of acetone to the combined organic phases. After centrifuging the
tubes for 10 minutes at 2800 rpm, the supernatants were poured off. The
protein pellets were washed 2 times in acetone, dried in a vacuum desiccator,
weighed, then processed for liquid scintillation counting.
Tissue preparation for liquid scintillation counting
Because radiolabeled biological samples could not be analyzed
directly using a liquid scintillation counter, sample preparation methods were
vitally important for obtaining accurate counts. A homogenous mixture of the
biological sample and the liquid scintillation cocktail was needed. Some
tissues such as urine could be added directly to the cocktail, while others
required extensive preparation (5.16).
Blood
To a 50 pi sample of blood was added 1 ml of a 50:50 mixture of
isopropanol:Soluene-350. The mixture was incubated for 30 minutes at 50°C.
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To decolorize the sample, 500 pi of 30% hydrogen peroxide was added
dropwise while swirling. The mixture was incubated for 60 minutes at 50°C.
Finally 4.5 ml of Hionic-Fluor™ scintillation cocktail was added for counting.

Urine
200 pi of urine was added directly to 5.5 ml of Hionic-Fluor™ Liquid
scintillation cocktail.
Methanol cage wash sample
200 pi of each methanol wash sample was added to 5.5 ml of HionicFluor™ Liquid scintillation cocktail.
Feces
100-200 ml of the mixed fecal solution was added to 1 ml of Soluene350, swirled till mixed, then incubated for 2 hours at 50°C. Isopropyl alcohol
(0.5 ml) was added, the mixture vortexed, then again incubated for 2 hours at
50°C. Hydrogen peroxide (300 pi of 30% solution), if needed, was added dropwise while swirling and the sample incubated for 60 minutes at 50°C. Four ml
of Hionic-Fluor™ scintillation cocktail was then added for counting.
Tissue
One ml of Soluene-350 was added to all sample tissues. Each sample
was incubated a minimum of 4 hours at 50°C. After digestion, 4.5 ml HionicFluor™ scintillation cocktail was added for counting. Hydrogen peroxide (200
pi of 30% solution), if needed, was added dropwise while swirling. The
samples were then incubated for 60 minutes at 50°C.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

184

Samples were dark adapted overnight then counted in a Packard TriCarb 1900 TR Liquid Scintillation Analyzer. Normalization and quench curves
were conducted before samples were run. Each sample was counted for 10
minutes.
Results
The stability of tritiated Ethacure
There appeared to be no significant differences in peak areas,
shapes, and retention times between the 3 chromatograms. There was no
obvious breakdown or exchange of label of the tritiated Ethacure occurring
under acidic, neutral, or basic conditions. This suggested that the tritiated
material would be stable under physiological conditions as well as under DNA
extraction protocols used in the isolation procedures.
Separation and purification of tritiated Ethacure
Final analysis depicted purity levels of 95.5% for the [3H]-2,4-DETDA
isomer. The identity of the 2,4-DETDA isomer was confirmed by the graphic
relationship of the UV chromatograph relative to the LS spectrometry (Figure
5.2). The purity level was considered adequate for the ensuing distribution and
excretion studies.
Distribution and excretion studies for 2.4-DETDA
Calculated values for the weights of the skin, stomach, small intestine,
caecum and colon used in determining the percent of administered dose in the
distribution and excretion studies are listed in Table 5.1. The average weight
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Graphical confirmation of tritiated 2,4-DETDA (bottom) after
separation of tritiated Ethacure’s (top) 2,4- and 2,6-DETDA
isomers.
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Table 5.1

Average organ weights used in the determination of percent of
administered dose in distribution and excretion experiments.
Tissues were from adult male Sprague Dawley rats obtained from
the L.S.U. School of Veterinary Medicine, Laboratory Animal
Medicine breeding colony.

Skin
Rat No. Tissue Wt. Body Wt. % Body Wt.
1
42.120
263
16.015
2
38.560
251
15.363
3
44.800
280
16.000
4
40.640
296
13.730
5
40.070
285
14.060
Avg.
15.033
S.D.
1.079

Stomach
Rat No. Tissue Wt. Body Wt. % Body Wt.
1
1.454
263
0.553
2
1.492
251
0.594
3
1.788
280
0.639
4
1.752
296
0.592
5
1.505
285
0.528
Avg.
0.581
S.D.
0.042

Duodenum
Rat No. Tissue Wt. BodyWt. % Body Wt.
1
4.038
263
1.535
2
4.771
251
1.901
3
4.264
280
1.523
4
3.481
296
1.176
5
3.950
285
1.386
Avg.
1.504
S.D.
0.265

Caecum
Tissue Wt. BodyWt. % Body Wt.
1.059
263
0.403
1.200
251
0.478
280
1.240
0.443
1.370
296
0.463
1.392
285
0.488
Avg.
0.455
S.D.
0.034

Rat No.
1
2
3
4
5

Colon
Rat No. Tissue Wt. BodyWt. % BodyWt.
1
1.033
263
0.393
2
1.016
251
0.405
3
1.342
280
0.479
4
1.270
296
0.429
5
0.911
285
0.320
Avg.
0.405
S.D.
0.058
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for the pancreas was determined to be 3.569 ± 0.438 mg/100 g of body weight.
Percent of body weight values used for blood (5.17), fat (5.18), and muscle
(5.19) were 7%, 7.6% and 50% respectively.
Results of the tritiated 2,4-DETDA tissue distribution study presented
as pmol of 2,4-DETDA per gram of tissue are depicted in Table 5.2 and Figures
5.3, 5.4 and 5.5. The data showed very high levels of label occurred in the
gastrointestinal system and bladder during the first 8 hours reflecting
compound that was either unabsorbed, distributed or excreted. The metabolic
and excretory organs, liver and kidney, also showed moderate levels. Label in
the thyroid and pancreas was much higher than expected, for non-excretory
organs, with thyroid levels exceeding even that of liver tissue. The
concentration of radioactivity in all tissues except the stomach, duodenum,
caecum, colon, bladder and thyroid was greatest at 4 hours. With the
exception of the stomach, duodenum, caecum, colon, bladder and thyroid,
tissues exhibited a classic biphasic model of distribution and excretion with the
onset of the slow phase occurring after the 4 hour time point. Thyroid levels, at
24 and 48 hours, were the highest of all tissues examined at that time point. As
can be gleaned from the 24 and 48 hour time frames, DETDA was rapidly
cleared from all tissues. Day 6 residual levels of label (Figure 5.5) were fairly
uniform in all tissues examined. Distribution levels for day 6 thyroid were
unavailable, but the 48 hour time point values suggested that the thyroid levels
at day 6 were probably elevated relative to other tissues.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 5.2

Tissue
Stomach
Duodenum
Caecum
Bladder
Colon
Thyroid
Pancreas
Liver
Kidney
Fat
Lung
Heart
Spleen
Blood
Skin
Muscle
Thymus
Brain

Summation of the tritiated 2,4-DETDA distribution study in the male Sprague Dawley rat. Values
represent pmol of 2,4-DETDA/g of tissue (n=4) and the standard deviation (S.D.) for each tissue and
time point.

1 hr
pmol/gm
2.0995
1.5464
0.1268
0.3338
0.2593
0.5114
0.1290
0.0993
0.0869
0.0401
0.0511
0.0222
0.0370
0.0230
0.0438
0.0217
0.0186
0.0221

S.D.
0.8939
1.1347
0.0552
0.1437
0.1440
0.5281
0.0726
0.0485
0.0379
0.0285
0.0158
0.0049
0.0265
0.0066
0.0255
0.0151
0.0007
0.0053

4 hr
pmol/gm
1.5740
1.0137
0.2263
0.3162
0.1806
0.2024
0.2454
0.2335
0.1237
0.1360
0.1211
0.0418
0.1077
0.0461
0.0755
0.0372
0.0380
0.0416

S.D.
0.7113
0.5575
0.2240
0.2209
0.0344
0.1897
0.0741
0.1502
0.0240
0.0229
0.0642
0.0032
0.0288
0.0035
0.0318
0.0153
0.0041
0.0066

8 hr
pmol/gm
1.1185
0.5623
0.5840
0.2930
0.2356
0.2335
0.1299
0.1627
0.1032
0.1020
0.0601
0.0332
0.0551
0.0440
0.0419
0.0276
0.0320
0.0318

S.D.
0.7555
0.2728
0.2663
0.1408
0.1052
0.1388
0.0149
0.0443
0.0403
0.0273
0.0086
0.0067
0.0145
0.0082
0.0021
0.0039
0.0079
0.0054

24 hr
pmol/gm
0.0277
0.0216
0.1762
0.0747
0.0679
0.1465
0.0174
0.0392
0.0309
0.0100
0.0280
0.0161
0.0174
0.0245
0.0220
0.0150
0.0170
0.0174

S.D.
0.0025
0.0049
0.2029
0.0438
0.0196
0.0766
0.0010
0.0140
0.0045
0.0051
0.0040
0.0037
0.0038
0.0016
0.0019
0.0017
0.0018
0.0027

48 hr
pmol/gm
0.0121
0.0116
0.0460
0.0172
0.0157
0.0987
0.0126
0.0277
0.0211
0.0061
0.0209
0.0097
0.0136
0.0169
0.0160
0.0130
0.0103
0.0118

S.D.
0.0007
0.0027
0.0362
0.0015
0.0045
0.0296
0.0024
0.0020
0.0043
0.0027
0.0027
0.0018
0.0038
0.0018
0.0032
0.0025
0.0026
0.0025
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Graphical representation of the tritiated 2,4-DETDA study in the adult male Sprague Dawley rat.
Values represent pmol of 2,4-DETDA/g of tissue (n=4). Higher and lower range of values are
presented in Figures 5.3 and 5.4 respectively.
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Graphical representation of the tritiated 2,4-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent pmol of 2,4-DETDA/g of tissue (n=4). Higher and lower range of values
are presented in Figures 5.3 and 5.4 respectively.
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Results of the tritiated 2,4-DETDA tissue distribution study in the adult male Sprague Dawley rat.
Values represent pmol of 2,4-DETDA/g of tissue remaining at the day 6 time point (n=5).
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The 2,4-DETDA tissue distribution results presented as percent of
administered dose are depicted in Table 5.3 and Figures 5.6, 5.7 and 5.8.
Radioactivity in the gastrointestinal system followed the expected profile of
declining values over the entire length. Label in the stomach and small
intestine peaked at 1 hour, reflecting the absorption of the compound, followed
by declining values over time. Caecal counts peaked at 8 hours then declined
at a steady rate. Large body mass tissues (muscle, skin and fat) had peaked
by the hour 4 time period and, as expected, accumulated relatively large
amounts of label. Fecal and urinary values represented an accumulation of
excreted label at each time point. By 8 hours, urinary excretion became the
primary route of elimination. By 24 hours, over 60% of the labeled compound
had been excreted and by 6 days (Table 5.4) only 3.7% of label remained in
the tissues. As expected, at day 6 , the majority of label was present in the
muscle, skin, and fat. Elevated levels in liver and kidney were probably
representative of metabolism and excretion functions. Blood levels remained
relatively constant up to 48 hours reflecting label diffusing out of body tissues
prior to excretion.
Figure 5.9 plots the accumulated excretion profile for the 2,4-DETDA
isomer over 6 days. Approximately 46% of the administered dose of tritiated
2,4-DETDA was excreted in the first 24 hours. Accumulated urine and fecal
levels of label peaked at 24 hours with urine levels double that of fecal. Urine
levels dropped rapidly over the next 24 hours while fecal levels remained
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Table 5.3

Summation of the tritiated 2,4-DETDA distribution study in the male Sprague Dawley rat. Values
represent the percent of administered dose (n=4) and the standard deviation (S.D.) for each tissue and
time point.

Tissue

193

Feces
Urine
Muscle
Skin
Blood
Fat
Liver
Caecum
Stomach
Sm. Intest.
Kidney
Thymus
Lung
Heart
Spleen
Pancreas
Bladder
Thyroid
Brain
Colon

1 hour
4 hour
8 hour
24 hour
48 hour
% of dose
S.D .
% of dose S.D. % of dose S.D . % of dose S.D . % of dose S.D.
7.752 11.464
12.279 9.721
14.108 2.7 43
22.923 2.7 05
24 .1 9 0 6.145
1.321
1.744
9.297 3.928
2 2 .538 5.359
42.992 4.5 45
40 .460 5.872
7.485
5.221
12.837 5.283
9.539 1.338
5.190 0.5 90
4.501 0.848
4.5 46
2.6 4 7
7.834 3.302
4.3 47 0.217
2.280 0.195
1.665 0.333
1.112
0.3 20
2.2 29 0.167
2.1 26 0.395
1.182 0.076
0.913 0.088
2.1 03
1.494
7.134 1.204
5.350 1.430
0.523 0.2 70
0.319 0.141
2.553
1.371
5.099 2.835
3.7 90 1.299
1.135 0.324
0.708 0.177
0.398
0.1 73
0.717 0.703
1.834 0.843
0.553 0.6 37
0.144 0.114
6.419
3.584
6.312 2.852
4.4 85 3.030
0.111 0.010
0.049 0.003
16.052 11.779
10.523 5.787
5.8 37 2.832
0.224 0.051
0.120 0.028
0.223
0.484
0.652 0.127
0.5 45 0.178
0.170 0.019
0.116 0.018
0.032
0.0 09
0.043 0.005
0.0 42 0.011
0.025 0.003
0.012 0.003
0.139
0.053
0.297 0.254
0.161 0.025
0.084 0.011
0.060 0.011
0.053
0.0 09
0.099 0.015
0.0 82 0.015
0.036 0.0 08
0.022 0.004
0.053
0.041
0.126 0.031
0.0 62 0.022
0.023 0.005
0.016 0.004
0.316
0.1 79
0.605 0.183
0.320 0.037
0.043 0.003
0.032 0.006
0.054
0.0 23
0.079 0.066
0.0 59 0.035
0.016 0.006
0.004 0.001
0.028
0.030
0.009 0.007
0.011 0.007
0.006 0.002
0.005 0.001
0.093
0.024
0.164 0.031
0.131 0.029
0.082 0.013
0.056 0.012
0.725
0.4 02
0.505 0.096
0.6 59 0.294
0.190 0.055
0.044 0.013
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Graphical representation of the tritiated 2,4-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent the percent of administered dose (n=4). Higher and lower range of
values are presented in Figures 5.6 and 5.7 respectively.
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Graphical representation of the tritiated 2,4-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent the percent of administered dose (n=4). Higher and lower range of
values are presented in Figures 5.6 and 5.7 respectively.
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Results of the tritiated 2,4-DETDA tissue distribution study in the adult male Sprague Dawley rat.
Values represent the percent of administered dose remaining in the tissues at the day 6 time point
(n=5).
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Table 5.4

Tissue

Summary for Day 6 of the tritiated 2,4-DETDA distribution study in
the male Sprague Dawley rat. Values represent either the
percent of administered dose or the ymol/g of 2,4-DETDA in the
tissue.

% of Dose Stnd. Dev.

Tissue

pmol/g Stnd.Dev.

Blood

0.360

0.079

Blood

0.0075

0.0016

Fat
Skin

0.192

0.080

Fat

0.0037

0.0015

0.718

0.127

Skin

0.0069

0.0009

Muscle

1.899

0.266

Muscle

0.0055

0.0008

Thymus

0.004

0.002

Thymus

0.0059

0.0013

Lung

0.022

0.002

Lung

0.0065

0.0009

Heart

0.013

0.001

Heart

0.0053

0.0009

Spleen

0.017

0.001

Spleen

0.0061

0.0010

Pancreas

0.014

0.003

Pancreas

0.0056

0.0012

Bladder

0.002

0.001

Bladder

0.0062

0.0013

Kidney

0.048

0.008

Kidney

0.0090

0.0018

Liver

0.253

0.039

Liver

0.0104

0.0020

Stomach

0.021

0.002

Stomach

0.0054

0.0006

Sm. Intest.

0.054

0.010

Duodenum

0.0054

0.0012

Caecum

0.013

0.003

Caecum

0.0042

0.0012

Colon

0.016

0.004

Colon

0.0059

0.0015

Brain

0.025

0.005

Brain

0.0066

0.0016

Total

3.671
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Urinary and fecal excretion profile of tritiated 2,4-DETDA over 6
days. Data points represent the percentage of administered dose
of 2,4-DETDA (n=5) accumulated over time from urine and fecal
samples.
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constant. By 48 hours, the excretion of 2,4-DETDA was almost complete with
only slight amounts excreted over the next 4 days. Approximately 44% of the
label was eliminated through the urinary system compared to about 36% in the
feces (Table 5.5). The amount of labeled material recovered in the 2,4-DETDA
6-day excretion study from the urine, feces, and tissue ranged from 62.1% to

91.5% with an average of 83.1 %. Individual rat recovery percentages were as
follows: 91.48%, 62.12%, 88 .66%, 89.97% and 85.15%.
Characterization of urine fractions
Analysis of the data from the 24-hour time point urine samples
revealed that 18.2% of labeled material was contained in the organic fraction.
Acid hydrolysis demonstrated that 37.6% of the labeled material was in the
form of acid-labile conjugates. The remaining 44.2% of the labeled material
was composed of the non acid-labile water soluble fraction (Table 5.6).
Ionic and hydrostatic binding of DETPA with DNA
An 8.7% reduction in label counts was recorded for tritiated 2,4DETDA samples incubated with the calf thymus DNA. Samples in which
Ethacure was used competitively to displace labeled compound from the DNA
resulted in a 6.1% decrease in counts. The decrease in label counts
suggested that some binding might be occurring, however, control samples
without DNA resulted in a 10.5% decrease. These results seem to indicate that
the decrease was due to the binding of label to the filter and not non-covalent
binding to the DNA.
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Table 5.5

Summary of the 6 day tritiated 2,4-DETDA excretion study in the
adult male Sprague Dawley rat. Values represent the percent of
administered dose of tritiated 2,4-DETDA excreted at each time
point (n=5).

Urines
Day

Feces

% of Dose Stnd. Dev.

% of Dose

Stnd. Dev.

1

29.32

2.46

16.19

3.00

2

11.44

3.64

15.86

3.63

3

1.43

0.18

2.14

0.22

4

0.76

0.16

0.99

0.25

5

0.54

0.16

0.38

0.04

6

0.47

0.08

0.29

0.08

Totals

43.96

35.85
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Table 5.6

Classification of labeled compounds extracted from the 24 hour
time point urine samples in the tritiated d2,4-DETDA excretion
study. Ethyl acetate extraction partitioned labeled compounds
into organic and water soluble fractions. Acid hydrolysis released
acid-labile conjugates from the water soluble fraction. Group
A=non extracted urine samples, Group B=ethyl acetate extracted
urine samples, Group C=acid hydrolyzed and ethyl acetate
extracted urine samples. Calculations: organic fraction = B/A,
acid-labile conjugates = (C-B)/A, non acid-labile water soluble
fraction = 100 - (organic fraction + acid labile conjugates).

Group A

Group B

Group C

Sample

DPM

Sample

DPM

Sample

DPM

1

1

4584.67
5575.56
6206.20
5951.76
3686.10

1

3
4
5

29304.2
29898.7
31473.9
31033.0
21284.4

17039.7
17122.3
18111.1
16746.6
10790.1

Avg.
S.D.

28598.8
4179.7

2

2

3
4
5

2

3
4
5

5200.9
1047.5

Percentage
Organic Fraction
18.2
Acid-Labile Conjugates
37.6
Non Acid-Labile Water Soluble Fraction_______ 44.2
Total
100.0
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Covalent binding studies
Binding study results of DETDA to DNA and protein is compiled in
Table 5.7. Relative to Ethacure (80.8% 2,4-DETDA, 19.2% 2,6-DETDA), 16
pmol of 2,4-DETDA/pmol of DNA was found covalently bound. For the 2,4DETDA isomer, 55% of the label was bound to the protein fraction equating to
108 nmol 2,4-DETDA per gram of liver protein. The 260/280 ratio for the
samples was 1.9.
Discussion
It is obvious from the data that the 2,4-DETDA isomer was rapidly
absorbed from the gastrointestinal system. The distribution profile suggests
that the compound has both water and fat soluble properties. The relatively
greater accumulation of label in the thyroid, pancreas, and liver tissue may
reflect the possible toxic qualities encountered in the long term feeding study.
The data also suggest that 2,4-DETDA was distributed to most, if not every
tissue in the body. Excretion data showed that the primary route of elimination
of the labeled 2,4-DETDA was the urinary system with fecal elimination closely
following. The majority of urinary elimination occurred during the first 24 hours
while fecal excretion occurred over 48 hours with equal amounts being
eliminated both days. The 83.1% recovery of labeled material was lower than
expected. Metabolism cages were rinsed with only 12 ml of water then washed
between time points. The low recovery of the number 2 rat (62.12%) and the
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Table 5.7

Tritiated 2,4-DETDA covalent binding on rat liver DNA and
protein.

Isomer

pmol DETDA
per pmol DNA

nmol DETDA
per g Protein

% of label on
protein

2,4-DETDA

16

108

55
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loss of label due to insufficient rinsing was credited for the lower than expected
recovery.
Acid hydrolysis of 24-hour time point urine samples resulted in 38%
acid-labile conjugated metabolites. This compared with the 34% and 39%
conjugates excreted in the urine of rats administered an oral dose of 50 and 60
mg/kg respectively for the structurally similar compound 2,4-TDA (5.20,5.21).
This conjugation data suggests that 2,4-DETDA may be metabolized in a
similar manner to 2,4-TDA. However, unlike 2,4-TDA which produced between
1.4 and 5.7% acetylated metabolites (5.20,5.22,5.23), early metabolic work on
2,4-DETDA resulted in no acetylated species (Chapter 4). How closely the
metabolic profile of DETDA is to TDA will remain unknown until further
metabolic studies are undertaken.
Cellular DNA is often the target of covalent addition. These DNA
adducts can have serious ramifications because of the critical role that DNA
plays in cellular functions and cell reproduction. The importance of persistent
in vivo DNA-arylamine adducts can be seen in the devastating consequences
of gene mutations and cancer (5.24-5.29).
This In vitro DNA binding study with 2,4-DETDA demonstrated that no,
or very little, non-covalent binding took place while this in vivo study showed
moderate levels (16 pmol of 2,4-DETDA/pmol DNA) of covalent binding.
When 30 pmol of 2,4-TDA was incubated with rat liver hepatocytes for
24 hours, approximately 145 pmol of TDA/pmol DNA resulted (5.30). This
compares to the 16 pmol of 2,4-DETDA/pmol DNA observed in the present
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study. Although the 2,4-TDA study was an in vitro assay, results suggest that
compared to TDA, 2,4-DETDA is less likely to be involved in covalent binding
to DNA. DETDA does however, seem to have considerable affinity for protein.
Consequences of this DETDA protein binding, if any, are unknown at the
present time.
Ethacure has been used successfully for over 20 years as a
replacement chemical for known toxic compounds. The results of this study
shows that 2,4-DETDA, the major component of Ethacure, clears quickly after
an orally administered dose, such that by 24 hours, less than one-third of the
label remains in the tissues. There also appears to be very little accumulation
in tissue by day 6 after exposure.
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CHAPTER 6
DISTRIBUTION, EXCRETION, AND COVALENT
BINDING OF 2,6-DIETHYLTOLUENEDIAMINE
Introduction
Diethyitoluenediamine (DETDA, CAS 68479-98-1) is an industrial
compound utilized as a polyurethane chain extender in reaction-injection
molded (RIM) applications. DETDA has also been used as a curing agent for
polyurethanes and epoxy resins, as an antioxidant, lubricant, a wire coating
and as a replacement for more toxic industrial compounds, such as
toluenediamine (TDA) and 4,4'-methylenebis-2-chloroaniline (MOCA) (6.1).
DETDA has been manufactured by Albemarle Corporation (formerly Ethyl
Corporation) under the name Ethacure®100 for more than 20 years. Ethacure
is a mixture of compounds (Figure 6 .1) composed mostly of 2 major isomers,
2,4-DETDA (75-81%) and 2,6-DETDA (18-20%). Because it is a proprietary
compound, there is little information in the literature on this material except for
patents dealing with synthesis and industrial use. DETDA is expected to be
absorbed, distributed, metabolized and excreted in a similar manner to TDA
(Figure 6.1), a widely used industrial compound, because of structural
similarities (6.2-6.4).
Standard laboratory studies, including acute and subchronic toxicity
tests, have been conducted on Ethacure. Results from a two-year feeding
study in rats, conducted by Albemarle suggested that DETDA may affect the
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Chemical structures of DETDA and TDA isomers.
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pancreas, liver, thyroid and eyes (6.5). These studies, and an interest by
Albemarle in full understanding of the potential toxicity of DETDA prompted a
metabolic study of the mixture. Understanding of the distribution and excretion
of DETDA in a mammalian system is important to help establish proper safety
guidelines.
Tritiated Ethacure was prepared by the catalytic exchange of tritium
gas on Ethacure. The tritium label is characteristically exchanged at the less
labile benzylic positions on the ring (6 .6 ). Amersham removed labile tritium
from the crude product but did not attempt purification or separation of
isomers.
Distribution, excretion and covalent DNA-binding studies on the 2,4and 2,6-DETDA isomers needed to be conducted. Before the tritiated Ethacure
could be used, it was necessary to determine the stability of the label then
separate the mixture into major isomers.
This study entailed the oral administration of tritiated 2,6-DETDA to
young adult male Sprague Dawley rats. Distribution and excretion profiles over
time in multiple tissues were acquired as well as DNA binding levels in liver
tissue.
Materials and Methods
Materials
Equipment
The Hitachi U-2000 Spectrophotometer was purchased from Hitachi
Instruments, Inc., Houston, Tx 77272. The Shimadzu LC-600 Liquid
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Chromatograph pump, Shimadzu SPD-10AV UV detector, Easychrome
software and DT 2802 A/D converter board were obtained from Shimadzu
Scientific Instruments, Columbia, MD 21046. The C18 Partisphere 5pm
4.6x250mm reverse-phase column (No. 4621-1502), guard column (No. 46410002) and holder (No. 4651-0002) were purchased from Whatman Laboratory
Division, Clifton, NJ 07014. The PrepPak 25x10 Bondapak™ cartridge, (10 pm
No.38505), PrepPak 25x10 pPorasil cartridge (10 pm No.38504) and RCM
25x10 cartridge holder (No. 15814) were purchased from Millipore Corporation,
Waters Chromatography Division, Milford, MA 01757. The Buchner
Fractomette® Alpha 400 fraction collector was purchased from Buchler
Instruments, Fort Lee, NJ 07024. The Packard Tri-Carb 4640 and 1900TR
Liquid Scintillation Analyzer were purchased from Packard Instrument Co.,
Meriden, CT 06450. The Wheaton Overhead Stirrer (No. 903475) was
purchased from Wheaton Instruments, Millville, NJ 08332. The 10 ml PotterElevehjem Grinder (No. 358038) was purchased from Wheaton, Millville, NJ
08332. The Burrell Model 75 Wrist Action® Shaker was obtained from Burrell
Corporation, Pittsburgh, PA 15201. The Sorvall GLC-2B General Lab
Centrifuge was from Dupont Instruments, Newtown, CN 06470. The Vortex-2
Genie was purchased from Scientific Industries, Inc., Bohemia, NY 11716. The
Eppendorf Microcentrifuge (No. 5415C) was purchased from Brinkmann
Instruments, Inc., Westbury, NY 11590. The Ohaus E400D balance was
purchased from Ohaus Corporation, Florham Park, NJ 07932. Sigma Plot

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

213

software was purchased from Jandel Scientific, San Rafael, CA 94901. The
Gilson Differential Respirometer (SC-14) was purchased from Gilson Medical
Electronics, Middleton, Wl 53562.
Chemicals and supplies
Ethacure®100 was obtained from the Albemarle Corporation, Baton
Rouge, LA 70801. Toluene, sodium hydroxide pellets, methanol (Nanograde®),
calcium chloride (No. 4160) and hydrochloric acid were obtained from
Mallinckrodt Chemicals, Paris, KY 40361. Ethanol (reagent grade, #AX04451), sodium chloride and potassium hydroxide (PX-1480-1) were purchased from
EM Science, Gibbstown, NJ 08027. Ethanol (dehydrated, absolute-200 proof)
was purchased from McCormick Distilling Co., Inc., Weston, MS 64098.
Acetonitrile, acetone (high purity) and ethyl acetate were purchased from Curtis
Matheson Scientific, Inc., Houston, TX 77251. Dibutylamine (99%),
magnesium chloride (hexahydrate, 99%), hydrogen peroxide (30 wt. %, No.
21,676-3) and phosphoric acid (99.999%) were purchased from Aldrich
Chemical Company, Inc., Milwaukee, Wl 53233. Guanidine isothiocyanate
ultrapure™ was purchased from Bethesda Research Laboratories,
Gaithersburg, MD 20877. Phenolichloroform premixed with isoamyl alcohol
and EDTA (disodium salt dihydrate, >99% purity) was obtained from Amresco®,
Solon, OH 44139. Ammonium acetate, Trizma® hydrochloride and calf thymus
DNA (Sodium salt, D-1501) were purchased from Sigma Chemical Co., St.
Louis, MO 63178. Tris base (ultrapure) was purchased from Tyron®, Okemos,
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Ml 48664. SDS (sodium dodecyl sulfate, ultrapure) was purchased from Life
Technologies, Inc., Gathensburg, MD 20898. Millipore ultra free-MC Low
binding Cellulose 5,000 NMWL (No. UFC3LCC00) filters were purchased from
Millipore Corp., Milford, MA 01757. Vericel Membrane Filters (0.45pm, FP-450,
47mm No.66480) were purchased from Gelman Sciences, Ann Arbor, Ml
48106. Hionic-Fluor™ liquid scintillation cocktail (No.6013319), Soluene®-350,
Pico-Prias vial, 6.5ml (No.6000192), and Vented Pico Holder Adapter (No.
6013400) were purchased from Packard Instrument Co., Meriden, CT 06450.
Harvard perfectum animal feeding needle (curved ball-tipped 18-gauge x 3",
No. 7914) was purchased from Popper & Sons, Inc., Newhyde Park, NY 11640.
Wayne®Autoclavable Rodent BLOX® 8656 diet (powdered 4% fat diet) was
purchased from Laboratory Diets, Madison, Wl 53711. 50 ml Coming
polypropylene centrifuge tubes (No. 25331-50) were purchased from Coming
Inc., Coming, NY 14631. Nalgene® Wide-Mouth HDPE Bottles (No. 21040004,125 ml) were purchased from the Nalge Company, Rochester, NY 14602.
Culture tubes (borosilicate) were purchased from Kimble Glass, Inc., Vineland,
NJ 08360. Micro-centrifuge tubes (flat top/graduated, 1.5 and 2.0 ml) were
purchased from Dot Scientific, Inc., Burton, Ml 48519. Chemicals purchased
were reagent grade quality unless otherwise indicated.
Tritiated Ethacure was prepared by Amersham Life Science, Inc.,
Arlington Heights, IL 60005. The product was stored and shipped in 25 ml of
ethanol, had a total activity of 6.72 mCi/ml, a specific activity of 1.2 Ci/mmol
and a concentration of 0.0082 mmol/ml.
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Experimental Methods
Determination of tritiated Ethacure stability
A 1 mg/ml solution of Ethacure (134 pCi/ml) was prepared by mixing
20 pi of the 6.72 pCi/ml tritiated compound with 980 pi of a 1 mg/ml solution of
unlabeled Ethacure. 100 pg/ml solutions in water, 0.1M HCL and 0.1 M NaOH
were prepared using the stock labeled solution then incubated for 1 hour.
Samples were then neutralized using sodium acetate or glacial acetic acid.
50 pi samples were chromatographed using a Shimadzu LC-600
Liquid Chromatograph, Shimadzu SPD-10AV detector (295 nm) and a
Whatman C18 Partisphere 5pm 4.6x250mm column. A 16.5% acetonitrile,
100mM dibutylamine phosphate buffer (pH 3.0) mobile phase (see Chapter 2)
was used at a 1 ml/min flow rate. Eluent was collected into 6.5 ml polyethylene
liquid scintillation vials using a Buchner Fractomette® Alpha 400 fraction
collector at 6 second intervals. Five ml of Hionic-Fluor™ liquid scintillation
cocktail was added to each vial and the radioactivity measured on a Packard
Tri-Carb 4640. Sigma Plot software was used to convert the raw data into
chromatographs for analysis.
Separation and purification of tritiated Ethacure
A 10 mCi aliquot of [3H]-ethacure (1.5 ml in ethanol) was evaporated
under a stream of nitrogen then restored to 0.75 ml using a toluene:ethanol
(60:40) solution. Isomer separation was achieved under a normal-phase
preparative HPLC method using a Shimadzu LC-600 Liquid Chromatograph, a
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Shimadzu SPD-10AV detector (295 nm) and a PrepPak 25x10 pPorasil
cartridge in a RCM 25x10 cartridge holder. The 10 mCi sample was injected
via a Rheodyne 1526 injector through a 1000 pi injection loop and eluted at
2ml/min for 60 minutes in a filtered 60:40 toluene:ethanol isocratic mobile
phase. The 2,4- and the 2,6-DETDA fractions were collected referenced to
unlabeled Ethacure chromatographed under identical parameters. Each
fraction was collected, diluted to 10 ml with toluene, then stored at -20°C (6.7).
The tritiated 2,6-DETDA fraction was checked for purity using a
Whatman C-18 reversed-phase column, a Shimadzu LC-600 Liquid
Chromatograph and a Shimadzu SPD-10AV detector (295 nm). To prepare the
sample, 2.40 pCi of [3H]-2,6-DETDA was placed into a 13x100mm borosilicate
culture tube and evaporated to dryness. One ml of a 50 pg/ml solution of
Ethacure dissolved in mobile phase was added to the tube and vortexed. A 50
pi sample was injected via a Rheodyne 1526 injector through a 50 pi injection
loop and eluted at 0.5 ml/min for 15 minutes in a 16.5% acetonitrile, 100 mM
dibutylamine phosphate buffer (pH 3.0) isocratic mobile phase (6 .8 ).
After injecting the sample, 63 fractions were collected into 6.5ml
Pico-Prias liquid scintillation vials at 0.2 minute intervals using a Buchner
Fractomette® Alpha 400 fraction collector. Five ml of Hionic-Fluor™ liquid
scintillation cocktail was added to each vial and the radioactivity measured on
a Packard Tri-Carb 4640 Liquid Scintillation Counter. Quattro Pro 6.0 was
used to generate graphs from the UV and CPM data. CPM values from each
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peak on the generated graphs were totaled and the sums used to compute
isomer purity.
Distribution studies
Five groups of 4 young adult male (10-12 weeks, 189-296 g) Sprague
Dawley rats (obtained from the L.S.U. School of Veterinary Medicine,
Laboratory Animal Medicine breeding colony) were randomly selected and
placed into individual metabolism cages for urine and feces collection. Rats
were placed into cages 72 hours prior to dosing, fed a powdered 4% fat diet
(Wayne®Autoclavable Rodent BLOX® 8656 diet) and maintained in a 12-hour
light-dark cycle environment. Rats were fasted for 16 hours prior to dosing
eliminating the effects of gastric contents on absorption. Water was given ad
libitum during the entire experiment. Tritiated 2,6-DETDA was diluted with nontritiated Ethacure (84 pmol/ml) in water to provide a labeled mixture with a
specific activity of 0.39 pCi/pmol. Rats were then orally dosed at 179 pmol/kg
from this solution of 84 pmol/ml of labeled Ethacure using a 1.0 ml Hamilton
#1001 syringe and a curved ball-tipped 18-gauge x 3" feeding needle.
Urine, feces, blood and tissues were collected at 5 time points: 1, 4, 8 ,
24 and 48 hours. A day 6 tissue distribution time point was incorporated in the
6 day excretion study. Rats were anesthetized with isoflurane at each time

point. Blood samples were taken by cardiac puncture using a heparinized 12
ml syringe with a 22-gauge needle then placed into labeled serum collection
tubes for later processing.
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Urine was collected into ice-filled containers until the time of
euthanasia. Each cage was washed with 20 ml of distilled water which was
added to the total urine collection. Urines were measured and samples were
refrigerated until analysis.
To remove any residual label, each cage was rinsed with
approximately 35 ml of methanol which was collected in 50 ml Coming
polypropylene centrifuge tubes. Tubes were centrifuged for 5 minutes at 2800
rpm in a Sorvall GLC-2B General Lab Centrifuge preparing a clarified
supernatant. After later analysis, methanol sample counts were added to urine
sample counts providing a total urine count.
All feces in the cage at each time point were collected and placed into
a 50 ml Coming polypropylene centrifuge tube. Small intestine contents were
placed into the tube along with the caecum and large intestine and a small
amount of water. This tissue was minced with a scissors then water added to
the 45 ml mark. The 24 and 48 hour samples required placement into 125 ml
polyethylene bottles which were filled to the 110 ml mark. All samples were
weighed then throughly mixed for a minimum of 48 hours using a Burrell Model
75 Wrist Action® Shaker.
The following tissues were removed from each rat at the time of death:
fat (epididymal fat pad), skin (ventral midline), skeletal muscle (right
quadriceps), thymus, lung (right caudal lobe), heart (apex), spleen (caudal
end), pancreas, bladder, kidney (right caudal area), liver (right caudal lobe),
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stomach (greater curvature), proximal duodenum, caecum (apex), colon
(proximal ascending), thyroid, brain (right frontal lobe) and testes (right cranial
pole). Each tissue was removed, trimmed and weighed. A small piece of
tissue (about 100 mg, except thyroid) was sampled from the same area of each
organ, weighed and placed into labeled 6.5 ml polyethylene liquid scintillation
counting vials for preparation.
In order to determine the percent of administered dose in each tissue
sampled, the organ weight was needed. The skin, stomach, small intestine,
caecum and colon presented difficult weighing problems at sampling time. To
obtain the needed weights, these organs were harvested from 5 untreated
young adult male Sprague Dawley rats. An average weight for each organ as a
percent of body weight was calculated. Also, the anatomy of the rat pancreas
made total dissection difficult and uncertain. To minimize variation, an average
pancreatic tissue weight from 30 rats in the distribution and excretion study was
calculated relative to body weight. This average weight was used in place of
individual weights for the purpose of calculating percent of administered dose.
Excretion studies
Five young adult male (10-12 weeks, 216-293 g) Sprague Dawley rats
(obtained from the L.S.U. School of Veterinary Medicine, Laboratory Animal
Medicine breeding colony) were randomly selected and placed into individual
metabolism cages for urine and feces collection. Rats were placed into cages
72 hours prior to dosing, fed a powdered 4% fat diet (Wayne®Autoclavable
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Rodent BLOX® 8656 diet) and maintained in a 12-hour light-dark cycle
environment. Rats were fasted for 16 hours prior to dosing eliminating the
effects of gastric contents on absorption. Water was given ad libitum during
the entire experiment.
Tritiated 2,4-DETDA was diluted with non-tritiated Ethacure (84
pmol/ml) in water to provide a labeled mixture with a specific activity of 0.295
pCi/pmol. Rats were then orally dosed at 179 pmol/kg from this solution of 84
pmol/ml of labeled Ethacure using a 1.0 ml Hamilton #1001 syringe and a
curved ball-tipped 18-gauge x 3" feeding needle.
Urine and feces were collected into ice-filled containers at 24 hour
intervals for 6 days. Each cage was washed with 20 ml of distilled water which
was added to the total urine collection. Urines were measured and samples
were refrigerated until analysis.
To remove any residual label, each cage was rinsed with
approximately 35 ml of methanol which was collected in 50 ml Coming
polypropylene centrifuge tubes. Tubes were centrifuged for 5 minutes at 2800
rpm in a Sorvall GLC-2B General Lab Centrifuge preparing a clarified
supernatant. After analysis, methanol sample counts were added to urine
sample counts providing a total urine count.
Feces in the cage at each time point were placed into 125 ml
polyethylene bottles. On day 6 , rats were anesthetized with isoflurane and
blood collected by cardiac puncture using a 12 ml heparinized syringe and 22gauge needle. Contents from the stomach, small intestine, caecum, and large
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intestine were added to the day 6 time points. Water was added to the 110 ml
level of all bottles and the weights recorded. Bottles were then shaken for a
minimum of 48 hours using a Burrell Model 75 Wrist Action® Shaker ensuring
equal and through mixing of intestinal contents.
The following tissues were removed from each rat at the time of death
for a day 6 distribution study: fat (epididymal fat pad), skin (ventral midline),
skeletal muscle (right quadriceps), thymus, lung (right caudal lobe), heart
(apex), spleen (caudal end), pancreas, bladder, kidney (right caudal area), liver
(right caudal lobe), stomach (greater curvature), proximal duodenum, caecum
(apex), colon (proximal ascending) and brain (right frontal lobe). Each tissue
was removed, trimmed and weighed. A small piece of tissue (about 100 mg,
except thyroid) was sampled from the same area of each organ, weighed and
placed into labeled 6.5 ml polyethylene liquid scintillation counting vials for
preparation.
Ionic and hydrostatic binding of DETDA with DNA
Besides the covalent binding seen between DNA and macromolecules
or xenobiotics, other forms of binding must be considered. Ionic or
electrostatic, hydrogen and Van der Waals bonds are sometimes formed
between these molecules (6.9). In order to determine if covalent binding had
occurred between DETDA and DNA, these other types of binding had to be
ruled out (6 .10).
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A 1 mg/ml solution of calf thymus DNA and a 5 mg/ml solution of
Ethacure was prepared in TE buffer. In a 15 ml borosilicate test tube was
mixed 1 ml of the DNA solution, 1.0 ml of TE buffer and 200 pi of a 2.98 pCi/ml
solution of [3H]-2,4-DETDA in TE buffer. The mixture was incubated for 1 hour
at 37°C in a Gilson shaking water bath. A 400 pi sample of this mixture was
pipetted into Hionic-Fluor™ scintillation cocktail and counted with a Packard
1900TR Liquid Scintillation Analyzer. To determine if DNA binding had
occurred, another 400 pi of the tritiated mixture was passed through a Millipore
5000 molecular weight cutoff filter. The filter was centrifuged for 30 minutes at
14,000 rpm on a Eppendorf microcentrifuge. The filter was then rinsed with
300 pi of TE buffer. The eluent, minus the DNA with possible labeled DETDA,
and the TE buffer wash was then counted. To release any DNA-bound tritiated
DETDA trapped by the filter, 500 pi of a 5 mg/ml solution of Ethacure was
passed through the filter system by centrifugation. The Ethacure, by
competitive binding, should have displaced any labeled DETDA from the DNA
and allowed it to be washed through the filter and counted.
To determine if any labeled DETDA was bound to the filter, control
samples without DNA were also run. 400 pi of the 2.98 pCi/ml solution of [3H]2,4-DETDA in TE buffer was added to 3.6 ml of TE buffer. 400 pi of this
solution was centrifuged through a Millipore filter. The filter was washed with
TE buffer and the combined eluents counted. Evidence of ionic binding was
achieved by comparing non-filtered labeled DETDA to labeled DETDA that
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passed through the cut-off filter before and after competitive binding with
Ethacure. This data was then compared to data obtained with the control
samples. All procedures were conducted in triplicate, the results of which were
averaged.
Covalent binding studies
Three young adult male (159-211g) Sprague Dawley rats (obtained
from the L.S.U. School of Veterinary Medicine, Laboratory Animal Medicine
breeding colony) were randomly selected and placed into individual
metabolism cages. Rats were placed into cages 72 hours prior to dosing, fed a
powdered 4% fat diet (Wayne®Autoclavable Rodent BLOX® 8656 diet) and
maintained in a 12-hour light-dark cycle environment. They were fasted for 16
hours prior to dosing to minimize the effects of gastric contents on absorption.
Water was given ad libitum during the entire experiment.
DNA extraction from the livers of rats previously exposed to tritiated
DETDA at levels of 0.05 pCi/g of body weight resulted in counts just above
background level. In order to place confidence in the study, a much higher
dose of tritiated DETDA was administered. Tritiated 2,6-DETDA was diluted
with unlabeled Ethacure to attain a specific activity of 4.41 pCi/pmol. Rats
were dosed at 179 pmol/kg from labeled solutions of 84 pmol/ml of Ethacure in
water prepared the morning of the experiment. A 1.0 ml Hamilton #1001
syringe and a curved ball-tipped 18-gauge x 3" feeding needle was used to
gavage the rats.
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Twenty-four hours after dosing, rats were placed under isoflurane
anesthesia then euthanized by exsanguination at which time the livers were
harvested and weighed. Small pieces of liver tissue (about 100 mg) were
excised, weighed and placed into labeled 6.5 ml polyethylene liquid scintillation
counting vials for preparation.
DNA extraction
The extraction of nucleic acid from the selected tissue required lysis of
the cellular membranes followed by the separation of the nucleic acid from the
resulting cellular debris. The nucleic acids were then partitioned into the
aqueous phase using phenol-chloroform-isoamyl alcohol. The remainder of the
cellular debris, including the proteins, entered into the organic fraction or the
interface phase.
Liver samples (about 1g) were weighed before DNA extraction. To
disrupt the cellular membranes, 10 volumes of 3M guanidine isothiocyanate
solution was added to each tissue. Using a Wheaton overhead stirrer and a 10
ml Potter-Elevehjem grinder, the mixture was throughly homogenized
(6.11-6.13). To partition the nucleic acids into the aqueous phase, 1 volume of
phenol:chloroform:isoamyl alcohol (25:24:1) was added to the homogenate.
After through mixing (45 seconds) with a Vortex-2 Genie, the phases were
separated by centrifuging the mixture at 2800 rpm for 10 minutes in a Sorvall
GLC-2B General Lab Centrifuge. The lower organic phase was removed and
transferred to a 50 ml Coming centrifuge tube. The entire process was
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repeated twice more after which the top aqueous phase was transferred to a
50 ml centrifuge tube.
Nucleic acid precipitation
One-tenth volume of 5M sodium chloride and 2 (original) volumes of
100% ethanol was added to the aqueous layer producing a stringy precipitate

of DNA. The 5M sodium chloride was used to reduced the amount of RNA in
the precipitated nucleic acid (6.14). Each tube was centrifuged for 10 minutes
at 2800 rpm and the supernatant poured off. The DNA was washed 2 times in
ethanol, dried, then resuspended in 4 ml of TE buffer by shaking overnight in a
60°C water bath.
Twenty units (0.2ml) of RNase A was added to each sample then
incubated for 60 min at 37°C to remove any residual RNA (6.11). The samples
were again extracted 3 times with 1 volume of phenol.chloroform: isoamyl
alcohol (25:24:1). DNA from the resulting aqueous layer was precipitated with
2 volumes of ethanol. The samples were centrifuged and the supernatant
removed. The DNA was washed 2 times in ethanol, dried under nitrogen, then
resuspended in 2 ml of TE buffer by shaking overnight in a 608C water bath.
DNA concentration was determined by absorbance using a Hitachi U-2000
spectrophotometer. 200 pi of each sample was placed into a 6.5 ml liquid
scintillation vial containing Hionic-Fluor™ scintillation cocktail then counted on
a Packard 1900TR Liquid Scintillation Analyzer.
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Protein precipitation
Precipitation of cellular protein was accomplished by adding 1.5
volumes of acetone to the combined organic phases. After centrifuging the
tubes for 10 minutes at 2800 rpm, the supernatants were poured off. The
protein pellets were washed 2 times in acetone, dried in a vacuum desiccator,
weighed, then processed for liquid scintillation counting.
Tissue preparation for liquid scintillation counting
Because radiolabeled biological samples could not be analyzed
directly using a liquid scintillation counter, sample preparation methods were
vitally important for obtaining accurate counts. A homogenous mixture of the
biological sample and the liquid scintillation cocktail was needed. Some
tissues such as urine could be added directly to the cocktail, while others
required extensive preparation (6.15).
Blood
To a 50 pi sample of blood was added 1 ml of a 50:50 mixture of
isopropanol:Soluene-350. The mixture was incubated for 30 minutes at 50°C.
To decolorize the sample, 500 pi of 30% hydrogen peroxide was added
dropwise while swirling. The mixture was incubated for 60 minutes at 50°C.
Finally 4.5 ml of Hionic-Fluor™ scintillation cocktail was added for counting.
Urine
200 pi of urine was added directly to 5.5 ml of Hionic-Fluor™ Liquid
scintillation cocktail.
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Methanol cage wash sample
200 pi of each methanol wash sample was added to 5.5 ml of HionicFluor™ Liquid scintillation cocktail.
Feces
100-200 ml of the mixed fecal solution was added to 1 ml of Soluene350, swirled till mixed, then incubated for 2 hours at 50°C. Isopropyl alcohol
(0.5 ml) was added, the mixture vortexed, then again incubated for 2 hours at
50°C. Hydrogen peroxide (300 pi of 30% solution), if needed, was added
dropwise while swirling and the sample incubated for 60 minutes at 50°C. Four
ml of Hionic-Fluor™ scintillation cocktail was then added for counting.
Tissue
One ml of Soluene-350 was added to all sample tissues. Each sample
was incubated a minimum of 4 hours at 50°C. After digestion, 4.5 ml HionicFluor™ scintillation cocktail was added for counting. Hydrogen peroxide (200
pi of 30% solution), if needed, was added dropwise while swirling. The
samples were then incubated for 60 minutes at 50°C.
Samples were dark adapted overnight then counted in a Packard TriCarb 1900 TR Liquid Scintillation Analyzer. Normalization and quench curves
were conducted before samples were run. Each sample was counted for 10
minutes.
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Results
The stability of tritiated Ethacure
There appeared to be no significant differences in peak areas,
shapes, and retention times between the 3 chromatographs. There was no
obvious breakdown or exchange of label of the tritiated Ethacure occurring
under acidic, neutral, or basic conditions. This suggested that the tritiated
material would be stable under physiological conditions as well as under DNA
extraction protocols used in the isolation procedures.
Separation and purification of tritiated Ethacure
Final analysis depicted purity levels of 95% for the [3H]-2,6-DETDA
isomer. The identity of the 2,6-DETDA isomer was confirmed by the graphic
relationship of the UV chromatograph relative to the LS spectrometry (Figure
6.2). The purity level was considered adequate for the ensuing distribution and
excretion studies.
Distribution and excretion studies for 2.6-DETDA
Calculated values for the weights of the skin, stomach, small intestine,
caecum and colon used in determining the percent of administered dose in the
distribution and excretion studies are listed in Chapter 5 (Table 5.1). The
average weight for the pancreas was determined to be 3.569 ± 0.438 mg/100 g
of body weight. Percent of body weight values used for blood (6.16), fat (6.17),
and muscle (6.18) were 7%, 7.6% and 50% respectively.
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Figure 6.2

Graphical confirmation of tritiated 2,6-DETDA (bottom) after
separation of tritiated Ethacure’s (top) 2,4- and 2,6-DETDA
isomers.
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Results of the tritiated 2,6-DETDA tissue distribution study presented
as (jmol of 2,6-DETDA per gram of tissue were depicted in Table 6.1 and
Figures 6.3, 6.4 and 6.5. The data revealed the highest levels of label
occurred in the gastrointestinal system during the first 8 hours reflecting both
absorbed and possibly unabsorbed 2,6-DETDA. Relatively high levels of
radioactivity was present in the bladder for the first 8 hours presumably
reflecting both distributed and excreted compound. The metabolic and
excretory organs, liver and kidney, contained moderate levels of label in
relatively equal amounts. Label in the thyroid and pancreas was much higher
than expected, for non-excretory organs, with thyroid levels exceeding even
that of liver tissue. The concentration of radioactivity in all tissues except the
stomach, caecum, colon, thyroid, pancreas and spleen was greatest at 4 hours.
With the exception of the stomach, thyroid, pancreas and spleen, tissues
exhibited a classic biphasic model of distribution and excretion with the onset
of the slow phase occurring after the 4 hour time point. As can be gleaned
from the 24 and 48 hour time frames, DETDA was rapidly cleared from all
tissues. Day 6 residual levels of label (Figure 6.5) was uniform in all tissues
except the thyroid gland which was almost 4 fold higher than any other tissue.
The 2,6-DETDA tissue distribution results presented as percent of
administered dose were depicted in Table 6.2 and Figures 6 .6 ,6.7 and 6 .8 .
Radioactivity in the gastrointestinal system followed the expected profile.
Stomach values were highest in the first hour with declining amounts over time.
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Table 6.1

Summation of the tritiated 2,6-DETDA distribution study in the male Sprague Dawley rat. Values
represent pmol of 2,6-DETDA/g of tissue (n=4, n=3 for 1 hr. lung) and the standard deviation (S.D.) for
each tissue and time point.

Tissue
S tom ach
D uodenum
C aecu m
B lad der
Colon
Thyroid
P an creas
Liver
K idney
F at
Lung
H ea rt
S pleen
Blood
Skin
M uscle
Thym us
Brain
T estes

1 hr
4 hr
8 hr
24
S .D .
pm ol/gm
pm ol/gm
S .D .
pm ol/gm
S .D .
pm ol/gm
0 .3 7 5 7 0 .1 7 4 1
0 .3 4 2 0 0 .1 4 3 6
0 .1 1 9 4 0 .0 6 6 1
0 .0 0 6 2
0 .1 8 5 4 0 .0 8 3 4
0 .2 1 1 5 0 .1 1 8 6
0 .0 6 9 0 0 .0 4 7 2
0 .0 0 4 7
0 .0 2 6 2 0 .0 1 4 0
0 .0 6 3 8 0 .0 4 7 3
0 .1 4 9 9 0 .0 6 4 2
0.0 201
0 .0 6 0 9 0 .0 3 4 0
0 .0 6 7 8 0 .0 1 9 9
0 .0 6 2 2 0 .0 3 0 1
0 .0 1 1 5
0 .0 2 6 8 0 .0 0 3 5
0 .0 3 0 0 0 .0 0 8 9
0 .0 4 3 3 0 .0 3 7 8
0.0 091
0 .1 6 7 8 0 .2 5 4 4
0 .0 8 5 7 0 .0 8 1 3
0 .0 5 5 3 0 .0 5 6 2
0 .0 1 3 4
0 .0 9 2 4 0 .0 5 0 9
0 .0 3 3 1 0 .0 1 5 1
0 .0 4 3 5 0 .0 5 8 0
0 .0 0 4 3
0 .0 2 7 4 0 .0 1 2 0
0 .0 3 6 4 0 .0 1 5 6
0 .0 2 4 7 0 .0 0 2 5
0 .0 0 6 7
0 .0 2 9 5 0 .0 1 5 7
0 .0 3 5 3 0 .0 0 5 8
0 .0 2 7 2 0 .0 0 5 9
0 .0 0 6 7
0 .0 2 3 4 0 .0 1 6 4
0 .0 2 6 5 0 .0 0 6 6
0 .0 1 0 5 0 .0 0 3 2
0 .0 0 2 2
0 .0 1 5 7 0 .0 1 0 1
0.0 241 0 .0 1 0 8
0 .0 121 0 .0 0 1 6
0 .0 0 4 6
0 .0 1 0 2 0 .0 0 6 6
0 .0 101 0 .0 0 1 0
0.0 071 0 .0 0 0 6
0 .0 0 3 5
0 .0 5 6 2 0 .0 5 2 8
0.0 2 1 1 0 .0 1 3 4
0 .0 1 6 0 0 .0 1 3 2
0 .0 0 3 9
0 .0071 0 .0 0 3 7
0 .0 1 1 7 0 .0 0 1 2
0 .0 1 0 6 0 .0 0 0 7
0 .0 0 6 4
0 .0 1 1 3 0 .0 0 6 1
0 .0 1 6 6 0 .0 0 7 2
0 .0 0 9 9 0 .0 0 2 3
0.0 051
0 .0 0 5 7 0 .0 0 2 9
0.0 071 0 .0 0 1 4
0 .0 0 5 8 0 .0 0 0 7
0 .0 0 3 5
0 .0 0 5 9 0 .0 0 2 8
0 .0 0 8 0 0 .0 0 1 1
0 .0 0 7 0 0 .0 0 0 9
0 .0 0 3 6
0 .0 1 3 4 0 .0 0 9 1
0 .0 1 8 7 0 .0 1 2 2
0.0 091 0 .0 0 1 8
0.0 041
0 .0 0 6 4 0 .0 0 3 8
0 .0 0 8 5 0 .0 0 1 2
0 .0 0 7 0 0 .0 0 0 5
0 .0 0 4 0

hr
S .D .
0 .0 0 2 0
0 .0 0 0 4
0 .0 1 0 5
0 .0 0 4 3
0 .0 0 2 2
0 .0 0 3 6
0 .0 0 0 2
0 .0 0 0 5
0 .0 0 0 8
0 .0 0 1 3
0 .0 0 0 3
0 .0 0 0 5
0 .0 0 0 2
0 .0 0 0 6
0 .0 0 0 7
0 .0 0 0 4
0 .0 0 0 6
0 .0 0 0 3
0 .0 0 0 7

48
pm ol/gm
0 .0 0 2 9
0 .0 0 2 9
0 .0 0 3 2
0 .0 0 3 8
0 .0 0 2 7
0 .0 1 0 4
0 .0 0 2 7
0 .0 0 4 7
0 .0 0 4 8
0 .0 011
0 .0 0 3 0
0 .0 0 2 6
0 .0 0 2 8
0 .0 0 4 0
0 .0 0 3 2
0 .0 0 2 6
0 .0 0 2 7
0 .0 0 3 2
0 .0 0 2 8

hr
S .D .
0 .0 0 0 2
0 .0 0 0 2
0 .0 0 1 5
0 .0 0 1 7
0 .0 0 0 2
0 .0 0 2 6
0 .0 0 0 2
0 .0 0 0 6
0 .0 0 0 4
0 .0 0 0 7
0 .0 0 0 4
0 .0 0 0 4
0 .0 0 0 2
0 .0 0 0 3
0 .0 0 0 4
0.0 0 0 1
0.0 0 0 1
0.0 0 0 1
0 .0 0 0 4
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Graphical representation of the tritiated 2,6-DETDA study in the adult male Sprague Dawley rat.
Values represent pmol of 2,6-DETDA/g of tissue (n=4, n=3 for 1 hr. lung). Higher and lower range of
values are presented in Figures 6.3 and 6.4 respectively.
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Graphical representation of the tritiated 2,6-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent pmol of 2,6-DETDA/g of tissue (n=4, n=3 for 1 hr. lung). Higher and
lower range of values are presented in Figures 6.3 and 6 .4 .
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Results of the tritiated 2,6-DETDA tissue distribution study in the adult male Sprague Dawley rat.
Values represent pmol of 2,6-DETDA/g of tissue remaining at the day 6 time point (n=5).
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Table 6.2

Summation of the tritiated 2,6-DETDA distribution study in the male Sprague Dawley rat. Values
represent the percent of administered dose (n=4, n=3 for 1 hr. lung) and the standard deviation (S.D.)
for each tissue and time point.
Tissues

235

1 hr
4 hr
8 hr
2 4 hr
48 hr
% D ose
S .D .
% Dose S .D . % D ose S .D . % D ose S .D . % Dose S .D .
Feces
1 2 .2 1 3 12.271
8.8 0 8 1.791
14 .168 1.292 2 4 .3 3 9 1.2 39 2 9 .7 0 6 0 .6 3 8
Urine
2 .1 8 8
1.774 15.417 2 .3 0 6 33.511 6 .5 0 0 4 4 .4 0 6 5.1 0 2 4 4 .0 3 4 2 .5 9 6
M uscle
8.271
4 .2 2 5 10.228 2 .0 5 4
8.3 5 3 1.006
5.071 0 .6 3 2
3.841 0.191
Skin
4 .9 4 7
2 .6 6 9
7.231 3 .1 5 6
4 .3 0 7 0 .9 8 6
2 .2 0 9 0 .3 2 0
1.375 0 .1 7 4
Blood
1.443
0.7 4 7
2.371 0 .2 4 4
2 .1 6 0 0 .1 3 8
1.3 06 0.1 2 3
0 .8 0 9 0 .0 7 0
Fat
5 .1 6 4
5.851 1.4 65
3.6 1 7
2 .3 1 7 0 .7 0 5
0 .4 8 5 0 .2 8 7
0 .2 4 2 0 .1 4 7
Liver
3.151
1.1 95
4 .0 9 2 2 .0 9 8
2 .6 4 2 0 .3 7 3
0 .9 4 0 0 .0 9 5
0 .6 3 0 0 .0 9 9
C aecum
0 .3 4 6
0 .1 8 5
0.8 4 2 0 .6 2 5
1.979 0 .8 4 7
0 .2 6 5 0.1 3 8
0 .0 4 2 0 .0 2 0
Stom ach
6 .3 3 3
2 .9 3 5
2 .0 1 3 1.114
5.7 6 4 2 .4 2 0
0.1 0 5 0.0 3 4
0 .0 4 8 0 .0 0 4
S m . Intest.
8 .0 9 0
3.6 3 8
9.2 2 7 5.1 7 4
3 .0 1 2 2 .0 5 9
0 .2 0 5 0 .0 1 5
0 .1 2 7 0 .0 1 0
Kidney
0.721
0.4 1 5
0.871 0 .1 2 9
0.6 2 0 0 .1 4 5
0.161 0 .0 2 2
0 .1 1 9 0.0 1 2
Thym us
0 .0 4 5
0.021
0 .0 5 7 0 .0 0 7
0.0 4 2 0 .0 0 7
0 .0 1 9 0 .0 0 3
0.0 1 3 0.001
0.201
Lung
0.1 3 2
0 .3 4 0 0.1 3 4
0 .1 4 5 0 .0 3 6
0 .0 6 2 0 .0 1 4
0.041 0.011
H eart
0 .1 1 4
0.111 0 .0 1 4
0.0 7 2
0 .0 7 9 0 .0 0 3
0 .0 3 9 0.0 0 8
0 .0 2 6 0 .0 0 2
0 .4 5 9
0.471
S pleen
0 .1 2 8 0 .0 7 5
0 .0 9 3 0 .0 8 9
0.021 0 .0 0 2
0 .0 1 8 0.0 0 3
P ancreas
0 .9 5 7
0 .5 2 7
0 .3 4 3 0 .1 5 6
0.4 5 0 0 .6 0 0
0 .0 4 5 0 .0 0 2
0 .0 2 8 0 .0 0 3
B ladder
0 .0 5 4
0.0 2 7
0.061 0 .0 2 0
0 .0 6 0 0 .0 4 0
0 .0 0 9 0 .0 0 3
0 .0 0 4 0 .0 0 2
Thyroid
0 .0 4 0
0.0 5 8
0 .0 1 6 0 .0 1 9
0.011 0.011
0 .0 0 3 0.0 0 0
0.0 0 2 0 .0 0 0
Brain
0 .2 5 3
0 .2 1 6
0.3 6 3 0 .2 1 7
0.1 8 7 0.031
0 .0 8 5 0 .0 1 5
0 .0 6 0 0 .0 0 3
Colon
0.3 1 5
0.2 1 4
0.3 5 3 0.1 0 5
0.5 0 8 0 .4 4 5
0 .1 0 6 0 .0 2 6
0 .0 3 2 0.0 0 2
Testes
0 .2 5 5
0.1 7 5
0.3 1 5 0 .0 3 3
0 .2 6 3 0 .0 2 4
0 .1 5 0 0 .0 2 9
0 .1 1 2 0.0 1 8
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Figure 6.6

236

Graphical representation of the tritiated 2,6-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent the percent of administered dose (n=4, n=3 for 1 hr. lung). Higher and
lower range of values are presented in Figures 6.6 and 6.7 respectively.
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Graphical representation of the tritiated 2,6-DETDA distribution study in the adult male Sprague
Dawley rat. Values represent the percent of administered dose (n=4, n=3 for 1 hr. lung). Higher and
lower range of values are presented in Figures 6.6 and 6.7 respectively.
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Results of the tritiated 2,6-DETDA tissue distribution study in the adult male Sprague Dawley rat.
Values represent the percent of administered dose remaining in the tissues at the day 6 time point
(n=5).
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The small intestine peaked at the 4-hour point then rapidly declined. Caecum
and colon both peaked at the 8-hour time point reflecting label being absorbed
as compound progressed down the intestinal tract. Large body mass tissues
(muscle, skin and fat), as expected, contained relatively large amounts of label.
Fecal and urinary values represented an accumulation of excreted label at
each time point. By 8 hours, urinary excretion became the primary route of
elimination. By 24 hours, over 68 % of the labeled compound had been
excreted and by 6 days (Table 6.3) only 3.4% of label remained in the tissues.
As expected, at day 6 , the majority of label was present in the large body mass
organs. Elevated levels in liver and kidney were probably denotative of
metabolism and excretion functions. Blood levels remained relatively constant
up to 48 hours reflecting label diffusing out of body tissues prior to excretion.
Figure 6.9 plots the accumulated excretion profile for the 2,6-DETDA
isomer over 6 days. Almost 72% of the administered dose of tritiated 2,6DETDA was excreted in the first 24 hours. The urinary system proved to be the
major route of elimination for the compound excreting 50% of the dose within
24 hours compared to 22% in the feces (Table 6.4). Label excretion was
nearly complete by 48 hours with only slight amounts excreted over the next 4
days. Almost twice as much label was eliminated through the urinary system
compared to fecal excretion. Recovery of label ranged between 85% and 96%
with an average of 94%.
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Table 6.3

Tissue

Summary for day 6 of the tritiated 2,6-DETDA distribution study in
the adult male Sprague Dawley rat. Values represent either the
percent of administered dose or the pmol of 2,6-DETDA in the
tissue (n=5).

% of dose Stnd. Dev.

Tissue

pmol/g Stnd. Dev.

Blood

0.340

0.053

Blood

0.0017

0.0003

Fat

0.062

0.018

Fat

0.0003

0.0001

Skin

0.852

0.106

Skin

0.0020

0.0002

Muscle

1.649

0.523

Muscle

0.0011

0.0004

Thymus

0.006

0.002

Thymus

0.0013

0.0002

Lung

0.020

0.005

Lung

0.0014

0.0002

Heart

0.011

0.002

Heart

0.0011

0.0002

Spleen

0.011

0.002

Spleen

0.0017

0.0002

Pancreas

0.012

0.003

Pancreas 0.0012

0.0003

Bladder

0.001

0.000

Bladder

0.0013

0.0003

Kidney

0.057

0.012

Kidney

0.0024

0.0005

Liver

0.275

0.028

Liver

0.0020

0.0002

Stomach

0.013

0.004

Stomach

0.0008

0.0002

Sm. Intest.

0.047

0.017

Duodenum 0.0011

0.0004

Caecum

0.013

0.004

Caecum

0.0010

0.0003

Colon

0.012

0.001

Colon

0.0011

0.0001

Thyroid

0.002

0.000

Thyroid

0.0156

0.0042

Brain

0.029

0.009

Brain

0.0015

0.0004

Total

3.412
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Figure 6.9

Urinary and fecal excretion profile of tritiated 2,6-DETDA over 6
days. Data points represent the percentage of administered dose
of 2,6-DETDA (n=5) accumulated over time from urine and fecal
samples.
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Table 6.4

Summary of the 6 day tritiated 2,6-DETDA excretion study in the
adult male Sprague Dawley rat. Values represent the percent of
administered dose of tritiated 2,6-DETDA excreted at each time
point (n=5).

Urines
Day % of Dose Stnd.Dev.

Feces
% of Dose Stnd.Dev.

1

49.98

7.84

21.68

4.39

2

4.56

3.32

7.87

4.90

3

1.44

0.27

1.02

0.22

4

1.00

0.28

0.68

0.24

5

0.71

0.18

0.48

0.20

6

0.53

0.14

0.84

0.44

Total

58.23

32.56

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

243

Covalent binding studies
Binding study results of DETDA to DNA and protein is compiled in
Table 6.5. Relative to Ethacure (80.8% 2,4-DETDA, 19.2% 2,6-DETDA), 5
pmol of 2,6-DETDA/|jmol of DNA was found covalently bound. For the 2,6DETDA isomer, 38% of the label was bound to the protein fraction equating to
31 nmol 2,6-DETDA per gram of liver protein. The 260/280 ratio for the
samples was 1.9.
Discussion
It is obvious from the data that the 2,6-DETDA isomer was rapidly
absorbed from the gastrointestinal system. The distribution profile suggests
that the compound has both water and fat soluble properties. The relatively
greater accumulation of label in the thyroid, pancreas, and liver tissue may
reflect the possible toxic qualities encountered in the long term feeding study.
The data also suggest that 2,6-DETDA was distributed to most, if not every
tissue in the body. The excretion profile showed that the primary route of
excretion for 2,6-DETDA was the urinary system with almost twice as much
label being eliminated compared to fecal excretion. The majority of urinary and
fecal elimination occurred during the first 24 hours of the study.
Cellular DNA is often the target of covalent addition. These DNA
adducts can have serious ramifications because of the critical role that DNA
plays in cellular functions and cell reproduction. The importance of persistent
in vivo DNA-arylamine adducts can be seen in the devastating consequences
of gene mutations and cancer (6.19-6.24).
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Table 6.5

Tritiated 2,6-DETDA covalent binding on rat liver DNA and
protein.

Isomer

pmol DETDA
per pmol DNA

nmol DETDA
per g Protein

% of label on
protein

2,6-DETDA

5

31

38

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

245

Furlong et al. conducted TDA in vitro binding studies on rat liver
hepatocytes. Incubating hepatocytes with 100 pmol of 2,6-TDA for 24 hours
resulted in approximately 51 pmol 2,6-TDA/pmol DNA (6.25). This compares to
5 pmol 2,6-DETDA/(jmol DNA carried out at a concentration of about 30 pmol.
Furlong’s study showed that 2,4-TDA binding to rat liver DNA was
concentration dependent below 100 pmol. Binding at 30 pmol concentrations
resulted in about 50% less binding. There were no concentration dependent
study results reported for the 2,6-TDA isomer. Although this was an in vitro
study, results suggest that compared to TDA, DETDA is less likely to be
involved in covalent binding to DNA. DETDA does however, seem to have
considerable affinity for protein. Consequences of DETDA protein binding, if
any are unknown at the present time.
Ethacure has been used successfully for over 20 years as a
replacement chemical for known toxic compounds. The results of this study
showed that 2,6-DETDA, a significant component of Ethacure, cleared quickly
after an orally administered dose such that by 24 hours, less than one-third of
the label remained in the tissues. With the exception of the 2,6-isomer in the
thyroid gland, there appeared to be very little accumulation in tissue 6 days
after exposure.
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CHAPTER 7
SUMMARY AND CONCLUSIONS
The pK, values of the 2 amine groups (2.5 and 4.6) and the absorption
characteristics determined for Ethacure (2790 mM'1cm'1) were used in HPLC
method development providing information needed for HPLC and
spectrophotometry analysis. A reverse-phase HPLC method using a Whatman
C18 Partisphere 5pm 4.6x250mm column, 100 mmol dibutylamine phosphate
buffer (pH 3.0) and a flow rate of 0.5 ml/min achieved the best separation and
resolution for both the 2,4- and 2,6-DETDA isomers. The HPLC-UV and
electrochemical detection methods developed allowed for detection of the 2,4and 2,6-DETDA isomers but not the anticipated acetylated metabolites. Gas
chromatography, using either FID or NP detection, proved to be the method of
choice for analysis providing excellent detection and quantitation of 2,4- and
2.6-DETDA as well as the mono- and di-acetylated metabolites.
The Varian Bond Elut LRC® C-8 bonded phase extraction columns
provided a clean, efficient and reproducible method for extracting 2,4- and 2,6DETDA as well as monoacetylated and diacetylated metabolites from urine.
The use of bonded phase extraction columns would allow for large scale
screening of urine samples using automation techniques.
The synthesis of both monoacetylated and diacetylated DETDA
metabolites were successful and reproducible. The structures of the 2,4- and
2.6-DETDA isomers and the 2,4- and 2,6-monoacetylated DETDA metabolites
249
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were confirmed by both NMR and GC/MS analysis. The 2,4- and 2,6diacetylated metabolites were confirmed by GC/MS spectra.
Because acetylation is considered to be a major biotransformation
reaction for aromatic amines compounds in most species, both monoacetylated
and/or diacetylated DETDA metabolites were also expected to be produced in
the biotransformation profile of DETDA. The total lack of acetylated
metabolites in the urine of the Ethacure treated male Sprague-Dawley rats was
unexpected. After oral administration of Ethacure, approximately 4% of the
mixture in the form of 2,4- and 2,6-DETDA was recovered in the urine. The
only structural difference between TDA and DETDA are the benzylic ethyl
groups at the 3 and 5 position on the ring. Since TDA has been shown to
undergo acetylation in the rat, one could conclude that the ethyl groups may be
responsible for the lack of or decrease in acetylation of DETDA. The ethyl
groups may possibly allow other biotransformation reactions to predominate in
the metabolism of DETDA.
Distribution profiles of labeled DETDA indicates the compound has
both water and fat soluble properties. There appears to be little difference in
the pattern of distribution between the 2,4-DETDA and the 2,6-DETDA isomers
with the possible exception of the thyroid gland. The thyroid and pancreatic
tissue accumulation of label may reflect the possible toxic qualities
encountered in the long term Ethacure feeding study.
Differences in the excretion profile between the 2,4- and 2,6-DETDA
isomers seem to signify variations in the biotransformation of each compound.
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The greater urinary excretion of 2,6-DETDA (58%) compared to 2,4-DETDA
(44%) suggests a more excretable, water soluble metabolite may have been
produced. This could be accomplished by greater phase II conjugation
reactions (glucuronidation, sulfation, glutathione) on the 2 ,6-isomer compared
to the 2,4-isomer (7.1). Restricted enzymatic access due to the flanking of the
4-position amino group by benzylic ethyl groups on the 2,4-isomer could effect
these results.
Ethacure has been used successfully for over 20 years as a
replacement chemical for known toxic compounds. The results of this study
shows that DETDA clears quickly after an orally administered dose, such that
by 24 hours, less than one-third of the label remains in the tissues. With the
exception of higher levels of DETDA in the thyroid gland, there appears to be
very little accumulation in tissue 6 days after exposure.
The data from this study should add confidence to the results from
early short and long term toxicity studies which indicated that DETDA was a
safer alternative to some of the products that it could replace. Future studies
delineating biotransformation products and the effects of DETDA on the thyroid
gland are recommended.
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APPENDIX A: BUFFERS AND SOLUTIONS
Dibutylamine: To distill, 200 ml of dibutylamine was mixed with 20 g of
potassium hydroxide and stirred for 45 minutes. The dibutylamine was filtered
through a ceramic filter and 10 g of barium oxide added. The solution was then
distilled (dibutylamine boiling point is 159°C), placed in an amber bottle, and
stored under argon.
EDTA 0.5M: Mix 18.61 grams of EDTA (disodium salt, dihydrate, mw 372.24)
in 60 ml of HPLC-grade water. Adjust pH to 8.0 using concentrated NaOH.
Pour into a 100 ml volumetric flask and fill to 100 ml with HPLC-grade water..
Guanidine lsothiocyanate-3M: Place 35.45 grams of guanidine isothiocyanate
(FW 118.16) into a small beaker. Add 60 ml of HPLC-grade water and stir until
dissolved. Pour into a 100 ml volumetric flask and fill to 100 ml with HPLCgrade water.
Potassium Phosphate Buffer, pH 7.0 (1 Liter): Weigh out 13.61 g of KH2P04
(MW 136.09). Place into a 1 liter volumetric flask. Dissolve the KH2P0 4 in 875
ml of 18 MO -cm water. Raise the pH to 7.0 using 1M potassium hydroxide
while continuously stirring. Add HPLC-grade water for a total volume of 1 liter.
Store at 5°C and discard after 30 days.
RNase A: To prepare 20 units/ml, mix 1.6 mg of RNase A with 1.44 ml of
HPLC-grade water. Add 200 pi to each DNA sample.
TE buffer: Place 5 ml of 2M Tris and 2 ml of 0.5M EDTA into a 1 liter volumetric
flask. Fill flask to 1 liter with HPLC-grade water.
252
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Tris 2M: Add 17.76 grams of Trizma® HCL and 10.6 grams of Tris base to 60
ml of HPLC-grade water in a 100 ml volumetric flask. Adjust pH to 8.0 using
concentrated HCL. Fill flask to 100 ml with HPLC-grade water.
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APPENDIX B: HPLC CHROMATOGRAM
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Figure B1

Representative sample of HPLC-UV chromatogram. Conditions
included a C18 Partisphere 5 pm 4.6x250 mm reverse phase
column, Shimadzu LC-600 pump, Shimadzu SPD-10AV UV
detector, and a 16.5% acetonitrile, 100 mM dibutylamine
phosphate buffer (pH 3.0). Approximate retention times: 2,4DETDA, 4.3; 2,6-DETDA, 5.0; 2,4-monoacetylated DETDA, 5.65.8, 2,6-monoacetylated DETDA, 7.6; 2,4-diacetylated DETDA,
11.2; 2,6-diacetylated DETDA, 19.2. Note excessive peak tailing
on the 2,4-monoacetylated metabolite.
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APPENDIX C: GC CHROMATOGRAMS
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Figure C1

Representative chromatogram from Chapter 4 metabolism
experiment. Chromatogram is of normal rat urine spiked with 2,4DETDA (5.96 min), 2,6-DETDA (6.28), 2,4-monoacetylated
DETDA (9.52, 9.67), 2,6-monoacetyiated (10.12) 2,4-diacetylated
DETDA (13.78), 2,6-diacetylated DETDA (14.35), and internal
standard diazepam (16.43). Compare to Figure C2 (Control
urine) and Figure C3 (8 hour urine sample from an Ethacure
treated rat.
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Figure C2

Representative chromatogram from Chapter 4 metabolism
experiment. Chromatogram is a normal rat urine control sample.
Note that there are no interfering peaks present when compared
to a spiked urine sample (Figure C1).
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Figure C3
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Representative chromatogram from Chapter 4 metabolism
experiment. Chromatogram is from a urine sample collected at an
8 hour time point in a rat treated with Ethacure. Note that only
2,4-DETDA (5.97 min.), 2,6-DETDA (6.28) and diazepam (16.43)
were detected in the sample. None of the expected acetylated
metabolites were observed at the limit of quantitation.
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